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1.1. Introduction 
 
Drugs have been administered nasally for therapeutic and recreational purposes since ancient 
times. Psychotropic drugs and hallucinogens were sniffed for these purposes by the Indians of 
South America and this practice is currently widespread among abusers of cocaine and heroine 
(Chien and Chang, 1987). 
Although intranasal delivery of peptides was already reported in the early 1920’s, the commercial 
application of the nasal route for systemic delivery of drugs only began during the 1980’s. One of 
the first peptides commercially available as a nasal spray was oxytocin, which stimulates uterine 
contraction and lactation. Meanwhile, several other peptide-based nasal formulations have 
entered the market. These are based on peptide drugs like desmopressin, luteinizing hormone-
releasing hormone (LHRH) and LHRH analogues, and calcitonin.  The nasal peptides form a 
first class amongst the currently marketed products for nasal administration. The second class of 
drugs regularly administered via the nose are low molecular weight drugs for treatment of local 
inflammation of the nasal mucosa (sinusitis and rhinitis): e.g. oxymetazolin hydrochloride, 
budenoside and levocabastine. A third group comprises low molecular weight drugs used in the 
treatment of migraine and intended for systemic delivery: e.g. sumatriptan and zolmatriptan. A 
number of other drugs, which have potential for nasal administration, are still in the research and 
development pipeline. 
The interest in and importance of the systemic delivery of drugs via the nasal route have 
expanded in recent decades since nasal administration offers an interesting alternative for the 
conventional drug delivery routes (e.g. oral or parenteral administration). This interest arises from 
the unique advantages presented by the nasal cavity for drug delivery purposes: (a) the nose has a 
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relatively large surface area available for drug absorption as the epithelium is covered with 
microvilli; (b) the epithelium is thin, porous and highly vascularized which ensures a rapid 
absorption of nasally administered drugs and a fast onset of therapeutic action; (c) nasal drug 
delivery avoids the hepatic first-pass effect and enzymatic activity in the gastrointestinal tract; and 
(d) after nasal delivery of insulin and human growth hormone, the normal pulsatile pattern of 
endogenous insulin and somatropin can be mimicked (Hinchcliffe and Illum, 1999; Hedin et al., 
1993). The nasal route is also interesting for vaccine delivery as almost all viral and bacterial 
agents causing common infectious diseases of the respiratory tract enter or infect the body 
through the nasal membrane (Mestecky et al., 1997). The nasal mucosa is an important part of 
the mucosal immune system since it is often the first point of contact for inhaled antigens and as 
a consequence, intranasal immunisation has emerged as possibly the most effective route of 
vaccination to obtain both humoral and mucosal immunity (McGhee et al., 1999; Renauld-
Mongénie et al., 1996). Other benefits for patients using nasal drugs are the non-invasive method 
of drug delivery which is suitable for self-medication, increased patient compliance and reduced 
risk of overdosing (Ugwoke et al., 2001).  
In contrast, there are also drawbacks associated with nasal administration: (a) the volume that can 
be sprayed into the nasal cavity is limited to approximately 150µl, which limits the dose to be 
administered; (b) the normal physiology of the nose presents some barriers to peptide and 
protein drug absorption: mucociliairy clearance mechanism (temporal barrier), enzymatic 
degradation in the mucus layer (chemical barrier) and low permeability of the nasal epithelium 
(physical barrier) (Cornaz and Buri, 1994; Hinchcliffe and Illum, 1999); (c) nasal administration 
has been associated with a high variability in the amount of drug absorbed; and (d) the nasal 
route is also less suitable for chronically administered drugs. In case of peptide and protein 
delivery, the bioavailability achieved following intranasal delivery tends to be low compared to 
parenteral routes (Eppstein and Longenecker, 1988; Lee and Yamamoto, 1990), which is 
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reflected in the fact that only a few intranasal peptide and protein preparations are currently 
available for systemic medication (Hinchcliffe and Illum, 1999). 
 
Drugs in liquid nasal sprays can be very well absorbed and liquid sprays are relatively simple, 
cost-effective and generally well accepted by the patients. However, a liquid spray has a tendency 
to run down the oesophagus, which may result in a bad taste. Another effect of swallowing a 
nasally administered fluid is the lower and more variable absorption. Moreover, absorption of 
polar and/or large drug molecules such as peptides from a liquid formulation may be suboptimal 
because of the short residence time in the nasal cavity or low permeability of the mucosa to the 
active component. Permeation enhancers (e.g. cyclodextrins, bile salts, chelating agents) can be 
added, but using these components there is an associated risk of harmful effects on the 
epithelium and mucociliairy clearance (Davis and Illum, 2003). 
The use of dry powder formulations as vehiculum for nasal delivery offers several benefits. Not 
only a better deposition and a longer residence time in the nasal cavity are achieved, but also a 
higher stability of the peptide and possibly absorption enhancement. Because nasal 
administration of a powder has been associated with greater sensory irritation than liquid sprays, 
the amount of powder should be kept as low as possible (below 20 mg) (Teshima et al., 2002). 
Mucoadhesive particle formulations have generally proven to be safe delivery systems with 
limited harmful effects even after repeated dosing (Holmberg et al., 1994; Pereswetoff-Morath et 
al., 1996; Callens et al., 2001). In this study, a spray-dried Amioca®/Carbopol® 974P powder is 
used for nasal administration of peptides like insulin, calcitonin and human growth hormone. 
This spray-dried combination of a maize starch (Amioca®, mainly consisting of amylopectine) 
and a cross-linked acrylic acid-based polymer (Carbopol® 974P) amplifies the mucoadhesive 
capacity of the formulation. The powder combination is also evaluated as carrier for nasal 
delivery of inactivated influenza virus combined with an LTR192G adjuvant.  
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1.2. Aim  
 
The objective of this doctoral thesis was to improve the mucoadhesive properties of a 
starch/poly(acrylic acid) powder intended for nasal drug delivery, and to evaluate its applications 
for systemic delivery of peptides (insulin, calcitonin and somatropin) as well as for nasal 
vaccination. 
More specifically the aims of the different chapters were: 
• To evaluate the effect of heat treatment on the properties (water-absorbing capacity, 
viscosity and elasticity) of the mucoadhesive Amioca®/Carbopol® 974P powder and on 
the bioavailability of insulin, calcitonin and somatropin after nasal administration to 
rabbits via the mucoadhesive powder. 
• To spray-dry the Amioca®/Carbopol® 974P powder with a model molecule metoprolol 
tartrate (MT) in order to develop a one-step manufacturing process. This spray-dried 
powder was compared with powder mixtures manufactured via different procedures 
(freeze-drying or physical mixing) to evaluate the effect of processing on the 
bioavailability of MT after nasal administration of the formulations to rabbits. 
• To investigate if the Amioca®/Carbopol® 974P powder was a suitable carrier for nasal 
influenza vaccination using rabbits as test species. The irritation potential of the powders 
was tested using the Slug Mucosal Irritation test. Furthermore, stability of the virion 
formulated in the powder as well as in a liquid formulation was tested (virion integrity and 
virion antigenicity). 
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 2.1. Anatomy and physiology 
 
The function of the nasal cavity is complex. The basic functions of the nose are heating and 
humidification of inspired air before reaching the lungs, but also olfaction, filtration of inhaled 
particles and mucociliairy clearance are essential functions. The nasal epithelium also has 
antimicrobial, antiviral and immunological activities (Druce, 1986). 
 
Figure 1 shows the cross-sectional structure of the human nose. The nasal cavity is divided into 
two halves by a longitudinal nasal septum and extends posteriorly to the nasopharynx, while the 
most anterior part of the nasal cavity, the nasal vestibule, opens to the face through the nostril. 
The nasal vestibule possesses numerous nasal hairs that filter large air-borne particles. The 
intermediate part between the vestibule and the respiratory region is the atrium. The respiratory 
region, which is important for the absorption of drugs into the systemic circulation, is the major 
part of the nasal cavity. This region consists of three conchae or turbinates: the superior, middle 
and inferior nasal turbinates. These folds offer the advantage of increasing the surface area in 
comparison to its small volume. Additionally to the nasal vestibule and the respiratory region, a 
third functional region is found in the roof of the nasal cavity, named the olfactory region. The 
nasal cavity has a total volume of 15-20 ml and a total surface area of about 150 cm² (Hinchcliffe 
et al., 1999; Ugwoke et al., 2001). 
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Figure 1. Cross-sectional structure of the human nose. NV = nasal vestibule; AT = atrium; NP = 
nasopharynx; IT = interior turbinate; MT = middle turbinate; ST = superior turbinate, olfactory region 
(Mygind et al., 1998)  
 
Three types of epithelium are lining the human nasal cavity: squamous, respiratory and olfactory. 
The mucosa in the anterior part of the nose is squamous and has no cilia. Translational 
epithelium, which precedes the respiratory epithelium, is found within 1 cm of the nostrils. The 
posterior part of the nasal cavity is covered by the olfactory epithelium (Marttin et al., 1998).   
Figure 2 shows a typical airway epithelium, which is ciliated, pseudostratified and columnar. It 
consists of different cell types. The basal cells are the progenitors of other cell types. They lie on 
the basement membrane and do not reach the airway lumen. The columnar cells include non-
ciliated and ciliated cells, the latter are covered by about 300 microvilli. These fingerlike structures 
increase the surface area of the epithelial cells and promote exchange processes across the 
epithelium. They are also responsible for moisturizing the epithelial surface which is essential for 
their function. A third variety of cells are the globlet cells. Globlet cells are having many secretory 
vesicles in the cytoplasm, which are related to the production of the mucus layer on the surface. 
Because most of the nasal secretion is delivered by submucosal glands, the globlet cell 
contribution is rather small. Globlet cells probably respond to physical and chemical irritants in 
the microenvironments. The epithelium rests upon a layer of collagen fibrils which is called 
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‘basement membrane’ and forms the separation with the highly vascularised lamina propria 
(Morita & Yamahara, 2005; Mygind & Dahl, 1998). 
 
 
 
 
 Figure 2. Cell types of the nasal epithelium showing ciliated cell (A), non-ciliated cell (B), globlet cell (C), 
gel mucus layer (D), sol layer (E), basal cell (F) and basement membrane (G) (Ugwoke et al., 2005).  
 
A very specific part of the nose, namely the nasal associated lymphoid tissue (NALT) deserves 
special attention in this research project. The NALT is an inductive site for the adaptive mucosal 
immune system. It is located in the submucosa of the nasopharyngeal area (tonsils) and is ideally 
positioned to encounter environmental antigens (McGhee & Kiyono, 1993). Presentation of an 
antigen with a suitable adjuvant to the NALT has the potential to induce humoral and cellular 
immune responses (Zeurcher et al., 2002)  (cfr. Chapter 6). 
 
Another well described nasal application is the possibility of exploiting the nasal route for direct 
transport of drugs from nose to brain. Therefore, the drug has to bypass the blood-brain barrier 
and reach the central nervous system (CNS) direct from the nasal cavity by targeting the olfactory 
epithelium. This modified form of respiratory epithelium is situated between the nasal septum 
and the lateral wall of each side of the two nasal cavities and just below the cribiform plate of the 
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ethmoid bone separating the nasal cavity from the cranial cavity. In order to reach the CNS from 
the nasal cavity, the drug will have to cross the olfactory membrane and depending on the 
pathway used also the arachnoid membrane surrouding the arachnoid space containing the 
cerebro-spinal fluid. Illum et al. (2003) describes that the drug can cross the olfactory pathway by 
one or a combination of pathways. Small lipophilic molecules mostly use the transcellular 
pathway while smaller hydrophilic molecules prefer transport by the paracellular pathway. The 
drug can also be transported through the olfactory neuron cells by intracellular axonal transport 
primarily to the olfactory bulb. It is evident that in situations where it is necessary to target 
receptors in the brain (e.g. Parkinson’s disease, Alzheimer’s disease) a specific delivery of to the 
CNS should be beneficial. 
 
 2.2. Barriers for nasal absorption 
  
2.2.1. Mucociliairy clearance 
 
The respiratory epithelium is covered with a mucus layer. Mucus is a complex mixture of many 
substances which consists of about 95% water, 2% mucin, 1% salts, 1% proteins (e.g. albumin, 
immunoglobulins, lysozyme and lactoferrin) and < 1% lipids (Kaliner et al., 1984). The daily 
mucus production is about 1.5-2 l. The most important physiological functions of the nasal 
mucus are protection of the mucosa, water-holding capacity, surface electrical activity, heat 
transfer and transport medium of particulates to the nasopharynx (Ugwoke et al., 2005). The 
mucosa is slightly acidic (pH 5.5-6.5), which is thought to be important for its antibacterial 
properties (Chien et al., 1989). 
The mucus layer is about 5 µm thick and consists of a lower sol layer and an upper gel layer. The 
lower layer, which embeds the cilia is of low viscosity whereas the upper layer that rests on the 
cilia is a high viscosity fluid. The viscosity of both layers affects the mucociliairy clearance which 
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is driven by the ciliairy activity. When noxious substances (e.g. allergens, bacteria, viruses, toxins, 
etc.) adhere to the nasal mucus, they are transported towards the nasopharynx for discharge in 
the gastrointestinal tract. In the normal state, a nasally administered substance will be cleared by 
this system in 15-30 min. Efficient mucociliairy clearance is due to a coordinated interaction 
between the overlying mucus layer and the metachronal wavelike movement of the underlying 
cilia which propagates mucus along the surface (Guirao et Joanny, 2007). The ciliairy activity 
regulates the secretory transport in the nose and has also a defensive function (Ugwoke et al., 
2001). In pathological conditions (e.g. common cold, rhinitis,…), the nasal function may be 
modified as exemplified with mucociliairy dysfunctioning, hypo- or hypersecretions and irritation 
of the nasal mucosa (Morita & Yamahara, 2005). 
 
2.2.2. Medication transfer through mucus and epithelium 
 
The mucus layer in the nasal cavity forms the first physical barrier to drugs and macromolecules 
deposited in the nasal cavity. It is possible that they interact with negatively charged sialic acid 
and sulphate groups of mucus glycoproteins (Hinchcliffe and Illum, 1999). Also hydrophobic and 
other non-specific interactions between drugs and mucus are responsible for the binding of some 
polar and non-polar drugs to mucus. Peptides and proteins may provide a sufficiently 
hydrophobic region (disulfide bridges and hydrophobic bonds) for adequate drug-protein 
interaction, depending on their amino acid sequence (Khanvilkar, 2001). Relative to many of the 
other factors which limit nasal absorption, the role of mucus is rather limited. 
 
In addition to the mucus layer, the nasal epithelium is a highly efficient barrier to the absorption 
of peptide and protein drugs. The low membrane permeability is the most important factor 
limiting the nasal absorption of polar drugs and especially of large molecular weight drugs such as 
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peptides and proteins. Absorption across the mucosal epithelial membrane occurs either via the 
transcellular or paracellular route (Figure 3). 
 
                           
Figure 3. Schematic representation of transport routes across nasal respiration mucosa  
(1) paracellular across tight junctions, (2) transcellular, (3) transcytotic.  
(Tj) tight junction, (G) globlet cell, (C) ciliated cell, (B) basal cell, (Bl) basal lamina,  
(Lp) lamina propria, (Junginger and Verhoef, 1998). 
 
The transcellular route is characterized by direct diffusion through cells by passive diffusion 
(activated by a concentration gradient) or by active processes which may involve receptor-
mediated carrier mechanisms and vesicular transport (transcytotic). 
In the paracellular route, molecules pass through the intercellular tight junctions and spaces 
between adjacent cells. Tight junctions hold the epithelial cells together at their apical surface and 
are dynamic structures consisting of plasma membranes which assemble and disassemble in 
response to various physiological stimuli (e.g. decrease in extracellular calcium).  
Depending on the properties of the drug molecule and the characteristics of the cellular barrier, 
the medication transfer through the nasal epithelium will be trans- or paracellular. Lipophilic 
compounds are usually transferred transcellular since they are able to partition into the bilayer of 
the cell membrane and diffuse into and traverse the cell via the cell cytoplasm. Pharmacokinetic 
profiles of those drugs are similar to those after intravenous administration and bioavailabilities 
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until 100% are reached. Polar drugs with molecular weight below 1000 Da will cross the 
epithelium via the paracellular route. Despite the fact that tight junctions are dynamic structures 
that can open and close to a certain degree, the mean size of the channels is in the order of less 
than 10 Å. Peptides and proteins are hydrophilic polar molecules of relatively high molecular 
weight. As a result they are poorly absorbed across biological membranes with bioavailabilities 
obtained in the region of 1-2% after nasal administration of a drug solution (Hinchcliffe and 
Illum, 1999; Khanvilkar et al., 2001; Illum, 2003). 
 
2.2.3. Enzymatic degradation 
 
A less important factor concerning the low transport of especially peptides and proteins across 
the nasal membrane is the possibility of an enzymatic degradation of the molecule either within 
the lumen of the nasal cavity or during passage across the epithelial barrier. Exopeptidases like 
mono- and diaminopeptidases that can cleave peptides at their N- and C-termini are found in 
both sites, as well as endopeptidases that can attack internal peptide bonds (Illum, 2003). 
 
2.3. The nasal cavity of the rabbit 
 
The use of rabbits in medication studies offers a number of advantages. They are suitable for 
pharmacokinetic and pharmacodynamic studies. The larger entrance into the nasal cavity 
compared with rats enables easy administration of both drug solutions and powder formulations. 
No anaesthesia is needed for performing the experiment, especially since some anesthetics can 
inhibit mucociliairy clearance (Raphael et al., 1996), which would affect drug absorption. Other 
advantages include the low cost, easy availability, maintenance and handling. The large blood 
volume (approximately 300 ml) allows repeated blood sampling if necessary (Ugwoke et al., 
2001). 
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Table 1 presents a comparison of the anatomical characteristics of the nasal cavities of humans 
and rabbits (Chien et al. 1989; Gizurarson, 1993). Despite minor differences, the anatomy of the 
nose of a rabbit resembles that of the human nose (Popesko et al., 1992). The rabbit conchal 
structures on the lateral sides are much more developed and wider compared with those in 
humans (Cöloğlu et al., 2006) which provide a large surface area. The ventral nasal conchae of the 
rabbit contain many globlet cells but few ciliated cells (Gizurarson, 1990) in comparison to 
human. 
 
Table 1. Comparative anatomy of the nasal cavities of rabbits and humans (Chien et al., 1989; Gizurarson, 
1993). 
 Rabbit Man 
Weight (kg) 3 70 
Cross-section (mm²) 3.1 140 
Bend in nose (°) 38 - 
Length (cm) 4.7 7-8 
Greatest vertical diameter (mm) 25 40-45 
Surface area (cm²) 61-90 160-181 
Volume (ml) 6 16-19 
Bend of nasopharynx (°) 45 61-90 
Turbinate complexity branching single scroll 
Volume administered (µl) 58 150 
Clearance half-life (min) 10 15 
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2.4. Formulation approach as strategy for the improvement of drug absorption 
 
After nasal administration most peptide and protein drugs have a low bioavailability. However, 
absorption can be improved by a number of strategies taking into account drug, disease and the 
region in the nose where the drug has to be deposited. Next to the use of absorption enhancers, 
enzyme inhibitors and the synthesis of more stable or lipid analogues, nasal absorption can be 
increased by focusing on the formulation itself. When a drug is nasally administered as a solution, 
the drug is quickly absorbed into the circulation and has a fast onset of therapeutic action. Since 
the rapid mucociliary clearance of the dosage form is a disadvantage to obtain reproducible 
absorption kinetics, mucoadhesive formulations are used for nasal drug therapy. The use of 
mucoadhesive nasal delivery systems provide a prolonged contact between the drug formulation 
and the absorptive sites in the nasal cavity by delaying the mucociliairy clearance (Illum, 2003; 
Morita and Yamahara, 2004).  
A common feature of most commercially available nasal preparations is the large fraction 
deposited in the anterior, non-ciliated region of the nose, anterior to the nasal valve. Anterior 
crusting and bleeding and inadequate distribution to target sites beyond the nasal valve make 
most existing delivery methods suboptimal for treatment via the nose (Djupesland, 2006). It is 
more efficient to target the posterior region which is rich in ciliated cells, having a large surface 
area available for drug absorption. In case of nasal vaccine delivery, the nasal associated lymphoid 
tissue (NALT) has to be targeted. The NALT is characterized by the presence of organized 
lymphoid tissue in the nasal mucosa with aggregates of lymphocyte-like follicles (Debertin et al., 
2003). An optimal formulation helps targeting the intended region in the nasal cavity and can 
convert a mediocre drug into a more effective and successful product (Behl et al., 1998). 
The most basic forms of nasal preparations are nasal drops or nasal sprays. These are perhaps the 
simplest and most convenient form of administering drug formulations into the nose. However, 
since mainly solutions are used, it is difficult to deliver the exact amount of drug and there is a 
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fast drainage from the nose. That is why viscosity-enhancing components like methylcellulose or 
hydroxyethylcellulose are added to these formulations in order to delay the clearance of the 
formulation from the nasal cavity resulting in a delayed absorption of peptides and drugs. Killian 
and Müller (1998) administered metoprolol tartrate nasally to rats formulated in an aqueous 
solution and solutions of the active ingredient combined methylcellulose (MC). Results indicated 
that the higher viscosity significantly improved the nasal absorption of the drug due to a longer 
contact time of metoprolol tartrate with the absorption surface. 
A more efficient approach to increase the residence time of peptides in the nasal cavity involves 
the use of polymeric materials in powder formulations which have bio- or mucoadhesive 
properties. Ahuja et al. (1997) defined bioadhesion as the attachment of a drug carrier system to a 
specific biological location. If the adhesive attachment is to a mucus coat, the phenomenon is 
referred to as mucoadhesion. The mucoadhesive components should be durable where required 
and degradable where necessary. In the following paragraphs, recently obtained in-vivo results 
after nasal delivery of peptides, proteins and conventional drugs with the most important 
bioadhesives are discussed. 
 
Chitosan is a positively charged linear polysaccharide comprising copolymers of glucosamine and 
N-acetylglucosamine and can be derived by the partial deacetylation of chitin. Illum and co-
workers have exploited the chitosan concept for the delivery of peptide and protein drugs (e.g. 
insulin, parathyroid hormone, calcitonin) and small molecular drugs (morphine, anti-migraine 
drugs). They also used chitosan as vehiculum for nasal influenza, pertussis and diphtheria 
vaccines which resulted in IgG serum responses similar to and secretory IgA levels superior to a 
parenteral reference formulation (Illum et al., 2001). Chitosan microspheres that were used for 
nasal delivery of progesterone in rabbits improved bioavailability of the drug considerably. 
Plasma levels of the drug remained nearly constant for 20 h before gradually declining (Jain, 
2007). Modified chitosan was also used for nasal delivery. Thiolated chitosan microparticles 
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loaded with insulin were nasally tested in rats and resulted in 1.5-fold higher absolute 
bioavailability (BA) (6.9%) compared to regular chitosan particles (Krauland et al., 2006). Nasal 
administration to rats of insulin via a chitosan gel formulation resulted in an absolute 
bioavailability of 46% (Varshosaz et al., 2006). Wu et al. (2007) used chitosan combined with 
poly(ethylene glycol) as a thermosensitive hydrogel for the nasal delivery of insulin to rats. Plasma 
glucose level fell sharply and stayed at low concentration for upto 5 h because of the superior 
adhesivity of the gel. 
 
Carbomers or poly(acrylic acids) are carboxyvinyl polymers of extremely high molecular weight 
with good mucoadhesive properties. The interaction of the polymer with mucin by physical chain 
entanglements is followed by hydrogen bond formation with sugar residues on the 
oligosaccharide chains, resulting in the formation of a strengthened gel network. Carbomer resins 
intended for oral and mucosal applications are designated as ‘P’-grades (e.g. 934P, 974P) (Singla 
et al., 2000). 
Tas et al. (2006) administered metoclopramide in the nose of sheep using a powder or gel 
formulation of Carbopol® 981P. Formulating the anti-emeticum in a gel induced a bioavailability 
of 57%, while only 23% was obtained with Carbopol powder combined with cyclodextrin. A 
nasally administered insulin gel spray (2 IU/kg) based on Carbopol 934P resulted in an absolute 
bioavailability of 21% in rabbits, while the bioavailability of a nasal solution was only 6% 
(Najafabadi et al., 2004). Ugwoke et al. (1999) nasally administered different concentrations 
apomorphine formulations to rabbits using Carbopol® 971P, Carbopol® 974P and polycarbophil 
as bioadhesive polymers: a higher drug loading increased the maximal plasma concentration and 
the rate of absorption, but decreased the time required to achieve the peak plasma drug 
concentration. The best results were obtained with Carbopol® 974P. 
Carbomers have been widely used in combination with other polymers, particularly celluloses 
(e.g. hydroxypropylmethylcellulose, hydroxypropylcellulose, ethyl cellulose). Combining these 
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polymers gives an interaction between the carboxyl groups of the carbomer and the cellulose 
molecules which increases viscosity and mucoadhesive capacities (Singla et al., 2000). 
 
Microspheres of different materials (degradable starch, dextran, hyaluronic acid, polyacrylic acid) 
have been evaluated in vivo for nasal drug delivery of peptides and proteins. Particle sizes from 1 
to 300 µm could be obtained (Pereswetoff-Morath, 1997). Dextran microspheres were 
investigated by Tabassi et al. (2008) for nasal tetanus vaccination in rabbits. These vehicles could 
be used as an efficient mucosal adjuvant and antigen delivery system for IgG induction, but no 
significant IgA levels were measured. 
 
Recently, lots of research has been done in the field of nanoparticles. As nanoparticles have a 
higher surface area in comparison with microparticles they have a better coverage of the highly 
vascularized nasal absorptive area (Jain et al., 2008).  Zhang et al. (2008) investigated nasal 
absorption enhancement of insulin using PEG-grafted chitosan nanoparticles. Those 
nanoparticles were able to lower blood glucose in rabbits to 54% of baseline values at 60 min 
post-administration and improved the nasal absorption of insulin compared with an insulin-
PEG-g-chitosan suspension and a control insulin solution. Another recent study reported that 
insulin incorporated in chitosan gold nanoparticles induced a reduction of 20% in blood glucose 
level 2h after nasal insulin administration in diabetic rats (Bhumkar et al., 2007). Jain et al. (2008) 
used starch nanoparticles combined with sodium glycocholate as permeation enhancer for nasal 
delivery of insulin in diabetic rats and reached a relative bioavailability of  44%. 
 
At the Laboratory of Pharmaceutical Technology (Ghent University, Belgium) mucoadhesive 
powder formulations based on a starch component and poly(acrylic acid) have been used 
extensively for nasal delivery of insulin (used as a model peptide). Callens et al. (1999) 
investigated physical mixtures consisting of drum-dried waxy maize starch (DDWM) or 
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maltodextrins combined with Carbopol® 974P. The highest bioavailability (14.4 %) was obtained 
with a powder formulation consisting of DDWM/Carbopol® 974P (ratio: 90/10) containing 1 IU 
insulin/mg powder. Pringels et al. (2007) obtained a bioavailability of 22.4 % using a co-spray-
dried starch/Carbopol® mixture (ratio: 25/75). Addition of calcium ions increased the 
bioavailability of insulin to 29.0% as binding of Ca-ions to poly(acrylates) depleted extracellular 
calcium and increased the paracellular permeability by opening the tight junctions. The research 
studies performed in this Ph.D. thesis are a continuation of the above cited references. 
 
The Amioca®/Carbopol® powder mixture has the desirable properties of a polymer: strong 
hydrogen bond-forming groups as carboxyl and hydroxyl, high molecular weight, anionic charge, 
sufficient chain flexibility, surface energy favoring spreading onto the mucus, non-toxic, non-
absorbable and non-interacting with the drug (Singla et al., 2000). Carbopol® polymers are GRAS 
(generally regarded as safe) materials that are commonly used in nasal formulations. Firstly, their 
mucoadhesive properties provide an intimate contact between the dosing formulation and the 
mucosal surface, resulting in a prolonged residence time at the site of absorption. Secondly, these 
polymers increase the stability of peptides at the mucosal surface by inhibiting Ca2+- or Zn2+-
dependent proteases (e.g. trypsin, chymotrypsin, carboxypeptidase A). Thirdly, Carbopol® 
polymers have been reported to open the cellular tight junctions when in contact with nasal 
epithelium, potentially improving peptide permeability across the epithelial barrier (Li et al., 
2005). When focusing on the disadvantages of carbomers, the mucosal irritation potential and the 
high sensitivity to changes in pH have to be considered (Singla et al., 2000; Adriaens et al., 2003). 
To attenuate the irritating capacities of the powder formulation, the poly(acrylic acid) was 
combined with Amioca® starch, mainly consisting of amylopectin. Its branched structure induces 
a strong physical entanglement between the starch component and the poly(acrylic acid) which 
increases viscosity after contact with the nasal mucosa. In the present study, a spray-dried 
formulation of Amioca® starch and Carbopol® was evaluated as platform for nasal delivery. 
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Chapter 3. Composition of powder formulations used for nasal 
delivery 
 
3.1. Spray-dried Amioca®/Carbopol® 974P mixtures 
 
Amioca®/Carbopol® 974P is a spray-dried starch/poly(acrylic acid) mixture, obtained from 
National Starch and Chemical Company (Bridgewater, New Jersey, USA). 
Starch is a polymeric material with a molecular formula of (C6H10O5)n, where n ranges from 300 
to 1000. Its main ingredients are amylose and amylopectin (Figure 1). Amylose is a linear polymer 
of α-D-glucopyranosyl units linked (1→4). Amylopectin is a branched polymer of α-D-
glucopyranosyl containing (1→4) linear linkages and (1→6) linkages at the branch points. 
Amylopectin is three or more times larger than amylose (Newman, 2002). 
 
 
Figure 1. Chemical structure of amylopectin (Mathews et al., 2000) 
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Amioca® starch (National Starch and Chemical Company, Bridgewater, New Jersey, USA) is a 
maize starch mainly consisting of amylopectin (waxy maize). It is often used in food industry as 
thickener. 
Carbopol® 974P (Noveon, Cleveland, Ohio, USA) is a synthetic, high molecular weight, cross-
linked polymer formed after cross-linking of acrylic acid with allyl pentaerythritol (Figure 2). The 
carboxyl groups provided by the acrylic acid backbone of the polymer are responsible for most of 
the product benefits. The product has a high water sorption capacity. When the pH of a 
Carbopol dispersion is 4 – 6, the carboxyl groups on the polymer backbone ionize (pKa 
Carbopol®: 6.0 ± 0.5), resulting in repulsion between the negative charges, which adds to the 
swelling of the polymer. Carbopol® 974P is an excellent thickening, emulsifying, suspending and 
gelling agent. Based on these properties this component is often used in controlled drug delivery 
(Ahuja et al., 1997). 
 
  
Figure 2. Chemical structure of Carbopol® 974P 
 
In this study, spray-dried mixtures of Amioca® and Carbopol® 974P are used as drug carriers for 
nasal drug delivery (Figure 3). Prior to spray-drying Amioca® starch was gelatinised by jetcooking 
in a custom made jet cooker. Steam jet cooking of starch was performed by bringing a slurry of 
granular starch in contact with high-pressure steam, leading to disruption, solubilisation  and 
gelatinization of the granules, and yielding an aqueous starch dispersion (Byars, 2003). The 
following parameters were used during jet cooking: temperature of 138°C, pressure of 3.1-3.2 
bar, flow rate of 1.2-1.5 l/min. Phase contrast optical microscopy (Olympus BH2-UMA, 
Olympus, New York, USA) was used to confirm that complete gelatinisation of starch granules. 
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After jet cooking, the aqueous starch dispersion was mixed with an aqueous dispersion of 
Carbopol® 974P. This mixture was spray-dried using a Bowen spray-dryer model BE-1393 
(Arnold Equipment Company, Cleveland, OH, USA). Dispersions with different ratios of 
Amioca®/Carbopol® 974P were spray-dried: 85/15, 50/50 and 25/75 (Ameye et al., 2003). 
 
 
Figure 3. SEM-photo of spray-dried Amioca®/Carbopol® 974P 
 
3.2. Insulin 
 
Insulin is a peptide hormone composed of 51 amino acid residues and has a molecular weight of 
5808 Da. Insulin consists of two peptide chains referred to as the A- and B-chain. A- and B-
chains are linked together by two disulfidebonds and an additional disulfide is formed within the 
A-chain. In most species, the A-chain consists of 21 amino acids and the B-chain of 30 amino 
acids. 
Insulin is produced within the β-cells of the islets of Langerhans in the pancreas. The synthesis of 
insulin begins at the translation of the insulin gene, which resides on chromosome 11. After 
outsplicing of two introns, a protein of 110 amino acids called ‘preproinsulin’ is made. It contains 
a signal peptide of 24 amino acids in length, which is required for the protein to cross the cell 
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membrane. When the preproinsulin is in the endoplasmatic reticulum, proinsulin is created by 
cleaving off the signal peptide. Proinsulin consists of three domains: an amino-terminal B-chain, 
a carboxyl-terminal A-chain and a connecting middle C-chain. Within the endoplasmatic 
reticulum specific peptidases remove the C-chain and generate the active form of insulin. Mature 
insulin consists of a A-chain (21 amino acids) and a B-chain (30 amino acids) connected by 
disulfide bonds. A third disulfide bridge binds the 6th and 11th residue (both cysteine residues) of 
the A-chain. Insulin is packed in secretory granules produced by the Golgi apparatus and 
accumulates in the cytoplasm of β-cells. Exocytosis of the granules is triggered by the entry of 
glucose into the β-cells (Dean and McEntyre, 2004). Figure 4 shows the amino acid sequence of 
insulin. 
An insulin molecule contains several ionisable groups, due to 6 amino acid residues capable of 
attaining a positive charge and 10 amino acid residues capable of attaining a negative charge. Its 
isoelectric point is 5.4 (Brange, 1987). 
 
A-chain 
Gly – Ile – Val – Glu – Gln – Cys – Cys – Thr – Ser – Ile – Cys – Ser – Leu – Tyr – Gln – Leu – Glu – Asn – Tyr – Cys – Asn  
 
     Phe – Val – Asn – Gln – His – Leu – Cys – Gly – Ser – His – Leu – Val – Glu – Ala – Leu – Tyr – Leu – Val – Cys – Gly -  Glu 
B-chain 
                     Arg 
 
                                     Thr – Lys – Pro – Thr – Tyr – Phe – Phe - Gly 
Figure 4. Amino acid sequence of insulin 
 
The major function of insulin is to counter the action of a number of hyperglycemia-generating 
hormones and to maintain low blood glucose levels. Next to its function as regulator of the 
glucose metabolism, insulin stimulates lipogenesis, diminishes lipolysis and increases transport of 
amino acids into the cells. 
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Insulin is used as therapy for diabetes mellitus. This disease is defined as a metabolic disorder in 
which there is an inability to oxidize carbohydrate due to disturbances in insulin function. 
Diabetes mellitus is characterized by elevated glucose in plasma, episodic ketoacidosis, excessive 
thirst, glucosuria, polyuria and hunger.  
Type 1 diabetes or insulin-dependent diabetes mellitus (IDDM) is an autoimmune-mediated 
destruction of insulin-producing β-cells in the pancreas resulting in absolute insulin deficiency. It 
often manifests in childhood and it has to be treated with subcutaneous administered insulin. 
Type 2 diabetes or non-insulin-dependent diabetes mellitus (NIDDM) is a chronic condition that 
is characterised by insulin resistance in cells requiring insulin for glucose absorption or a lack of 
insulin production. There is an influence of genetic susceptibility and environmental factors as 
obesity, age and physical inactivity. It commonly occurs in people older than 40 who are obese 
(Brange, 1987). Generally, type II diabetes patients often tend to respond early to oral drugs to 
lower blood sugar but may need insulin at some point. 
 
Insulin was discovered in 1921 by Banting and Best. Initially insulin was obtained by extraction of 
the pancreas of cows, pigs or sheep. Because bovine and porcine insulins were impure, they had 
to be purified by crystallization, HPLC or ion-exchange chromatography. Highly purified 
preparations were commercially available for clinical use but worldwide requirement could not be 
fulfilled because of the large numbers of animals needed (Trehan and Ali, 1998). Therefore, a 
breakthrough occurred with the use of DNA-recombinant technology. In 1982, biosynthetic 
human insulin became the first marketed human health-care product derived from rDNA 
technology. This novel technology opened new ways for the development of insulin analogues or 
‘designer insulins’ with changed amino sequences. As a consequence, those products had new 
structural, physicochemical and biological properties (Brange and Vølund, 1999). 
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3.3. Calcitonin 
 
Calcitonin is a polypeptide hormone consisting of 32 amino acids and has a molecular weight of 
approximately 3500 Da. Figure 5 shows the amino-acid sequence of calcitonin. The basic 
structure of calcitonin is characterized by a disulfide bridge between the cysteine residues at 
positions 1 and 7 and a proline amide moiety at the C-terminus.  
Despite the fact that salmon calcitonin is more potent in mammals, especially in man, than the 
actual human calcitonin, the reason for this phenomenon is not fully understood (Potts, 1992). 
Calcitonin was initially reported in 1962 as a novel hypocalcemic peptide hormone and is secreted 
by the C-cells of the thyroid gland. Its major physiological role is to control the calcium 
concentration as well as its metabolism in the body. In order to reduce the amount of calcium in 
the blood stream, it also reduces the amount of calcium excreted by the bone by inhibiting the 
osteoclast activity (decrease of bone resorption). Its final function is decreasing the amount of 
calcium that could be absorbed from the intestine. 
When calcium concentration is decreased beyond normal levels, its production is inhibited and 
the parathyroid hormone is secreted. Parathyroid hormone promotes the opposite reactions in 
the body than calcitonin. In conjunction, these two hormones act to maintain a normal calcium 
concentration in the bloodstream. 
Therefore, calcitonin is used in the treatment of bone diseases such as Paget’s disease, 
hypercalcemia and osteoporosis (Torres-Lugo and Peppas, 2000). 
 
   
Cys1 – Ser – Asn – Leu – Ser – Thr – Cys7 – Val – Leu – Gly – Lys  –  
Leu – Ser – Gln – Glu – Leu – His – Lys18 – Leu – Gln – Thr – Tyr – 
Pro – Arg – Thr – Asn – Thr – Gly – Ser – Gly – Thr – Pro32 – NH2 
Figure 5. Amino acid sequence of salmon calcitonin 
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3.4. Somatropin 
 
Somatropin or recombinant human growth hormone is manufactured by recombinant DNA 
technology. It is a polypeptide hormone consisting of 191 amino acids and has a molecular 
weight of 22 kDa. The amino acid sequence and the two internal disulphide bridges are identical 
to that of the major component of human pituitary growth hormone (Pearlman and Bewley, 
1993). The structure includes four helices necessary for functional interaction with the growth 
hormone (GH) receptor. Figure 6 shows the amino acid sequence of somatropin. 
   
       
Figure 6. Amino acid sequence of somatropin (A=alanine; C=cysteine; D=aspartic acid; E=glutamic 
acid; F=phenylalanine; G=glycine; H=histidine; I=isoleucine; K=lysine; L=leucine; M=methionine; 
N=asparagine; P=proline; Q=glutamine; R=arginine; S=serine; T=threonine; V=valine; W=tryptofane; 
Y=tyrosine) 
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Human growth hormone (GH) is the product of the GH-1 gene located on chromosome 17 and 
expressed in pituitary cells. Growth hormone-releasing hormone and somatostatin are produced 
in the neurosecretory nuclei of the hypothalamus and control the release of somatropin in the 
portal venous blood surrounding the pituitary (Figure 7). Although the balance of the stimulating 
and inhibiting peptides determines GH release, this balance is affected by many physiological 
simulators (e.g. exercise, sleep, hypoglycaemia) and inhibitors of GH secretion (e.g. 
hyperglycemia, glucocorticoids, estradiol). 
 
 
Figure 7. Regulation of somatropin release 
http://www.mfi.ku.dk/ppaulev/chapter30/images/30-1.jpg 
 
Effects of growth hormone on the tissues of the body can generally be described as anabolic. 
Somatropin induces growth of the skeleton, increases muscle mass, calcium retention, lipolysis 
and protein synthesis, gluconeogenesis and stimulates the immune system. 
Therapeutically, somatropin is used in children to treat growth retardation, for example short 
stature due to insufficient growth hormone secretion, Turner’s syndrome or chronic renal 
insufficiency (Cheng, 2005). In adults it is used as a treatment for growth hormone deficiency and 
for management of HIV-related cachexia (Sweetman, 2002). 
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3.5. Metoprolol tartrate 
 
Metoprolol is a cardioselective ß1 receptor blocker used in treatment of cardiovascular diseases as 
hypertension and angina pectoris (Frishman, 2002). Metoprolol is administered as a racemic 
mixture of its enantiomers, (S)- and (R)-metoprolol, with the (S)-enantiomer being responsible for 
the β-blocking activity (Hoffman and Lefkowitz, 1990). The active substance metoprolol is 
employed either as metoprolol tartrate or metoprolol succinate used as conventional-release or 
prolonged-release oral formulations. Metoprolol tartrate is commercially available under the 
brand name Lopressor® (Novartis). Metoprolol tartrate is (±)-1-(isopropylamino)-3-[p-(2-
methoxyethyl)phenoxyl]-2-propanol (2:1) dextro-tartrate salt and its structural formula is shown 
in Figure 8.  
Metoprolol tartrate (pKa 9.68) is a white odourless, crystalline powder with a molecular weight of 
649 g/mol. It is very soluble in water. A 10% solution in water has a pH between 6 and 7. 
Since metoprolol has a low melting point (± 45°C), metoprolol salts are used in dosage forms, as 
drugs with melting points below 100°C are difficult to process within a manufacturing 
environment. Metoprolol tartrate has a melting point of 120°C.  
The drug is almost completely (95%) absorbed from the gastro-intestinal tract, but is subject to 
significant first-pass metabolism (Regårdh and Johnsson, 1980). The drug is metabolised by 
oxidative deamination, aliphatic hydroxylation and O-dealkylation with subsequent oxidation. 
Protein binding of metoprolol is low (12%) and the elimination half-life in man 3-7h. 
 
 
Figure 8. Metoprolol tartrate       (http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=727) 
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4.1. Influence of heat treatment on spray-dried mixtures of Amioca® starch 
and Carbopol®  used as carriers for the nasal delivery of insulin 
 
 
Abstract 
 
A mucoadhesive spray-dried starch/poly(acrylic acid) powder underwent different heat 
treatments in order to induce crosslinking between the functional groups of starch (Amioca®) and 
poly(acrylic acid) (Carbopol® 974P). After heat treatment the water-absorbing capacity, viscosity 
and elasticity of the muco-adhesive powder increased. NMR analysis in combination with FT-IR 
indicated that heat treatment induced a low degree of cross-linking between the polymers. Nasal 
administration of Amioca®/Carbopol® 974P powders without heat treatment resulted in an 
absolute bioavailability in rabbits of 8.2 ± 3.0 % for insulin. Due to the difference in water-
absorbing capacity (which probably opened the tight junctions of the nasal mucosa), elasticity and 
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plasticity (which reduced mucociliairy clearance and prolonged residence time) heat treatment at 
120°C improved the bioavailability: 26.4 ± 21.9, 36.5 ± 11.0 and 19.3 ± 17.3 % after heat 
treatment during 30min, 1h and 4h, respectively. Heat treatment at 60°C was less efficient. This 
study demonstrated that the nasal insulin absorption improved via heat treatment of the 
Amioca®/Carbopol® 974P powder (prior to the addition of insulin).  
 
Keywords: nasal delivery; heat treatment; Amioca®/Carbopol® powder formulation; insulin; 
NMR-spectroscopy 
 
 4.1.1. Introduction 
 
Replacement of parenteral administration of proteins and peptides by administration via the nasal 
route offers great opportunities as it eliminates several of the problems associated with parenteral 
drug delivery (poor patient compliance, pain during administration, high cost, trained personnel 
required) (Ugwoke et al., 2005). The large surface area of the thin, highly vascularized nasal 
epithelium is ideal for the absorption of peptides and can mimic the pulsatile delivery pattern of 
some drugs like insulin. Absorbed peptides pass directly into the systemic circulation thereby 
avoiding hepato-gastrointestinal first-pass metabolism (Chang and Chien, 1984; Chien and 
Chang, 1985). In spite of the potential of nasal drug delivery, some limitations have to be 
overcome: (a) only a limited quantity can be administered via the nose, (b) enzyme activity in the 
nasal cavity, (c) residence time of the formulation is limited by the mucociliairy clearance 
mechanism and (d) the mucus layers and nasal epithelium are barriers that obstruct peptide 
absorption (Ugwoke et al., 2005). To avoid fast clearance of the formulation from the nasal 
cavity, viscosity-enhancing or mucoadhesive polymers can be used to reduce ciliairy beat 
frequency (Nagai et al., 1984; Critchley et al., 1994; Illum et al., 2001; Callens et al., 2003). In this 
study, a spray-dried Amioca®/Carbopol® 974P powder was used for nasal administration of the 
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model peptide insulin. This spray-dried combination of a maize starch (Amioca®, mainly 
consisting of amylopectine) and a cross-linked acrylic acid-based polymer (Carbopol® 974P) 
amplifies the mucoadhesive capacity of the formulation. The viscosity-enhancing capacity of the 
powder after hydration in contact with the nasal mucosa allows insulin delivery without 
additional absorption enhancers as bile salts, surfactants, chelating agents or fatty acids 
(Hinchcliffe and Illum, 1999).  
In order to crosslink the network of Amioca® and Carbopol® 974P (ratio 25/75), the spray-dried 
powder underwent different heat treatments (temperature and duration as variables). After 
physico-chemical analysis (liquid uptake, rheological properties, NMR) these heat treated 
mixtures of starch and Carbopol® 974P were evaluated as platform for the nasal delivery of 
insulin as model peptide in rabbits.  
 
 4.1.2. Materials and methods 
  
 4.1.2.1. Materials 
 
Actrapid® HM 100 (100 IU/ml) (human monocomponent insulin) was obtained from Novo-
Nordisk (Bagsvaerd, Denmark). Spray-dried Amioca® starch and spray-dried mixtures of 
Amioca® starch and Carbopol® 974P (ratio: 25/75, w/w) (SD 25/75) (batch: 13724-4A), (ratio: 
50/50, w/w) (SD 50/50) (batch: 13898-104C) were prepared by National Starch and Chemical 
Company (Bridgewater, New Jersey, USA). Carbopol® 974P was supplied by Noveon (Cleveland, 
Ohio, USA). All other chemicals were of analytical grade. 
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  4.1.2.2. Heat treatment of Amioca®/Carbopol® 974P  
 
SD 25/75 powder was packed in sealed Alu-bags and stored for 30 min, 1 h and 4 h in an oven 
(Memmert, type U50, Schwabach, Germany) at 60 and 120°C. SD 25/75 was also heat treated at 
110 and 130°C during 1 h. A physical mixture of Amioca® and Carbopol® 974P (ratio: 25/75) 
was heat treated at 120°C during 1 h. SD 50/50 underwent a heat treatment at 40°C during 4 h 
and at 80°C during 1 h. 
 
  4.1.2.3. Liquid uptake rate 
 
The liquid uptake rate was studied hydrodynamically. 50 mg powder formulation was placed on 
the upper side of a filter connected to a reservoir filled with simulated nasal fluid (SNF) (7.45 
mg/ml NaCl, 1.29 mg/ml KCl and 0.32 mg/ml CaCl2, (Melon, 1967)). The measurements were 
performed at a temperature of 32 ± 0.5°C, simulating the temperature of the nasal cavity. The 
amount of absorbed SNF was determined volumetrically in function of time. 
 
  4.1.2.4. Rheological properties 
 
The elasticity (G’) and viscosity (G’’) of the powder formulations were determined by means of a 
TA Instruments AR 1000-N Rheometer (Zellik, Belgium). Different powders were dispersed in 
SNF (10%, w/w) before measuring G’ and G’’. The measurements were performed at 32 ± 0.5°C 
using a cone of 4 cm with an angle of 1° and applying an oscillation stress of 30 Pa and a 
frequency of 0.1 Hz. 
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 4.1.2.5. Physical analysis 
 
1H liquid-state NMR. The 1H NMR spectra were recorded from a solution in D2O (or gel for the 
heat-treated specimen) at room temperature on a 300 MHz Varian Inova spectrometer. Spectra 
were acquired with a 90° pulse of 5 μs, a spectral width of 4500 Hz, an acquisition time of 3.5 s, a 
preparation delay of 6 s and 300 accumulations. 
1H wideline solid-state NMR. Solid echo (Powles and Strange, 1963) proton wide-line NMR 
measurements were carried out on a Varian Inova 400 spectrometer in a dedicated wide-line 
probe equipped with a 5 mm coil. Hereto, on-resonance Free Induction Decays (FIDs) were 
acquired by applying the solid echo technique (90°x’ - tse - 90°y’ - tse - acquire), in an effort to 
overcome the effect of the dead-time of the receiver. The 90° pulse length was set to 1.2 µs and 
spectra were recorded with a spectral width of 2 MHz (0.5 µs dwell time) allowing an accurate 
determination of the echo maximum (the data point with maximum intensity). The solid-echo 
delay is formed with a maximum at  τ = (3t90/2 + 2tse) = 6 µs, where t90 is the duration of the 90° 
pulse. The samples were placed in 5 mm glass tubes, which were closed tightly with teflon 
stoppers. A preparation delay of 5 times the T1H relaxation decay time was always respected 
between successive accumulations to obtain quantitative results.  
To obtain the T2H (spin-spin relaxation) decay times, on-resonance FID curves were acquired 
with 64 accumulations and the time point of the echo-maximum has been calibrated to time zero. 
These FID curves were converted into ASCII files and analyzed bi-exponentially by means of 
Origin Version 6.0 software as a function of the acquisition time t (non-linear least-squares fit 
according Levenberg-Marquardt algorithm) with the following equation: 
   I(t) = IoS.exp((-0.5(-t/T2HS)2 + IoL.exp(t/T2HL) 
in which the superscripts S (short decay time) and L (long decay time) refer to the fast (Gaussian 
shape function) and slow (Lorentzian shape function) decaying proton fractions, respectively. 
The T1H relaxation decay times (spin-lattice relaxation in the lab frame) were measured by placing 
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an inversion recovery filter in front of the solid echo part (180°x’ – t - 90°x’ - tse  - 90°y’ - tse – 
acquire). The integrated proton signal intensity was analysed mono-exponentially (non-linear 
least-squares fit by Levenberg-Marquardt algorithm) as a function of the variable inversion time t 
according to: 
I(t) = Io.(1 - 2.exp(-t/T1H))  
in which I0 is the intensity of the resonance at equilibrium.  
The average 95% confidence limit for the T1H and T2H decay times and proton fractions is about 
1-2%. 
13C solid-state NMR. The 13C CP/MAS NMR spectra were recorded at room temperature on a 
Unity 200 Varian spectrometer operating at a static magnetic field of 4.7 T. Magic angle spinning 
was performed at 7 kHz, making use of ceramic Si3N4 rotors. The aromatic signal of 
hexamethylbenzene was used to determine the Hartmann-Hahn condition (ω1H = γH B1H = γC B1C 
= ω1C) for cross-polarization and to calibrate the carbon chemical shift scale (132.1 ppm). Other 
spectral parameters used were a 90° pulse length of 8.4 μs, a spectral width of 50 kHz, an 
acquisition time of 20 ms, a preparation delay of 2.5 s and 10000 accumulations. High power 
decoupling was set to 65 kHz during the acquisition time. 
 
FT-IR.   
FT-IR spectra of the reference formulation and the heat-treated (120°C, 1h) powder were 
obtained using KBr pellets on a Bruker Vertex 70 FT-IR spectrometer with a DTGS detector at a 
resolution 4 cm-1. 32 scans were acquired. 
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 4.1.2.6. Preparation of insulin formulations  
   
 4.1.2.6.1. Insulin solution for intravenous administration  
An insulin solution of 0.8 IU/ml was prepared by diluting Actrapid® HM 100 in a phosphate 
buffered saline solution (PBS, pH 7.4), of which 0.5 ml was administered intravenously to rabbits 
(3.0 ± 0.5 kg, n = 10). 
 
 4.1.2.6.2. Nasal powder formulations 
After different heat treatment procedures 500 mg powder (spray-dried mixture of starch and 
Carbopol® 974P, ratio 25/75 or 50/50) was dispersed in 15 ml distilled water, followed by a 
neutralisation step to pH 7.4 using NaOH 2M. Afterwards the insulin solution (Actrapid® HM 
100) was added to obtain a final concentration of 1 IU insulin per mg powder. The aqueous 
dispersion was freeze-dried using an Amsco-Finn Aqua GT4 freeze-dryer (Amsco, Germany). 
The dispersion was frozen to 228 K within 175 min at 1000 mbar. Primary drying was performed 
at 258 K and at a pressure varying between 0.8 and 1 mbar during 13 h, followed by secondary 
drying at elevated temperature (283 K) and reduced pressure (0.1 - 0.2 mbar) for 7 h. After 
freeze-drying the powder was sieved (63 µm) at low relative humidity (20 %) and ambient 
temperature. The fraction below 63 µm was stored in a desiccator at 4 - 8 °C until use. 
 
 4.1.2.7. Nasal bioavailability study 
 
The protocol of the animal experiments was approved by the Ethics Committee of the Institute 
for Agricultural and Fisheries Research (ILVO) (Merelbeke, Belgium). New Zealand white rabbits 
(3.0 ± 0.5 kg) were fasted 16 h prior to the experiment. Water was available ad libitum. They were 
sedated with an intramuscular injection of 0.05 ml/kg Placivet® (Codifar, Florida, USA) 
immediately after administration. A first group of rabbits received 0.4 IU insulin intravenously. 
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Ten mg powder formulation (equivalent to 10 IU insulin) was administered in each nostril of a 
second group of rabbits. The tubes were filled under conditions of low relative humidity (20 %) 
and ambient temperature. Blood samples were collected from the ear veins at -5, 1, 5, 10, 15, 20, 
30, 40, 50 and 60 min after intravenous administration and at -5, 2, 5, 10, 15, 20, 25, 30, 35, 45, 
60, 90, 120, 150 and 180 min after nasal delivery of the powder formulations. The sera were 
separated by centrifugation (700g, 5 min) and samples were stored frozen at –20 °C until RIA-
analysis (Coat-A-Count® kit, DPC, Humbeek, Belgium). The radioactivity of the samples was 
quantified using a Cobra gamma counter (Canberra Packard Benelux, Zellik, Belgium).  
  
4.1.2.8. Statistical analysis 
 
The individual serum concentration-time profiles were analysed by MW/Pharm version 3.15 
(Medi-ware, Utrecht, The Netherlands) and the maximum insulin serum concentrations (Cmax) 
and tmax values were determined from the individual serum concentration-time profiles. The 
influence of the powder formulations on the absolute bioavailability, Cmax and tmax of insulin was 
analysed using One-way ANOVA. Normal distribution of the data was tested using the 
Kolmogorov-Smirnov test and the homogeneity of variances was tested using the Levene’s test. 
If the distribution of the data was not normal or the variances were not homogeneous, the data 
were logarithmically transformed. When only two groups were compared, an Independent sample 
T-test was executed. 
The software program SPSS version 15.0 was used for statistical analysis. 
 
4.1.2.9. Nasal delivery device 
 
The powders were administered using an experimental device (Figure 1) composed of a 
polyethylene tube (inner diameter: 1.5 mm, length: 5.5 cm) (Medisize, Hillegom, The 
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Netherlands), valve and polypropylene syringe (10 ml with Luer-Lok® needle holder). A 
polyethylene tube filled with the powder formulation was connected to a syringe containing 1 ml 
compressed air (2.5 bar). The powder formulation was sprayed into the nostrils of the rabbits by 
opening the valve, releasing the compressed air. This device was based on a system developed by 
Sørensen (1991). 
 
   
Figure 1. Picture of experimental delivery device and nasal powder delivery to rabbits. 
  
4.1.3. Results and discussion 
 
4.1.3.1. Influence of heat treatment procedure 
 
In this study, heat treatment was investigated as a method to induce crosslinks between the 
functional groups of pre-gelatinized amylopectin (Amioca®) and poly(acrylic acid) (Carbopol® 
974P) in order to improve the mucoadhesive properties of the powder and increase the 
bioavailability after nasal administration. Whereas Yu and Hui-min (2006) created a novel 
superabsorbing polymer by chemical graft polymerization of acrylic acid onto a 
carboxymethylchitosan chain and subsequent crosslinking, heat treatment was selected in the 
present study as a soft and widely available technique to possibly create a polymer with improved 
liquid absorbing capacity. 
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The uptake of simulated nasal fluid (SNF) after heat treatment of the muco-adhesive powders 
(SD 25/75) at 60 and 120°C is presented in Figure 2 and 3, respectively. After 60 min the SD 
25/75 powder heated for 1h at 60°C had absorbed 20.1 ml/g powder, while the liquid uptake of 
the reference formulation was 14.7 ml/g over the same period. Heat treatment at 60°C during 
30min and 4h resulted in a slower SNF uptake. In contrast, heating the SD 25/75 powder at 
120°C for 4 h induced a fast hydration rate: hydration of the polymer chains (water uptake: 23.3 
ml/g) was complete within 3 minutes, versus. 2.2 ml/g for the reference formulation (Figure 3). 
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Figure 2. Influence of heat treatment of Amioca®/Carbopol® powder (ratio: 25/75) (SD 25/75) at 60°C 
during 0min (♦), 30min (■), 1h (▲) and 4h (●) on simulated nasal fluid (SNF) uptake profiles of SD 
25/75 powder formulation (n=3, mean ± S.D.). 
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Figure 3. Influence of heat treatment of Amioca®/Carbopol® powder (ratio: 25/75) (SD 25/75) at 120°C 
during 0min (♦), 30min (■), 1h (▲) and 4h (●) on simulated nasal fluid (SNF) uptake profiles of SD 
25/75 powder formulation (n=3, mean ± S.D.). 
 
The viscosity and elasticity after dispersion of heat treated SD 25/75 powders in SNF are shown 
in Table 1. The storage modulus (G’) reflects the solid-like component of a visco-elastic material 
and will be large if a sample is predominantly elastic or highly structured, the loss modulus (G’’) is 
a measure of the liquid-like component which will be large when a sample is predominantly 
viscous (Ceulemans and Ludwig, 2002). In case of a crosslinked system G’ (elastic) >> G’’ 
(viscous), while G’ > G’’ indicates a network consisting of secondary bonds and G’ < G’’ a 
physically entangled polymer solution (Fery, 1970). The elasticity or storage (G’) modulus of the 
SD 25/75 powder heated at 60°C during 1h was slightly higher compared with the reference 
formulation. Its G’’ value was similar to the reference formulation. G’ and G’’ values increased in 
function of heat treatment at 120°C. Since G’ is larger than G’’, it indicated that a cross-linked gel 
is formed after hydration of the Amioca®/Carbopol® powder (Madsen et al., 1998). The viscosity 
of the heat-treated samples resulted not only from the mechanical entanglement of the hydrated 
polymers and the high density of hydrogen bonding groups in Amioca starch and Carbopol®, but 
also cross-linking of the polymers during heat treatment was a contributing factor.  
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Table 1. Influence of heat treatment of Amioca®/Carbopol® powder (ratio: 25/75) (SD 25/75) on 
elasticity (G’) and viscosity (G’’) after dispersion into simulated nasal fluid (mean ± S.D., n=3). 
Heat treatment procedure G’ (Pa) G’’ (Pa) 
 without heat treatment 1886 ± 26 196 ± 27 
60°C - 30min 1983 ± 154 162 ± 28 
60°C - 1u 2477 ± 63 155 ± 14 
60°C - 4u 2297 ± 11 158 ± 5 
 
120°C - 30min 
 
3879 ± 54 
 
256 ± 24 
120°C - 1u 7168 ± 558 553 ± 73 
120°C - 4u 18753 ± 714 1263 ± 211 
 
Based on the rheological properties and the liquid uptake rate, the reference formulation (without 
heat treatment) and the SD 25/75 powder after 1h heat treatment at 120°C were evaluated via 
NMR to identify any structural changes in the powder after heat treatment.  
A first indication of cross-linking resulted from liquid-state 1H-NMR measurements. Whereas the 
native specimen (reference formulation without heat treatment) dissolved easily in D2O, the heat 
treated specimen formed a gel (even at half the concentration). In the 1H-spectra, the cross-
linking of the heat treated specimen resulted in an increase of the line-widths. This is 
demonstrated in Figure 4 which compares the spectra of the native and heat treated specimens: 
the increase in line-width was specifically prominent in the spectral region 1-4 ppm.  
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Figure 4. Liquid-state 1H-NMR spectrum of Amioca®/Carbopol® 974P powder (ratio: 25/75) 
(concentration: 1 mg/ml) without heat treatment (upper profile) and after heat treatment at 120°C during 
1h (lower profile).  
 
One of the very few techniques available to confirm cross-linking (and to determine the relative 
degree of cross-linking) can be found in solid-state proton wide-line-NMR relaxometry 
measurements. By this technique, the proton relaxation decay times, which are sensitive to the 
freedom of molecular motions, can be studied. In the solid-state, the T2H (spin-spin) decay times 
are extremely short, typically between 10-100 μs, and represent the strength of the dipolar 
interactions. For the specimens studied here, the T2H relaxation had to be analyzed bi-
exponentially with a short (T2HS) and long (T2HL) decay time, corresponding to a very rigid and a 
more mobile proton fraction (Table 2). This table showed that specifically the long decay time 
dropped upon heat treatment. This was a direct indication of a reduced molecular mobility. 
Measuring at 40°C, which speeds up the molecular motions, resulted in a longer T2HL decay time 
and larger mobile proton fraction (Table 2).  
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Table 2. Proton relaxation decay times T1H (s) and T2H (μs) of Amioca®/Carbopol® 974P powder (ratio: 
25/75) without heat treatment and after heat treatment at 120°C during 1h. The average 95% confidence 
limit for the T1H and T2H decay times and proton fractions is about 1-2%. The proton fractions of the 
T2H analysis are given between brackets.   
 Decay time 
 T1H (sec) T2HS (µsec) T2HL (µsec) 
 without heat treatment 2.31 9.90 (85.7) 65 (14.3) 
120°C - 1h 2.49 9.84 (85.8) 61 (14.2) 
120°C - 1h / measured at 40°C 2.00 9.89 (81.1) 82 (18.9) 
 
The T1H relaxation (in the order of seconds) on the other hand was dominated by the spectral 
density of segmental chain motions in the MHz region. The T1H relaxation behaved mono-
exponentially and increased upon heat treatment. Since a correlation diagram (a plot of log T1H 
versus the correlation time of segmental chain motion) showed a distinct minimum, a T1H 
measurement at 40°C (so for a shorter correlation time) demonstrated that the T1H relaxation 
was situated at the right site of the minimum of the correlation curve. This allowed to confirm 
the T2H results, i.e. that the longer T1H decay time measured for the heat treated specimen 
pointed to a reduced molecular mobility due to cross-linking.  
Since both FT-IR and solid-state 13C-CP/MAS NMR spectroscopy (results not shown) did not 
show any sign of ester (cross-linking) functionalities, it was concluded that the degree of cross-
linking introduced by the heat treatment was low.  
A similar thermal ageing phenomenon with the formation of crosslinks was already described by 
Bodek and Bak (1999) for a chitosan-diclofenac sodium system: thermal ageing of chitosan 
pellets at temperatures between 20 and 80°C reduced the polarisation and dielectric properties 
due to cross-linking (resulting in additional confinement of molecular movements). This 
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phenomenon was confirmed by IR spectroscopy and the influence on molecular weight 
distribution. 
 
Figure 5 and Table 3 show the pharmacokinetic parameters of insulin after intranasal 
administration of SD 25/75 powder heated at 60°C. Using SD 25/75 heat treated at 60°C during 
1 h resulted in a significantly higher Cmax compared to the other formulations heated at 60°C. The 
highest bioavailability (18.5%) obtained after heat treatment at 60°C during 1h corresponded with 
the highest uptake of SNF (Figure 2). After heat treatment at 60°C powders with similar G’ and 
G’’ values resulted in a similar bioavailability, except for the powder heated at 60°C during 4 h 
which had a significantly lower value (0.05 > P > 0.01) compared to the powder heated during 1 
hour. 
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Figure 5. Influence of heat treatment of Amioca®/Carbopol® powder (ratio: 25/75) (SD 25/75) at 60°C 
during 0min (♦), 30min (■), 1h (▲) and 4h (●) on insulin serum concentration profiles (mean ± S.D.) 
after nasal delivery to rabbits of SD 25/75 powder formulation (1IU insulin/mg). 
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Table 3. Absolute bioavailability, Cmax and tmax (mean ± S.D.) of insulin after nasal delivery to rabbits of 
Amioca®/Carbopol® 974P powders (ratio: 25/75) (1 IU insulin/mg) after different heat treatment 
procedures in comparison with a reference formulation. 
Heat treatment procedure BA (%)  Cmax (µIU/ml) tmax (min) n 
without heat treatment 
(reference) 
8.2 ± 3.0 352.3 ± 150.7* 33.6 ± 9.0 7 
60 °C - 30 min 12.4 ± 5.1 513.0 ± 318.3* 37.2 ± 7.7 7 
60 °C - 1h 18.5 ± 13.8 1092.9 ± 378.7 37.9 ± 10.0 7 
60 °C - 4h 5.4 ± 1.8* 227.5 ± 81.0*** 36.9 ± 8.0 7 
 
120 °C - 30 min 
 
26.4 ± 21.9b 
 
3288.0 ± 1345.1b 
 
33.8 ± 6.8 
 
6 
120 °C - 1h 36.5 ± 11.0c 1178.3 ± 494.6a 36.4 ± 6.3 8 
120 °C - 4u 19.3 ± 17.3d 1967.5 ± 1294.0a 22.5 ± 12.2d 6 
 
*  significantly lower than SD 25/75 treated at 60 °C during 1h (0.05 ≥ P > 0.01) 
***  significantly lower than SD 25/75 treated at 60 °C during 1h ( P ≤ 0.001) 
 
a  significantly higher than reference formulation (0.05 ≥ P > 0.01) 
b  significantly higher than reference formulation (0.01 ≥ P > 0.001) 
c significantly higher than reference formulation ( P ≤ 0.001) 
d significantly lower than SD 25/75 treated at 120 °C during 1 h (0.05  ≥ P > 0.01) 
 
 
Figure 6 and Table 3 show the serum profile and the pharmacokinetic parameters of insulin after 
intranasal administration of SD 25/75 powder heated at 120°C. Heat treatment at 120°C during 
1h resulted in the highest bioavailability (36.5%), whereas heating the SD 25/75 powder at 120°C 
during 4 h gave a significantly lower bioavailability and tmax (0.05  ≥ P > 0.01). The fast liquid 
saturation of the powder heated during 4h (Figure 3) correlated with a significantly lower tmax of 
22.5 min (Table 3). The high bioavailability obtained with the SD 25/75 powder heated at 120°C 
during 1h was correlated with a high water absorbing capacity (Figure 3).  
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Figure 6. Influence of heat treatment of Amioca®/Carbopol® powder (ratio: 25/75) (SD 25/75) at 120°C 
during 0min (♦), 30min (■), 1h (▲) and 4h (●) on insulin serum concentration profiles (mean ± S.D.) 
after nasal delivery to rabbits of SD 25/75 powder formulation (1IU insulin/mg).  
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The reduced mucociliairy clearance and prolonged residence time of the formulation stimulated 
insulin uptake as the formation of a gelled system after contact of the SD powder with the nasal 
mucosa provided a high drug concentration at the epithelial absorptive surface (Illum et al., 
2001). Although the highest G’ and G’’ values were obtained after heat treatment at 120°C during 
4h (in combination with the fastest liquid uptake), the nasal insulin bioavailability was lower and 
highly variable (19.3 ± 17.3%). A possible explanation for this phenomenon is that insulin is 
entrapped in the highly viscous and elastic polymeric network and is not able to diffuse from this 
dense structure towards the nasal capillaries. The reason for the high standard deviations of BA 
and Cmax values is not fully understood. The variability could be due to formulation effects (e.g. 
particle size) or differences in nasal anatomy of the test animals (e.g. nasal length, the bend from 
the nostrils into the cavity, the structure of the turbinates). 
 
The higher nasal absorption of insulin observed with this mucoadhesive powder is not only due 
to the prolonged residence time in the nasal cavity (Pereswetoff-Morath, 1998). An important 
role is also played by the fast hydration rate of the powder upon contact with the nasal mucosa, 
53
Chapter 4.1. Influence of heat treatment on Amioca®/Carbopol® mixtures used as carriers for nasal delivery of insulin 
 
thereby shrinking the epithelial cells and probably opening the tight junctions (Edman and Bjork, 
1992; Illum et al., 1994). Since this paracellular process (opening of the tight junctions) is 
reversible, a faster absorption of drugs transported via this pathway will mainly occur during the 
short period when tight junctions are opened (Pereswetoff-Morath, 1998) after hydration of the 
polymers. This explained the low tmax values measured after nasal insulin administration in SD 
25/75 powders.  
 
The improvement of bioavailability via thermal treatment was reproducible as repeating the entire 
procedure (i.e. heat treatment at 120°C for 1h, drug loading, freeze-drying, bioavailability testing, 
...) did not result in significant differences for water uptake, rheological properties and 
pharmacokinetic parameters of the insulin-containing replicates.  
 
 4.1.3.2. Optimisation of heat treatment procedure 
 
The previous data indicated that insulin bioavailability was maximized after heat treatment of the 
SD 25/75 powder at higher temperature (i.e. at 120°C during 1 h). In this part of the study, it was 
investigated if the behaviour of the powder could be optimized by varying the treatment 
temperature between 110 and 130°C. 
From the results shown in Figure 7 and Table 4 it was clear that there was no significant 
difference between the pharmacokinetic parameters after the additional heat treatments. This was 
also reflected in their similar SNF uptake profiles (Figure 8). 
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Figure 7. Influence of heat treatment of Amioca®/Carbopol® 974P powder (ratio: 25/75) (SD 25/75) at 
110°C (-), 120°C (■) and 130°C (●) during 1h on insulin serum concentration profiles (mean ± S.D.) after 
nasal delivery to rabbits of SD 25/75 powder formulation (1IU insulin/mg). 
 
 
Table 4. Influence of heat treatment of Amioca®/Carbopol® 974P powder (ratio: 25/75) (SD 25/75) on 
the pharmacokinetic parameters (mean ± S.D.) of insulin after nasal delivery to rabbits.  
Heat treatment BA (%)  Cmax (µIU/ml) tmax  (min) n 
110 °C - 1h 21.0 ± 11.2 926.5 ± 578.7 40.7 ± 11.7 8 
120 °C - 1 h 36.5 ± 11.0** 1178.3 ± 494.6 36.4 ± 6.3 8 
130 °C - 1h 25.4 ± 13.5* 1253.4 ± 774.7 27.7 ± 9.7 8 
*  significantly higher than the reference formulation (0.05 ≥ p > 0.01) 
**  significantly higher than the reference formulation (0.01 ≥ p > 0.001) 
 
 
55
Chapter 4.1. Influence of heat treatment on Amioca®/Carbopol® mixtures used as carriers for nasal delivery of insulin 
 
0
5
10
15
20
25
30
35
0 10 20 30 40 50 6
Time (min)
SN
F 
up
ta
ke
 (m
l/g
)
0
 
Figure 8. Influence of heat treatment of Amioca®/Carbopol® 974P powder (ratio: 25/75) (SD 25/75) at 
110°C (-), 120°C (■) and 130°C (●) during 1h on simulated nasal fluid uptake profiles (n=3, mean ± S.D.) 
. 
 
 4.1.3.3. Spray-drying versus physical mixing 
 
The importance of using a spray-dried mixture of Amioca® starch and Carbopol® 974P was 
emphasised in Figure 9 and Table 5. Nasal delivery of heat treated (120°C, 1 h) powders based on 
a physical mixture of Amioca® starch and Carbopol® 974P resulted in a significantly (P<0.001) 
lower absorption of insulin. Also a significant lower Cmax was reported (P<0.001).  
Callens et al. (1999) investigated nasal bioavailability of insulin in physical mixtures consisting of 
drum-dried waxy maize starch (DDWM) or maltodextrins combined with Carbopol® 974P. The 
highest bioavailability (14.4 %) was obtained with a powder formulation consisting of 
DDWM/Carbopol® 974P (ratio: 90/10) containing 1 IU insulin/mg powder. In contrast, Pringels 
et al. (2007) obtained a bioavailability of 22.4 % using a co-spray-dried starch/Carbopol® mixture 
(ratio: 25/75) (SD 25/75). In this study, nasal insulin BA after heat treatment of the co-spray-
dried Amioca® /Carbopol® 974P 25/75 increased to 36.5%. 
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Figure 9. Insulin serum concentration-time profiles (mean ± S.D.) after nasal delivery of heat treated 
(120°C, 1h) Amioca®/Carbopol® 974P powders (1 IU insulin/mg) manufactured via co-spray-drying (SD 
25/75, ■) and physical mixing (PM 25/75, ♦).  
 
Table 5. Absolute bioavailability, Cmax and tmax (mean ± S.D.) of insulin after nasal delivery to rabbits of 
heat treated (120°C, 1h) Amioca®/Carbopol® 974P powders (1 IU insulin/mg) manufactured via co-
spray-drying (SD 25/75) and physical mixing (PM 25/75). 
Formulation BA (%)  Cmax  (µIU/mL) tmax (min) n 
SD 25/75 36.5 ± 11.0*** 1178.3 ± 494.6*** 36.4 ± 11.0* 8 
PM 25/75 5.6 ± 3.4 144.8 ± 110.3 53.6 ± 10.0 8 
*** significantly higher than PM 25/75 (P ≤ 0.001) 
*   significantly lower than PM 25/75 (0.05 ≥ P > 0.01) 
 
 
The reduced drug absorption from the physical mixture could be attributed to the slower and 
lower hydration of this formulation compared to the equivalent spray-dried formulation (Figure 
10). This was reflected in a significantly higher tmax (0.05 ≥ P > 0.01) obtained after nasal 
administration of insulin incorporated in the physical mixture. 
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Figure 10. Simulated nasal fluid uptake (n=3, mean ± S.D.) by SD 25/75 treated at 120°C during 1h (■) 
and PM 25/75 treated at 120°C during 1h (♦) powder. 
 
 4.1.3.4. Heat treatment of Amioca®/Carbopol® 974P 50/50 
 
To investigate if the positive influence of the heat treatment procedure on bioavailability could be 
extended to other ratios of spray-dried Amioca®/Carbopol® powders, SD 50/50 underwent 
different heat treatments (40°C - 4 h and 80°C - 1 h). Compared to SD 25/75 powders the heat 
treatment was done at a lower temperature due to the larger Amioca fraction in the formulation 
as the starch/poly(acrylic acid) network was broken at higher temperature due to thermal 
degradation of the starch fraction. Figure 11 and Table 6 show that there was no significant 
difference in pharmacokinetic parameters after nasal insulin administration between the reference 
formulation and the heat treated SD 50/50 powder.  
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Figure 11. Influence of heat treatment of Amioca®/Carbopol® 974P powder (ratio: 50/50) (SD 50/50) at 
80°C during 1h (■), 40°C during 4h (▲) and without heat treatment (♦) on insulin serum concentration 
profiles (mean ± S.D.) after nasal delivery to rabbits of SD 50.50 powder formulation (1IU insulin/mg). 
 
Table 6. Absolute bioavailability, Cmax and tmax (mean ± S.D.) of insulin after nasal delivery to rabbits of 
Amioca®/Carbopol® 974P powders (ratio: 50/50) (1 IU insulin/mg) after different heat treatment 
procedures in comparison with a reference formulation (i.e. without heat treatment). 
Heat treatment procedure BA (%) Cmax  (µIU/mL) tmax (min) n 
 reference formulation 5.3 ± 2,3 179.3 ± 90,7 46.3 ± 19.5 8 
80°C - 1h 6.1 ± 3.0 224.3 ± 171.9 42.1 ± 9.9 8 
40°C - 4h 6.1 ± 4.1 285.3 ± 163.3 27.3 ± 19.1 8 
 
No significant difference was seen between the SNF uptake profiles (Figure 12) of the reference 
formulation and the heat treated powders. The lower bioavailability values could be due to the 
lower Carbopol® 974P concentration in the formulation which decreased the water absorbing 
capacity of the powder. As pure Amioca® is water soluble, most of the water-absorbing and 
viscosity-enhancing capacities of the powder carrier is due to Carbopol® 974P. Callens et al. 
(2003) investigated the rheological capacities of Amioca®/Carbopol® 974P powder in different 
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ratios and concluded that viscosity values, related with the water-absorbing properties of 
Carbopol® 974P, were higher when more poly(acrylic acid) was incorporated in the formulation. 
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Figure 12. Influence of heat treatment of Amioca®/Carbopol® 974P powder (ratio: 50/50) (SD 50/50) at 
80°C during 1h (■), 40°C during 4h (▲) and without heat treatment (♦) on simulated nasal fluid uptake 
(n=3, mean ± SD). 
 
4.1.4. Conclusion 
 
The present study demonstrated that nasal absorption of the model peptide insulin could be 
improved via heat treatment of a spray-dried Amioca®/Carbopol® 974P powder (ratio: 25/75) 
prior to the addition of active ingredient. Heat treatment of the powder at 120°C during 1h 
resulted in low levels of crosslinking which are responsible for a fast liquid uptake rate as well as 
higher elasticity and viscosity values. After nasal administration of an insulin-containing powder 
to rabbits a reproducible absolute bioavailability of 30% was obtained.  
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Chapter 4.2. Influence of heat treatment on spray-dried mixtures of Amioca® 
starch and Carbopol® as carriers for the nasal delivery of salmon calcitonin 
and somatropin 
 
 4.2.1. Introduction 
 
All heat treatment experiments in Chapter 4.1. were performed with insulin as model peptide 
(5808 Da). Due to a low degree of cross-linking between starch and poly(acrylic acid) after heat 
treatment of the Amioca®/Carbopol® 974P 25/75 powder at 120°C during 1h, water uptake, 
elasticity (G’) and viscosity (G’’) values increased. This improved insulin absorption and 
bioavailability after nasal delivery of the model peptide. This part of the study aims to investigate 
if the principle of cross-linking to improve nasal bioavailability could be extended to other 
peptides. In order to investigate the universal applicability of this procedure to improve 
bioavailability, the powder carrier was combined with a smaller (salmon calcitonin, 3432 Da) and 
a larger (somatropin, 22 kDa) peptide. 
 
 4.2.2. Materials and methods 
 
 4.2.2.1. Materials 
 
Miacalcic® syringe (100 IU/ml) and Miacalcic® nasal spray (100 IU/dose) (salmon calcitonin) 
were purchased from Novartis Pharma (Brussels, Belgium). Genotonorm® (12 mg/ml) 
(somatropin) was obtained from Pfizer (Puurs, Belgium). The spray-dried mixture of Amioca® 
starch and Carbopol® 974P (ratio: 25/75, w/w) (SD 25/75) (batch: 13724-4A) was prepared by 
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National Starch and Chemical Company (Bridgewater, New Jersey, USA). All other chemicals 
were of analytical grade. 
 
 4.2.2.2. Heat treatment of Amioca®/Carbopol® 974P 25/75 
 
SD 25/75 powder was packed in sealed Alu-bags and stored for 1 h in an oven (Memmert, type 
U50, Schwabach, Germany) at 120°C. 
 
4.2.2.3. Preparation of formulations  
 
4.2.2.3.1. Salmon calcitonin solution for intravenous administration 
A salmon calcitonin solution of 20 IU/ml was prepared by diluting Miacalcic® (100 IU/ml) in a 
phosphate buffered saline solution (pH 7.4) of which 0.5 ml (10 IU/0.5ml) was administered 
intravenously to rabbits (n = 2). 
 
4.2.2.3.2. Somatropin solution for intravenous administration 
A somatropin solution of 0.145 mg/ml was prepared by diluting Genotonorm® (12mg/ml) in a 
phosphate buffered saline solution (pH 7.4) of which 0.3 ml (43.5 µg/0.3ml) was administered 
intravenously to rabbits (n = 2). 
 
4.2.2.3.3. Nasal powder formulations 
After heat treatment of the spray-dried Amioca®/Carbopol® 974P powder (ratio 25/75) at 120°C 
during 1h, 500 mg powder was dispersed in 15 ml distilled water, followed by a neutralisation 
step to pH 7.4 using NaOH 2M. Afterwards the salmon calcitonin solution (Miacalcic®) or 
somatropin solution (Genotonorm®) were added to obtain a final concentration of 2 IU salmon 
calcitonin or 0.045 mg somatropin per mg powder.  
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To obtain the powders, the aqueous dispersions were freeze-dried using an Amsco-Finn Aqua 
GT4 freeze-dryer (Amsco, Germany). The dispersions were frozen to 228 K within 175 min at 
1000 mbar. Primary drying was performed at 258 K and at a pressure varying between 0.8 and 1 
mbar during 13 h, followed by secondary drying at elevated temperature (283 K) and reduced 
pressure (0.1 - 0.2 mbar) for 7 h. After freeze-drying the powders were sieved (63 µm) at low 
relative humidity (20 %) and ambient temperature. The fractions below 63 µm were stored in a 
desiccator at 4 - 8 °C until use. 
   
 4.2.2.4. Nasal bioavailability study 
 
The protocol of the animal experiments was approved by the Ethics Committee of the Institute 
for Agricultural and Fisheries Research (ILVO) (Merelbeke, Belgium). New Zealand white rabbits 
(3.0 ± 0.5 kg) were fasted 16 h prior to the experiment. Water was available ad libitum. They were 
sedated with an intramuscular injection of 0.05 ml/kg Placivet® (Codifar, Florida, USA) 
immediately after administration. A first group of rabbits received 10 IU salmon calcitonin or 
43.5 µg somatropin intravenously. Ten mg powder formulation (equivalent to 20 IU salmon 
calcitonin or 0.45 mg somatropin) was administered in each nostril of a second group of rabbits 
using polyethylene tubes (Medisize, Hillegom, The Netherlands). The powder was released from 
the tubes using a syringe containing 1 ml compressed air (2.5 bar). This device was based on a 
system developed by Sørensen (1991). During the salmon calcitonin study a third group (n=6) 
received one dose of the commercial Miacalcic® spray (100 IU/dose), alternating in left and right 
nostril of the rabbits. 
The tubes were filled under conditions of low relative humidity (20 %) and ambient temperature. 
Blood samples were collected from the ear veins at -5, 1, 5, 10, 15, 20, 30, 40, 50 and 60 min after 
intravenous administration at -5, 2, 5, 10, 15, 20, 25, 30, 35, 45, 60, 90, 120, 150 and 180 min after 
nasal delivery of the salmon calcitonin formulation and at -5, 10, 20, 30, 40, 50, 60, 75, 90, 120, 
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180 and 240 min after nasal somatropin delivery. The sera were separated by centrifugation 
(700g, 5 min) and samples were stored frozen at –20 °C until ELISA-analysis. The samples 
containing salmon calcitonin and somatropin were analysed using an Enzyme-Linked 
Immunosorbent kit (Active® Ultra-sensitive salmon calcitonin and DSL-10-1900, Diagnostic 
Systems Laboratories, Texas, USA). The fluorescence measurements were carried out on a 
fluorometer (Wallac 1420 multilabel counter, PerkinElmer, Turku, Finland) at 450 nm.  
The basal levels of salmon calcitonin were determined by collecting blood samples from the ear 
veins of an untreated rabbit at -5, 2, 5, 10, 15, 20, 25, 30, 35, 45, 60, 90, 120, 150 and 180 min (n 
= 1).  
   
 4.2.2.5. Statistical analysis 
 
The individual serum concentration-time profiles were analysed by MW/Pharm version 3.15 
(Medi-ware, Utrecht, The Netherlands) and the maximum calcitonin and somatropin serum 
concentrations (Cmax) and tmax values were determined from the individual serum concentration-
time profiles. In order to calculate the absolute bioavailability (BA) the weight of the rabbits and 
the concentration of the salmon calcitonin or somatropin in the powder formulations were taken 
into account. The influence of the calcitonin powder formulations on the absolute bioavailability, 
Cmax and tmax of salmon calcitonin was analysed using One-way ANOVA. Normal distribution of 
the data was tested using the Kolmogorov-Smirnov test and the homogeneity of variances was 
tested using the Levene’s test. Because the variances of Cmax values were not homogeneous, the 
data were logarithmically transformed.  
The statistical analysis of the somatropin data were performed with an Independent Sample T-
test. Normality of the data was tested using the Kolmogorov-Smirnov test and the homogeneity 
of variances was tested using the Levene’s test.  
The software program SPSS version 15.0 was used for statistical analysis. 
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4.2.3. Results and discussion 
 
 4.2.3.1. Salmon calcitonin 
 
In Figure 1 the salmon calcitonin concentration versus time profile after intravenous 
administration of 10 IU salmon calcitonin to rabbits is shown. The basal levels of calcitonin were 
determined in serum samples of untreated rabbits and varied between 15 and 20 pg/ml (Figure 
2). As these concentrations were not negligible in comparison with the concentrations obtained 
after nasal delivery of the peptide, the basal levels were taken into account to calculate the 
absolute bioavailability. Basal calcitonin levels were subtracted from the salmon calcitonin serum 
concentration from treated rabbits before calculation of the pharmacokinetic parameters. 
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Figure 1. Salmon calcitonin serum concentration-time profiles after intravenous administration of 10 IU 
salmon calcitonin to rabbits (n = 2).  
 
The salmon calcitonin serum concentration-time profiles obtained after nasal delivery of non-
heated SD 25/75, heat treated SD 25/75 (120°C, 1h) and Miacalcic® spray are shown in Figure 2. 
Table 1 shows that Cmax of salmon calcitonin after heat treatment of SD 25/75 was significantly 
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higher (0.05 ≥ P > 0.01) than the non-heat treated SD 25/75 powder. Although the Miacalcic® 
spray contained a 2.5-fold higher dose, bioavailability was not significantly different in 
comparison with the mucoadhesive powder formulations. In contrast, Cmax of Miacalcic® was 
significantly higher (P ≤ 0.001) than the untreated SD 25/75 powder. As discussed in Chapter 
4.1. the higher bioavailability of the heat-treated samples correlated with a higher water-absorbing 
capacity and increased viscosity and elasticity values. The fast hydration rate of the powder 
probably opened the tight junctions as the epithelial cells shrinked, whereas the higher viscosity 
reduced mucociliairy clearance and prolonged the residence time of the formulation in the 
nostrils. 
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Figure 2. Basal serum levels (x) and serum concentration-time profiles (mean ± S.D.) of salmon 
calcitonin after nasal delivery of Miacalcic® spray (100 IU/dose) (▲) and Amioca®/Carbopol® (ratio: 
25/75) (SD 25/75) powder after heat treatment at 120°C during 0h (reference formulation) (♦) and 1h (■) 
(2 IU salmon calcitonin/mg). 
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Table 1. Absolute bioavailability, Cmax and tmax (mean ± S.D.) of salmon calcitonin formulated in nasal 
Miacalcic® spray (100 IU/dose) and nasal Amioca®/Carbopol® (ratio: 25/75) (SD 25/75) powder after 
heat treatment at 120°C during 0h (reference formulation) and 1h (2 IU salmon calcitonin/mg). 
Formulation BA (%)  Cmax (pg/ml) tmax (min) n
SD 25/75 reference  5.1 ± 2.1 55.4 ± 22.5 16.8 ± 6.8 8 
SD 25/75 120°C 1h 9.6 ± 5.6 112.2 ± 67.6* 10.5 ± 6.6 8 
Miacalcic® spray 6.4 ± 2.3 168.1 ± 49.8*** 20.3 ± 12.0 8 
*  significantly higher than  SD 25/75 reference formulation (0.05 ≥ P > 0.01) 
***  significantly higher than SD 25/75 reference formulation ( P ≤ 0.001) 
 
Hinchcliffe et al. (2005) administered salmon calcitonin (dose: 17 IU/kg) via 3 formulations in 
the nostrils of sheep: control solution, Miacalcic® spray and calcitonin/chitosan solution. The 
relative bioavailability in comparison with a subcutaneous injection, were 0.3, 0.6 and 1%, 
respectively.  
The nasal absorption of salmon calcitonin is lower than insulin despite its lower molecular 
weight. This could be explained by the higher susceptibility of salmon calcitonin to enzymatic 
degradation in comparison with insulin (Gizurarson and Bechgaard, 1991; Ishikawa et al., 2001). 
 
  4.2.3.2. Somatropin 
 
In Figure 3 the somatropin concentration versus time profile after intravenous administration of 
43.5 µg somatropin to rabbits is shown. Because basal levels of growth hormone in plasma 
amount to less than 1 ng/ml and are negligible in comparison with the concentrations obtained 
after nasal delivery of the peptide, they were not taken into account to calculate bioavailability 
(Juul and Jorgensen, 1996; Nindl et al., 2001). 
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Figure 3. Somatropin serum concentration-time profiles after intravenous administration of 43.5 µg 
somatropin to rabbits (n = 2).  
 
As shown in Figure 4 serum concentration-time profiles of somatropin incorporated in heated 
SD 25/75 were higher than the reference formulation. A bioavailability of 28% and Cmax of 62 
ng/ml (Table 2) were reached after heat treatment which were significantly higher than the 
reference formulation (p ≤ 0.001) (mean ± S.D.).  
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Figure 4. Serum concentration-time profiles after nasal delivery of somatropin formulated in 
Amioca®/Carbopol® (ratio: 25/75) (SD 25/75) powder after heat treatment at 120°C during 0h (reference 
formulation) (♦) and 1h (■) (0.045 mg somatropin/mg). 
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Table 2. Absolute bioavailability, Cmax and tmax (mean ± S.D.) of somatropin formulated in 
Amioca®/Carbopol® (ratio: 25/75) (SD 25/75) powder after heat treatment at 120°C during 0h (reference 
formulation) and 1h (0.045 mg somatropin/mg). 
Formulation BA (%) Cmax  (ng/ml) tmax (min) n 
SD 25/75 reference 7.4 ± 4.0 15.9 ± 7.7 54.6 ± 12.2 8 
SD 25/75 120°C 1h 27.9 ± 8.0*** 61.7 ± 13.0*** 57.0 ± 16.2 8 
*** significantly higher than SD 25/75 reference formulation (p ≤ 0.001) 
  
Kagatani et al. (1998) nasally administered human growth hormone in a solution (2.5 mg/kg) 
with acylcarnitine to rats. The addition of this absorption enhancer increased bioavailability from 
0.4% to 17%. Rabbits received growth hormone via the nose in a formulation with 
didecanoylphosphatidylcholine (DDPC) or α-cyclodextrin (α-CD) (0.3mg/kg). Bioavailability 
increased from 8% (control formulation) to 22 and 24% in the DDPC- and α-CD-formulation, 
respectively (Vermehren et al., 1996). After nasal delivery to sheep of somatropin in a chitosan 
powder formulation (0.3 mg/kg), a relative bioavailability of 14% was measured (Cheng et al., 
2005). A thiomer/glutathione microparticulate delivery system containing somatropin for nasal 
delivery gave a bioavailability of 8% in rats (Leitner et al., 2004). Bioavailability obtained with the 
Amioca®/Carbopol® 974P formulation was remarkably higher than the cited experimental results. 
Nasal delivery of somatropin can be an interesting alternative for subcutaneous injections 
because the endogenous pulsatile secretory pattern of human growth hormone may be better 
mimicked due to the rapid nasal absorption. The results of this study are in contrast with the 
hypothesis in literature that the clinical applicability of this peptide is compromised by its low 
bioavailability (1-2%) due to a high molecular weight, high hydrophilicity and metabolic liability 
(Leitner et al., 2004). 
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 4.2.4. Conclusion 
 
The present study demonstrated that Amioca®/Carbopol® 974P powder after heat treatment 
(120°C, 1h) is not only a promising delivery platform for insulin, but also for other peptides like 
salmon calcitonin and somatropin. For both peptides a significant increase of bioavailability was 
observed after nasal administration of heat treated SD 25/75: a 2-fold and 4-fold increase of 
bioavailability for calcitonin and somatropin, respectively. 
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Abstract  
 
A mucoadhesive combination of a maize starch (Amioca®, mainly consisting of amylopectine) 
and a cross-linked acrylic acid-based polymer (Carbopol® 974P) was spray-dried with metoprolol 
tartrate (used as model molecule) in order to develop a powder suitable for nasal drug delivery via 
a one-step manufacturing process. The bioavailability of metoprolol tartrate after nasal 
administration of this powder to rabbits was compared with powders manufactured via other 
procedures: (a) freeze-drying of a dispersion prepared using the co-spray-dried powder, (b) 
freeze-drying of a dispersion prepared using a physical mixture of drug and mucoadhesive 
polymers. After coprocessing via spray-drying a low bioavailability (BA 10.8 ± 2.3%) was 
obtained, whereas manufacturing procedures based on freeze-drying yielded a higher BA: 37.9 ± 
12.8% using the coprocessed powder and 73.6 ± 24.9% using the physical mixture. The higher 
bioavailability was due to the deprotonation of poly(acrylic acid) during neutralisation of the 
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dispersion prior to freeze-drying. This induced repulsion of the ionised carboxylgroups and a 
lower interaction between poly(acrylic acid) and starch, creating a less compact matrix upon 
hydration of the polymer and allowing an easier escape of metoprolol tartrate from the matrix. 
This study showed that co-processing of a mucoadhesive Amioca®/Carbopol® 974P formulation 
with metoprolol tartrate via co-spray-drying did not provide any added value towards the 
bioavailability of the drug after nasal administration of the mucoadhesive powder. 
 
Keywords: co-spray-drying as all-in-one process; nasal administration; Amioca®/Carbopol® 974P 
powder formulation; metoprolol tartrate 
 
5.1. Introduction 
 
The nasal cavity offers great opportunities for systemic drug delivery as the nasal epithelium has a 
large surface area which is thin and highly vascularized (Hinchcliffe and Illum, 1999). The nasal 
route is also suitable for self-medication and absorbed drugs pass directly into the systemic 
circulation thereby avoiding hepato-gastrointestinal first-pass metabolism (Chang and Chien, 
1984; Chien and Chang, 1985). In spite of the potential of nasal drug delivery, some limitations 
have to be overcome: (a) only a low drug dose can be administered as the amount of liquid or 
powder delivered to the nose is limited to 150 µl and 20 mg, respectively (Hinchcliffe and Illum, 
1999; Teshima et al., 2002), (b) enzyme activity in the nasal cavity, (c) residence time of the 
formulation is limited by mucociliairy clearance and (d) the mucus layer and nasal epithelium are 
barriers for drug absorption (Ugwoke et al., 2005). This study focussed on the development of a 
bioadhesive nasal delivery system that provides a prolonged contact between the formulation and 
the absorptive sites in the nasal cavity by reducing the mucociliairy clearance rate. 
The mucoadhesive powder formulation used in this study was a spray-dried combination of a 
maize starch (Amioca®, mainly consisting of amylopectine) and a cross-linked acrylic acid-based 
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polymer (Carbopol® 974P) that amplified the mucoadhesive capacity of the formulation (Callens 
and Remon, 2000). Ameye et al. (2005) showed that co-processing of the powder mixture via 
spray-drying yielded a product with a higher buccal bioadhesive capacity and bioavailability 
compared with a physical mixture of Amioca® starch and Carbopol®. When this powder carrier 
was used in previous studies for nasal delivery (Callens and Remon, 2000; Pringels, 2005), post-
processing of spray-dried Amioca®/Carbopol® powder was required to incorporate the drug into 
the formulation: the drug was mixed with an aqueous dispersion prepared from the 
mucoadhesive powder and after freeze-drying the solid cake  was sieved to obtain a powder with 
particle size suitable for nasal delivery. 
In this study, it was investigated if this time-consuming procedure could be replaced by a one-
step manufacturing process using spray drying to co-process an aqueous dispersion of Amioca®, 
Carbopol® and drug into a mucoadhesive powder. This single-step manufacturing technique 
would not only reduce the number of unit operations, improve production efficiency and reduce 
costs, it also yields a homogeneous and free-flowing powder (Gonnissen et al., 2008) with an 
optimal particle size for nasal delivery. 
A mucoadhesive powder containing Amioca®, Carbopol® and metoprolol tartrate (used a model 
drug) was manufactured via different procedures to evaluate the effect of processing on the 
bioavailability of metoprolol tartrate after nasal administration of the mucoadhesive powder 
formulations to rabbits: the formulations were co-processed via spray-drying or prepared via 
freeze-drying of an aqueous dispersion of the different ingredients. It was also investigated if the 
heat treatment principle (Chapter 4) could be extended to small molecules such as metoprolol 
tartrate by additionally heating all formulations at 120°C during 1h before nasal delivery in 
rabbits. 
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5.2. Materials and methods 
  
5.2.1. Materials 
 
Metoprolol tartrate was kindly donated by EQ Esteve (Barcelona, Spain). The spray-dried 
mixture of Amioca® starch and Carbopol® 974P (ratio: 25/75, w/w) (SD 25/75) (batch: 13724-
8E) was prepared by National Starch and Chemical Company (Bridgewater, New Jersey, USA). 
All other chemicals were of analytical grade. 
 
5.2.2. Preparation of metoprolol tartrate formulations 
  
 5.2.2.1. Intravenous and nasal PBS formulations 
A metoprolol tartrate solution of 2 mg/ml was prepared in a phosphate buffered saline solution 
(PBS, pH 7.4) (2.38 g Na2HPO4.2H2O, 0.19 g KH2PO4 and 8.0 g NaCl per liter distilled water), of 
which 300 µl was intravenously administered to rabbits (n = 6). 
A metoprolol tartrate solution of 64 mg/ml was prepared in PBS (pH 7.4), of which 50 µl per 
nostril was nasally administered to the rabbits (n = 6). 
 
5.2.2.2. Nasal powder formulations 
 
5.2.2.2.1. Co-processing of Amioca®, Carbopol® and metoprolol tartrate via spray-drying  
A dispersion of 12 g MT and 30 g SD 25/75 was prepared in 1 l distilled water and homogenised 
with a rotor-stator mixer (L4RT, Silverson, East Longmeadow, USA) during 5 minutes. This 
aqueous dispersion was diluted to a volume of 3 l and spray-dried in a lab-scale Mobile Minor 
spray-dryer (GEA NIRO, Copenhagen, Denmark). The process conditions during spray-drying 
are shown in Table 1. The solution was fed to a two-fluid nozzle (diameter: 2 mm) at the top of 
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the spray-dryer by means of a peristaltic pump, type 520U (Watson Marlow, Cornwall, UK). The 
spray-dryer operated in co-current airflow. The spray-dried particles were collected in a reservoir 
attached to a cyclone, cooled down to room temperature and had a concentration of 5.7 mg MT 
per 20 mg powder. Part of this powder (further identified as Formulation M1) was stored in a 
sealed vial (room temperature, ambient relative humidity) prior to its further use. The remaining 
part of the spray-dried powder was stored in sealed Alu-bags and underwent a heat treatment in 
an oven (Memmert, type U50, Schwabach, Germany) for 1h at 120°C. The resulting powder after 
heat treatment is further identified as Formulation M2. 
 
Table 1. Process conditions during spray-drying in the Mobile Minor spray-dryer (GEA     
NIRO). 
Process Parameters  
Feed rate (g/min) 28.4 
Inlet Drying Air Temperature (°C) 160 
Outlet Drying Air Temperature (°C) 80 
Drying Gas Rate (kg/h) 80 
Atomising Air Pressure (bar) 2 
Compressed Air Flow (%) 60 
   
5.2.2.2.2. Freeze-drying of a co-processed mixture of Amioca®, Carbopol® and metoprolol tartrate 
500 mg M1 or M2 powder was dispersed in 15 ml distilled water and the pH of this dispersion 
was adjusted to 7.4 using 2M NaOH. After neutralisation a concentration of 4.8 mg MT per 20 
mg powder was obtained. The aqueous dispersion was freeze-dried using an Amsco-Finn Aqua 
GT4 freeze-dryer (Amsco, Germany). The dispersion was frozen to 228 K within 175 min at 
1000 mbar. Primary drying was performed at 258 K and at a pressure varying between 0.8 and 1 
mbar during 13 h, followed by secondary drying at elevated temperature (283 K) and reduced 
pressure (0.1 - 0.2 mbar) for 7 h. After freeze-drying the powder was sieved (63 µm) at low 
relative humidity (20 %) and ambient temperature. The fraction below 63 µm was stored in a 
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sealed vial (room temperature, ambient relative humidity) until use. The powders prepared using 
formulation M1 and M2 as starting material are further identified as formulation M3 and M4, 
respectively. 
 
5.2.2.2.3. Freeze-drying of a physical mixture of Amioca®, Carbopol® and metoprolol tartrate 
To obtain the powder identified as M5 an aqueous dispersion of 500 mg SD 25/75 and 201 mg 
MT in 15 ml distilled water was neutralised to pH 7.4 with NaOH (2M) and the resulting gel 
(containing 4.8 mg MT per 20 mg powder) was freeze-dried under the same conditions as 
described in 2.2.2.2. After lyophilisation the powder was sieved (63 µm) at low relative humidity 
(20%) and ambient temperature. This fraction below 63 µm was stored in a sealed vial (room 
temperature, ambient relative humidity) until use. The same procedure was used to prepare 
formulation M6 using SD 25/75 that was heat treated for 1h at 120°C prior to preparing the 
aqueous dispersion with MT. 
For sake of clarity an overview of the different formulations evaluated in this study and their 
production procedure is shown in Table 2. 
 
Table 2. Overview of the different powder formulations evaluated in this study and their production 
method 
Formulation Procedure 
M1 Coprocessing of SD 25/75 and MT via spray-drying 
M2 Coprocessing of SD 25/75 and MT via spray-drying and subsequent heat-
treatment 
M3 Freeze-drying of dispersion of Formulation M1 and subsequent sieving 
M4 Freeze-drying of dispersion of Formulation M2 and subsequent sieving 
M5 Freeze-drying of dispersion of SD/25 and MT and subsequent sieving 
M6 Freeze-drying of dispersion of heat-treated SD/25 and MT and subsequent 
sieving 
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5.2.3. Metoprolol tartrate assay in bioadhesive powders 
 
Metoprolol tartrate concentration in the powder formulations was determined by means of a 
calibration curve (concentration range: 0-3.5 mg metoprolol tartrate/ml distilled water). To 
extract metoprolol tartrate from the powder, 10 mg of each powder formulation (M1-M6) was 
dissolved in 5 ml distilled water before addition of 100 µl hydrochloric acid (37%). The 
suspension was centrifuged (700g, 5 min) and the supernatant was filtered over a cellulose 
membrane (Spartan 30/0.2 µm, Whatman, Dassel, Germany). Afterwards, the filtrate was 200-
fold diluted and injected on the HPLC column. 
 
5.2.4. Nasal bioavailability study 
   
5.2.4.1. Study design 
The protocol of the animal experiments was approved by the Ethics Committee of the Institute 
for Agricultural and Fisheries Research (ILVO) (Merelbeke, Belgium). New Zealand white rabbits 
(3.0 ± 0.5 kg) were fasted 16 h prior to the experiment. Water was available ad libitum. The 
rabbits were sedated with an intramuscular injection of 0.05 ml/kg Placivet® (Codifar, Florida, 
USA) immediately after administration. A first group of six rabbits received 0.6 mg MT 
intravenously. Ten mg powder (M1-M6) was administered in each nostril of a second group of 
six rabbits using polyethylene tubes (Medisize, Hillegom, The Netherlands). The powder was 
released from the tubes using a syringe containing 1 ml compressed air (2.5 bar). This device was 
based on a system developed by Sørensen (1991).  
The tubes were filled under conditions of low relative humidity (20 %) and ambient temperature. 
Blood samples were collected from the ear veins at -5, 1, 2, 5, 10, 15, 20, 30, 40, 50 and 60 min 
after intravenous administration and at -5, 10, 20, 30, 45, 60, 90, 120, 180, 240, 300 and 360 min 
after nasal delivery of the powder formulations. After adding heparin (LEO Pharma, Wilrijk, 
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Belgium) to the test tubes, plasma samples were separated by centrifugation (700g, 5 min) and 
samples were stored frozen at –20 °C until HPLC-analysis.  
 
5.2.4.2. HPLC analysis of metoprolol tartrate in plasma 
The metoprolol tartrate plasma concentrations were determined by a validated HPLC-
fluorescence method. All chemicals were of analytical grade. 
Samples were prepared by adding twenty microliters of an internal standard solution (5.6 µg/ml 
of alprenolol in water for analysis of blood samples after nasal administration and 1.9 µg/ml 
alprenolol in water for analysis of the intravenous samples) and 680 µl PBS to 300 µl plasma 
sample. The drug was extracted using a solid phase extraction (SPE) method. The SPE columns 
were conditioned consecutively with 1 ml methanol, 1 ml water and 1 ml PBS. Next, the plasma 
samples were spiked on the SPE columns. Columns were rinsed with 1 ml water and metoprolol 
tartrate was eluted with 1 ml methanol. The eluates were evaporated to dryness under a nitrogen 
flow, the residue was dissolved in 150 µl water and 20 µl was injected. The plasma concentrations 
were determined via a calibration curve. The standards for the calibration curve (20 µl of internal 
standard solution, 20 µl of a standard solution with known MT concentration in water, 280 µl 
blank plasma and 680 µl PBS) underwent the same treatment as the plasma samples. The 
concentrations of the standard solutions were 0.375; 0.5625; 0.75; 2.25; 5.625; 7.5; 15.0; 22.5 
µg/ml metoprolol tartrate in water for analysing the samples after nasal administration and 0.275; 
0.550; 0.875; 1.1; 1.925; 2.75; 4.4 µg/ml MT in water for analysing the intravenous samples. 
The HPLC equipment (Hitachi, Darmstadt, Germany) consisted of a solvent pump (L-7110 
pump) set at a constant flow rate of 0.800 ml/min, a fluorescence detector (L-7480) set at 275 
nm as excitation wavelength and 300 nm as emission wavelength, a LiChrosper® 100 CN column 
(5 µm, 250 mm x 4 mm) and precolumn LiChrosper® (5µm, 4 mm x 4 mm), an autosampler and 
injector (Gilson 234 autoinjector, Wisconsin, USA) with an injection loop of 50 µl (Valco 
Instruments Corporation, Houston, Texas, USA). The area under the curve was calculated with 
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the softwarepack D-7000 Multi-Manager (Merck, Darmstadt, Germany). The SPE-equipment 
consisted of OASIS HLB (1 ml, 30 mg) cartridges (Waters, Brussels, Belgium) and a 16-port 
vacuum manifold (Alltech Europe, Laarne, Belgium). The eluens had the following composition: 
5 ml of a 2 M NaH2PO4 buffer solution, 50 ml acetonitrile and 945 ml water, adjusted to pH 3 
with 150 µl fosforic acid. 
 
5.2.4.3. Validation of the HPLC method 
The HPLC analysis method was validated based on the guidelines stated by the International 
Conference on Harmonisation (ICH) for validation of analytical procedures (1994). The 
following criteria were considered: specificity, linearity, accuracy, precision, recovery, detection 
and quantification limit. 
 
Specificity 
Specificity is the ability to assess unequivocally the analyte in the presence of interfering 
components. It was evaluated by comparing the chromatogram of blank rabbit plasma with the 
one obtained after extraction of blank plasma spiked with metoprolol tartrate (conc 22.5 µg/ml) 
and the internal standard alprenolol (5.625 µg/ml). Figure 3 shows the chromatograms after 
extraction of (a) blank rabbit plasma and (b) plasma spiked with metoprolol tartrate and 
alprenolol.  
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(a) 
 
 
(b)
 
Figure 3. Specificity of the HPLC method. Chromatogram after extraction of (a) blank rabbit plasma and 
(b) plasma spiked with metoprolol tartrate (retention time after 17.7 min) and alprenolol (retention time 
after 58.1 min). 
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It could be concluded that the method is selective to determine metoprolol tartrate in rabbit 
plasma as no interfering peaks between metoprolol tartrate, alprenolol and endogenous 
components of plasma and components used for extraction were observed. 
 
Linearity 
The linearity of an analytical procedure is its ability (within a given range) to obtain test results 
which are directly proportional to the concentration of analyte in the sample.  
During validation of the HPLC method and analysis of the samples, several calibration curves 
were created. The linearity of the calibration curves was evaluated by the determination 
coefficient R². The mean determination coefficient (n=9) for the calibration curves was 0.9885 ± 
0.0120, which proves that the relationship between response (y) and concentration (x) was linear.  
 
The equation of the mean calibration curve was: y = 0.354 (± 0.060) x + 0.153 (± 0.098)  
with x = concentration of metoprolol tartrate (µg/ml)  
        y = fluorescence 
 
Accuracy 
The accuracy of an analytical procedure expresses the closeness of agreement between the value 
which is accepted either as a conventional true value or an accepted reference value and the value 
found. 
The accuracy was investigated at three concentration levels on rabbit plasma spiked with known 
amounts of metoprolol tartrate (0.375; 5.625 and 22.5 µg/ml). Afterwards, these solutions were 
treated following the described method. Each concentration was determined five times. The 
mean accuracies of the measured metoprolol tartrate concentrations from spiked plasma samples 
are listed in Table 4. 
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Table 4. Mean accuracies (± S.D.) (n=5) of determination of metoprolol tartrate in rabbit plasma. 
Accuracy (%) Concentration 
(µg/ml) Within-day Between-day 
0.375 99.9 ± 0.2 101.0 ± 1.9 
5.625 99.9 ± 0.0 99.9 ± 0.2 
22.5 100.1 ± 0.1 100.0 ± 0.2 
 
At the three concentrations tested, the mean values are within 15% of the actual concentration 
(Acceptance criteria: within 15% of the actual value) (Shah et al., 1992). It can be concluded that 
the method is accurate. 
 
Precision 
The precision of an analytical procedure expresses the closeness of agreement (degree of scatter) 
between a series of measurements obtained from multiple sampling of the same homogeneous 
sample under the prescribed conditions. Precision may be considered at three levels: repeatability 
(intra-assay precision), which is the precision under the same operating conditions over a short 
interval of time; intermediate precision (within-laboratory precision), which expresses within-
laboratory variations; and reproducibility which is the precision between different laboratories. 
Because all measurements were performed in the same laboratory, by the same person using the 
same equipment only the repeatability (within-day and between-day) of the measurements was 
evaluated (Table 5).  
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Table 5. Precision (expressed as coefficient of variation) of the HPLC method (n=3). 
Precision (%CV) Concentration 
(µg/ml) Within-day Between-day 
0.375 7.9 13.1 
0.75 - 6.4 
2.25 - 12.1 
5.625 1.3 13.1 
7.5 - 9.5 
15 - 9.5 
22.5 1.2 3.3 
 
Precision is expressed as the coefficient of variation (CV, %) of series of measurements for each 
standard concentration of the calibration curve (Lee et al., 2004). The acceptance criteria are 
coefficients of variation less than 15%, except for the lowest concentration, where it should not 
exceed 20% CV. Considering the results, it is clear that this method is precise to determine 
metoprolol tartrate in rabbit plasma. 
 
Recovery 
Sample preparation (extraction with organic solvents, evaporation of the solvent) can influence 
the amount of analyte in biological samples. Recovery can be expressed as the closeness of 
agreement (in %) between the peak surface areas of an extracted sample versus a non-extracted 
sample. The recovery was determined for three calibration standards of metoprolol tartrate 
(concentrations of 0.375µg/ml; 5.625 µg/ml and 22.5 µg/ml) and for the internal standard 
alprenolol (concentration: 5.625 µg/ml). The mean recoveries (± S.D.) for the calibration 
standards and for the internal standard are shown in Table 6. 
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Table 6. Mean recoveries (n=3) (± S.D.) for the calibration standards and for the internal standard. 
 Concentration 
(µg/ml) 
Recovery (%) 
metoprolol 0.375 80.0 ± 12.7 
 5.625 81.0 ± 10.2 
 22.5 88.4 ± 9.8 
alprenolol 5.625 83.6 ± 6.6 
 
 
Quantification limit (LOQ) 
 
The quantification limit is the lowest amount of analyte in a sample which can be adequately 
determined with suitable precision and accuray. Calculation of LOQ was based on the signal-to-
noise ratio. The analyte response at the LOQ should be at last 10 times the response compared to 
the blank response. 
 
Because the signal to noise ratio of the lowest calibration standard (0.375 µg/ml) was 11.53 ± 
2.15 and precision and accuracy values at the lowest metoprolol concentration were within the 
accepted limits (Shah et al., 1992), a concentration of 0.375 µg/ml was considered as limit of 
quantification.  
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5.2.4.4. Data analysis  
The individual serum concentration-time profiles were analysed by MW/Pharm version 3.15 
(Medi-ware, Utrecht, The Netherlands) and the maximum metoprolol tartrate serum 
concentrations (Cmax) and tmax values were determined from the individual serum concentration-
time profiles. Data were normalised (Cmax and AUC) in order to adjust for differences in 
administered dose (due to differences in the initial drug concentration of the formulations and 
degradation of the active ingredient during spray-drying). The influence of the powder 
formulations on the absolute bioavailability, Cmax and tmax of metoprolol tartrate was analysed 
using One-way ANOVA. Normal distribution of the data was tested using the Kolmogorov-
Smirnov test and the homogeneity of variances was tested using the Levene’s test. If the 
distribution of the data was not normal or the variances were not homogeneous, the data were 
transformed (logarithm). The software program SPSS version 15.0 was used for statistical 
analysis. 
 
5.2.4.5. FT-IR analysis 
ATR FT-IR spectra were recorded for Amioca®, Carbopol®, metoprolol tartrate, SD 25/75 and 
M1-M6 samples using a Bruker Vertex 70 FT- IR spectrometer equipped with a Hyperion IR 
microscope. A Ge ATR crystal was pressed against the powder for obtaining the ATR FT-IR 
spectrum (4 cm-1 resolution, 50 scans). 
 
 
5.3. Results and discussion 
 
In this study, co-processing of Amioca®/Carbopol® 974P 25/75 with the model molecule 
metoprolol tartrate via spray-drying was investigated to develop a nasal drug delivery system via 
an all-in-one process. Bioadhesive Amioca®/Carbopol® 974P (ratio 25/75) carriers containing 
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metoprolol tartrate were prepared using different procedures (Table 2) and the absolute 
bioavailability of all formulations was evaluated after nasal administration in rabbits. To evaluate 
the effect of neutralisation of poly(acrylic acid) on nasal bioavailability a dispersion of the 
coprocessed formulation was neutralised with NaOH and the resulting gel was freeze-dried. 
Neutralisation of the carboxylic groups of Carbopol® 974P prior to spray drying was not possible 
as the viscosity of the dispersion was too high for spray-drying. Dilution of such a viscous 
dispersion was not recommended due to the low process yield when spray-drying a highly diluted 
dispersion. 
In other studies Coucke et al. used the mucoadhesive Amioca®/Carbopol® powder formulation 
as carrier for nasal delivery of peptides (insulin, calcitonin, human growth hormone; Chapter 4) 
and proteins (inactivated influenza vaccine; Chapter 6). Because of the heat-lability of these active 
components and the high temperature required for the spray-drying process, a heat-stabile small 
model molecule (metoprolol tartrate) was selected for the study. Metoprolol tartrate is a 
cardioselective β1-blocker and is one of the first-line drugs for the management of systemic 
hypertension and angina pectoris (Frishman and Alwarshetty, 2002). When orally administered, 
metoprolol tartrate is completely absorbed but due to an intensive first-pass effect, only 50% of 
the given dose is found in the systemic circulation. Therefore, metoprolol tartrate is an interesting 
molecule to incorporate in a formulation for nasal delivery. 
 
The plasma concentration profiles of metoprolol tartrate after nasal delivery of M1, M3 and M5 
powders and a control solution are shown in Figure 4, the corresponding pharmacokinetic 
parameters are detailed in Table 7. All pharmacokinetic data were normalised to compensate for 
differences in delivered dose due to a variable initial drug content in the formulations and drug 
loss during processing (Table 8).  
The coprocessed M1 powder formulation had a significantly lower bioavailability (10.8 ± 2.3%) 
and slower metoprolol tartrate release rate (Figure 4) compared with the neutralised samples: 37.9 
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± 12.8% (0.01 ≥ P > 0.001) and 73.6 ± 20.1% (P ≤ 0.001) for formulations M3 and M5, 
respectively. Formulation M5, which was neutralised, resulted in significantly higher metoprolol 
tartrate plasma concentrations (P ≤ 0.001) compared to co-spray-dried M1 powder.  
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Figure 4. Plasma concentration profiles of metoprolol tartrate after nasal delivery of MT via different 
Amioca®/Carbopol® 974P 25/75 powder formulations (M1 (♦), M3 (■) and M5 (▲)) and a nasal solution 
(-) to rabbits. Data were normalised to compensate for the difference in administered dose per 
formulation.  
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Table 7. Absolute bioavailability, Cmax- and tmax-values after nasal delivery of MT via different 
Amioca®/Carbopol® 974P 25/75 powder formulations (M1 – M6, see Table 2) or a nasal solution in 
rabbits. Data were normalised to compensate for the difference in administered dose per formulation 
(mean ± S.D.). 
 
Formulation BA (%) Cmax  (µIU/mL) tmax (min) N 
M1 10.8 ± 2.3 3.1 ± 1.3 33.6 ± 13.5 6 
M2 20.0 ± 5.8 3.7 ± 1.8 59.9 ± 38.3 6 
M3 37.9 ± 12.8 7.0 ± 2.1 12.3 ± 3.9 6 
M4 53.7 ± 20.1 11.4 ± 2.3 14.1 ± 4.6 6 
M5 73.6 ± 24.9 13.3 ± 4.9 20.8 ± 9.2 6 
M6 99.2 ± 44.5 19.7 ± 3.5 15.3 ± 9.5 5 
MT solution 20.6 ± 17.5 6.0 ± 3.2 22.5 ± 5.1 6 
 
 
Table 8.  Metoprolol tartrate (MT) content (expressed as a percentage of the theoretical concentration) in 
formulations M1-M6 (mean ± S.D.) 
 
Formulation MT content (%) ± SD 
M1 80.5 ± 0.2 
M2 83.3 ± 1.7 
M3 71.9 ± 0.7 
M4 76.8 ± 1.4 
M5 99.0 ± 1.4 
M6 96.2 ± 0.2 
 
These differences in pharmacokinetic parameters can be explained by changes in molecular 
interactions between the different components of the mucoadhesive formulation as identified by 
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the FT-IR spectra of metoprolol tartrate, SD 25/75, M1 and M3 shown in Figure 5 (M3 powder 
had a similar spectrum as M5).  
 
Figure 5. IR-spectra of metoprolol tartrate, Amioca®/Carbopol® 974P powder and formulations M1 and 
M3. 
 
The specific absorption band of metoprolol tartrate was found at 1513 cm-1, while the carbonyl 
absorption band of poly(acrylic acid) appeared at 1700 cm-1. This band was very prominent in 
formulation M1, indicating that the carboxylic acid groups were not ionized. This observation in 
combination with the broad hydroxyl absorption band at 3500-3000 cm-1 (due to the O-H 
function of Carbopol® 974P) indicated that strong interaction via H-bridges between poly(acrylic 
acid) and starch was possible. As a result a compact matrix was obtained (even after hydration of 
the polymer upon nasal administration) in which MT was entrapped. Hence release of MT from 
the mucoadhesive matrix was hindered, yielding a low bioavailability. This was in contrast to the 
dispersions of formulations M3 and M5 which were neutralised to pH 7.4 with NaOH prior to 
freeze-drying. The carboxylate (band positions at 1551 en 1400 cm-1) formed in the Carbopol-
polymer at higher pH induced repulsion between the negatively charged deprotonated 
carboxylate groups and reduced the H-bridges between Amioca® starch and poly(acrylic acid). In 
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addition there was a strong interaction between the carboxylate groups and water. These factors 
all contributed to the formation of a less compact matrix from which metoprolol tartrate needs 
to escape, yielding a faster release and higher bioavailability of metoprolol tartrate after nasal 
administration for the formulations M3 and M5. The effect of a less compact mucoadhesive 
matrix is probably partly negated by the higher viscosity of the neutralized formulations upon 
hydration of the polymers. The broad hydroxyl absorption band between 3500-3000 cm-1 in the 
spectrum of M1, due to the stretch vibrations of carboxylic O-H functions of Carbopol® 974P, 
was no longer present in the spectrum of M5. The low wavenumber shoulder, between 3000-
2500 cm-1 in the spectrum of M5, arises from metoprolol tartrate while the Amioca® starch 
hydroxylic O-H vibrations appear in the explicit band around 3350 cm-1. Although release of 
metoprolol (pKa 9.68, i.e. positively charged in the mucoadhesive powder, independent if the 
powder was neutralized) could be hampered by complex formation with negatively charged 
carboxylate, interaction between both is unlikely as metoprolol is strongly surrounded by H-
bridges of tartrate. Formulation M5 had a significantly higher (0.01 ≥ P > 0.001) bioavailability 
than the nasal control solution and a higher, but not significantly different bioavailability 
compared to powder M3 since M5 was prepared via physical mixing of the ingredients in 
combination with freeze-drying, whereas M3 particles were spray-dried prior to freeze-drying 
ensuring a stronger entrapment of the active in the polymer matrix. 
Another factor that could have contributed (although to a lesser extent) to the difference in 
bioavailability between the formulations is the particle size of the nasally administered 
formulations since particles smaller than 10 µm have the potential to be deposited in the lower 
respiratory tract when nasally administered, thus reducing the dose fraction reaching the intended 
delivery site (Hinds, 1999; Garmise et al., 2006): 3.4% of the co-spray-dried M1 particles were 
smaller than 10 µm versus only 0.5% of the formulation which was freeze-dried after spray-
drying. 
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Bioavailability and Cmax of the powders after heat treatment (M2, M4 and M6) were higher than 
the conventional formulations (M1, M3 and M5), although the differences were not significant. 
Coucke et al. already showed that heating of SD 25/75 powders (for 1h at 120°C) had a positive 
effect on insulin bioavailability (Chapter 4) since a crosslinked network of Amioca® and 
Carbopol® 974P was formed at higher temperature, increasing the viscosity and elasticity of the 
mucoadhesive powder and thus reducing the mucociliairy clearance rate of the formulation.  
The plasma concentration profiles of metoprolol tartrate after nasal delivery of formulations M2, 
M4 and M6 which were obtained by heat treatment at 120°C during 1h of powders M1, M3 and 
M5, respectively, are shown in Figure 6. Heating the M1 formulation at 120°C during 1h 
increased bioavailability from 10.8 ± 2.3% to 20.0 ± 5.8%. The M2 profile showed a slow release 
of MT and this reflected in the Cmax value that was measured after 59.9 ± 38.3 min. The M4 
formulation, which was obtained by freeze-drying of M2, showed a significantly (0.05 > P > 0.01) 
higher bioavailability (53.7 ± 20.1%) than the M2 formulation (20.0 ± 5.8%). Heating the SD 
25/75 powder at 120°C during 1h before mixing with metoprolol tartrate (M6) resulted in an 
absolute bioavailability of 99.2 ± 44.5% which was significantly higher than the co-spray-dried 
Amioca®/Carbopol® 974P – MT powder (P ≤ 0.001).  
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Figure 6. Plasma concentration profiles of metoprolol tartrate after nasal delivery of MT via different 
Amioca®/Carbopol® 974P 25/75 powder formulations (M2 (♦), M4 (■) and M6 (▲)) to rabbits. Data 
were normalised to compensate for the difference in administered dose per formulation (mean ± S.D.). 
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When evaluating the heat treatment procedure, similar concentration-time profiles were obtained 
after nasal administration of M2, M4 and M6 as for M1, M3 and M5 powders which indicated 
that the influence of processing was unchanged after heating the powders. Bioavailability and 
Cmax values increased after heat treatment at 120°C during 1h but were not significantly different 
from their reference formulations. 
 
Limited research has been done in the field of nasal delivery of metoprolol tartrate. Rajinikanth et 
al. (2003) investigated the nasal administration of metoprolol tartrate incorporated in bioadhesive 
sodium alginate microspheres. In vivo studies in rabbits showed a significant improvement of an 
metoprolol tartrate isoprenaline-induced tachycardia in comparison with the oral and nasal 
administration of a MT solution. Absolute bioavailabilities of 30% were obtained after nasal 
delivery in microspheres. 
Kilian and Müller (1998) studied the effect of a viscosity enhancer (methyl cellulose) and a 
surfactant (polysorbate-80) incorporated in a nasal metoprolol tartrate solution given to rats. The 
viscosity-enhancing capacities of methyl cellulose increased contact time of the drug with the 
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absorption surface which was reflected in higher AUC values. The nasal use of a surfactant did 
not improve the bioavailability, probably because of inclusion of the drug in micelles. 
Bioavailabilities obtained after nasal administration of the co-spray-dried Amioca®/Carbopol® 
974P-metoprolol tartrate formulation and the physical mixture of Amioca®/Carbopol® 974P 
combined with metoprolol tartrate were remarkably higher than those in the cited experiments.  
 
5.4. Conclusion 
 
The present study demonstrated that co-processing of a mucoadhesive Amioca®/Carbopol® 
974P powder formulation with metoprolol tartrate (used as model drug) via spray-drying to 
obtain a powder for nasal drug delivery via a one-step process, did not have an added value 
towards the bioavailability of metoprolol tartrate after nasal delivery. Bioavailability improved 
using a mucoadhesive matrix that was neutralized to pH 7.4 prior to manufacturing via freeze-
drying since, due to repulsion of the carboxylate groups of poly(acrylic acid), a less dense matrix 
was formed upon hydration. Heat treatment of the physical mixed Amioca®/Carbopol® with 
metoprolol tartrate at 120°C during 1h resulted in low levels of crosslinking which increased 
bioavailability to 100% after nasal administration in rabbits. 
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Chapter 6.1. Nasal vaccination study. 
 
Abstract 
 
Mucosal vaccination has several advantages over parenteral vaccination. In this study, viscosity-
enhancing mucosal delivery systems for the induction of an adaptive immune response against 
viral antigen were investigated. Powder formulations based on spray-dried mixtures of starch 
(Amioca®) / poly(acrylic acid) (Carbopol® 974P) in different ratios were used as carriers of the 
viral antigen. A comparison of these formulations for intranasal delivery of heat-inactivated 
influenza virus combined with LTR192G adjuvant was made in vivo in a rabbit model. Individual 
rabbit sera were tested for seroconversion against hemagglutinin (HA), the major surface antigen 
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of influenza. The powder vaccine formulations were able to induce systemic anti-HA IgG 
responses. The presence of Carbopol® 974P improved the kinetics of the immune responses and 
the level of IgG titers in a dose-dependent way which was correlated with the moderately 
irritating capacity of the formulation. In contrast, mucosal IgA responses were not detected. In 
conclusion, it was demonstrated that the use of bioadhesive carriers based on Amioca® starch 
and poly(acrylic acid) facilitates the induction of a systemic anti-HA antibody response after 
intranasal vaccination with a whole virus influenza vaccine. 
 
Keywords: nasal vaccination; powder formulation; nasal delivery; muco-adhesion 
 
6.1.1. Introduction 
 
Mucosal vaccination is an attractive alternative to parenteral vaccination. It is safer, promotes 
immune responses in mucosal-associated lymphoid tissue (MALT) and can be administered by 
non-medically trained personnel. These advantages may be beneficial during large-scale 
vaccination campaigns, for example during a pandemic influenza outbreak and in remote 
communities. 
The highly vascularized epithelial layer and a large surface area of the nasal cavity offer great 
opportunities for drug delivery (Davis, 2001). The intranasal route also promotes induction of 
strong adaptive immunity in the upper respiratory tract, the entry site of most respiratory 
infectious microbial organisms, such as influenza viruses (Holmgren and Czerkinsky, 2005). On 
the other hand, absorption of vaccines in the nasal cavity is limited by the mucus layer, 
mucociliary clearance and enzymatic activity (O’Hagan and Illum, 1990). In humans, a nasal 
formulation is deposited mainly in the anterior part of the nasal cavity, and the mucociliary 
clearance mechanism of the ciliated cells will clear a liquid formulation from the nasal cavity 
within 15-20 minutes (Soane et al., 1999). This time is too short for effective uptake of antigens 
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by antigen-presenting cells or tissues (O’Hagan and Illum, 1990). Therefore, viscosity-enhancing 
delivery systems have been designed to slow down mucociliary clearance and to prolong the 
contact time between formulation and nasal tissues. These systems not only increase the 
residence time of drugs in the nasal cavity, but they may also facilitate permeation of the drug 
through the mucosa by loosening the tight junctions between the epithelial cells (Callens et al., 
2003). This can result in enhanced humoral and cellular immune responses both locally and 
systemically (McNeela et al., 2000). Furthermore, these viscosity enhancers are not absorbed and 
so they are not expected to lead to systemic toxicity (Callens and Remon, 2000). Pringels et al. 
(Pringels et al., 2006) demonstrated that a viscosity-enhancing mixture of starch and poly(acrylic 
acid) improved systemic delivery of insulin following nasal administration.  
Influenza is an appropriate target for intranasal vaccine development: it can be prevented by 
vaccination, the causative virus enters the host through the epithelium of the upper respiratory 
tract, and the annual epidemics and unpredictable pandemics prompt further vaccine 
development. Influenza A viruses have a broad host range, with pigs, birds and humans as the 
most important species. These viruses can cause mild to severe illness in humans, sometimes 
leading to death. Due to genetic drift and shift of the major surface antigen hemagglutinin (HA) 
and to a lesser extent neuraminidase (NA), the virus can escape recognition by the adaptive 
immune system and vaccinations need to be repeated every year (Nichol and Treanor, 2006). 
Influenza epidemics occur annually but influenza A viruses also cause occasional and 
unpredictable pandemics. Such a pandemic outbreak is associated with the introduction of a new 
influenza subtype virus in the population, which could be devastating because the human host is 
immunologically naïve to the new strains. Licensed influenza vaccines are based on purified 
antigens (mainly HA) derived from inactivated viruses, or are life-attenuated. These vaccines are 
trivalent, consisting of two influenza A viruses and one influenza B virus strain that will likely 
cause the next epidemic (H1N1, H3N2 and a B virus). These vaccines can be 70-90% effective in 
preventing influenza-induced illness in children and adults and 30-50% in the elderly (Jefferson et 
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al., 2005; Treanor, 2007). 
In this study, we compared different viscosity-enhancing powder formulations for the intranasal 
delivery of a whole virus influenza vaccine, using rabbits as animal model since it offered specific 
advantages such as a nasal cavity size comparable to humans, ease of handling and low 
maintenance cost (Dondeti et al., 1995). 
Heat-inactivated influenza virus combined with LTR192G adjuvant was incorporated in Amioca® 
starch/poly(acrylic acid) powder and nasally administered to rabbits. The influence of different 
ratios of starch and poly(acrylic acid) on systemic and mucosal immune responses was 
investigated. Powder characteristics such as irritation, rheological properties and particle size were 
correlated with the obtained immune responses. We demonstrated that the use of these 
bioadhesive carriers facilitated the induction of a systemic anti-HA antibody response and that a 
starch/poly(acrylic acid) carrier performed better than a pure starch formulation. 
 
6.1.2. Materials and methods 
 
6.1.2.1. Materials 
 
The spray-dried (SD) mixtures of amylopectin starch (Amioca®) and crosslinked poly(acrylic acid) 
(Carbopol® 974P) were prepared in different (w/w) ratios by the National Starch and Chemical 
Company (Bridgewater, NJ) (SD 0/100, 25/75, 50/50, 85/15 and 100/0). X47 (H3N2) influenza 
virus was prepared at the Department for Molecular Biomedical Research (VIB and Ghent 
University, Ghent, Belgium). LTR192G (heat-labile enterotoxin R192G mutant) was kindly 
provided by Prof. John Clements (New Orleans). Ribi adjuvant (25µg monophosphoryl lipid A 
(MPL) and 25 µg synthetic trehalose-6,6-dimycolate (TDM) in an oil-in-water emulsion) was 
obtained from Sigma (Bornem, Belgium). All other chemicals were of analytical grade. 
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6.1.2.2. Preparation of formulations 
 
6.1.2.2.1. Virus preparation 
X47 is a re-assortant influenza A virus (H3N2) consisting of HA- and NA-coding genome 
segments of the A/Victoria/3/1975 (H3N2) strain, and internal genes of the A/PR/8/1935 
(H1N1) strain. Virus was grown on embryonated chicken eggs, purified on sucrose gradient, and 
heat-inactivated at 56°C for 30 minutes (Hirst, 1948). Complete inactivation of the virus was 
confirmed by absence of viral replication on MDCK cells. Total protein in the inactivated virus 
was determined by the colorimetric Pierce BCA (bicinchoninic acid) Protein Assay (Pierce, 
Rockford, IL), using bovine serum albumin (BSA) as a standard. 
 
6.1.2.2.2. Preparation of intramuscular formulations 
Heat-inactivated (56°C, 30 min) X47 influenza virus (H3N2) in PBS was used without adjuvant, 
mixed with LTR192G adjuvant (10/1 ratio (w/w)) or mixed with Ribi adjuvant according to the 
instructions of the manufacturer. A volume of the different vaccine preparations corresponding 
to 100 µg of viral protein was then administered intramuscularly in the quadriceps of the hind leg 
of the rabbits. 
 
6.1.2.2.3. Preparation of nasal powder formulations 
The following amounts of spray-dried mixtures of Amioca® and Carbopol® 974P were dispersed 
in 8 ml distilled water and neutralised (except SD 100/0) to pH 7.4 with 1 M or 2 M NaOH:  170 
mg SD 0/100, 270 mg SD 25/75, 300 mg SD 50/50, 335 mg SD 85/15, and 350 mg SD 100/0. 
Five micrograms heat-inactivated X47 influenza virus and 0.5 µg adjuvant LTR192G/mg powder 
were added to each dispersion. Negative control powders (SD 25/75 and SD 100/0) were 
prepared without adding antigen. To obtain a powder, the aqueous dispersion was freeze-dried in 
an Amsco-Finn Aqua GT4 freeze-dryer (Amsco, Hürth, Germany). The dispersion was frozen to 
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228 K within 175 min at 1000 mbar. Primary drying was performed at 258 K and a pressure of 
0.8–1 mbar for 13 h, followed by secondary drying at an elevated temperature (283 K) and 
reduced pressure (0.1– 0.2 mbar) for 7 h. After freeze-drying, the powder was manually milled at 
low relative humidity (20%) and ambient temperature. It was stored in a desiccator at 4–8°C until 
use.  
 
6.1.2.2.4. Preparation of liquid nasal PBS vaccines 
Heat-inactivated X47 influenza virus (H3N2) and LTR192G adjuvant were dissolved in LPS-free 
phosphate buffered saline (pH 7.4) at 700 µg/ml and 70µg/ml, respectively, of which 70 µl per 
nostril was administered to the rabbits. 
 
6.1.2.3. Rabbit immunization study 
 
The protocol of the animal experiments was approved by the Ethics Committee of the Institute 
for Agricultural and Fisheries Research (ILVO) (Merelbeke, Belgium). New Zealand white rabbits 
(3.0 ± 0.5 kg) were housed in cages where food and water were available ad libitum.  
Ten milligrams of powder formulation (equivalent to 50 µg influenza virus and 5 µg LTR192G) 
was instilled into each nostril through polyethylene tubes (Medisize, Hillegom, The Netherlands). 
A syringe containing 1 ml compressed air (2.5 bar) assisted the release of the powder from the 
tubes. This device was based on a system developed by Sørensen (1991). The tubes were filled 
under conditions of low relative humidity (20%) and ambient temperature. Groups of 6 rabbits 
underwent 3 successive intranasal (IN) immunizations (1 primer and 2 boosters at 3-week 
intervals) with heat-inactivated X47 influenza virus formulated in SD 0/100, 25/75, 50/50, 
85/15 and 100/0. The negative control rabbits (n=6) received SD 25/75 and SD 100/0 powder 
without antigen. A second control group (n=6) was immunized by dropwise administration of 50 
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µg influenza virus in PBS combined with 5 µg LTR192G per nostril. The positive control rabbits 
(n=3) were immunised intramuscularly (IM) in the quadriceps with Ribi-adjuvanted antigen. 
In an additional study to check the effect of the booster vaccinations, antigen in SD 25/75 and 
SD 100/0 were administered only as a primer, as a primer with one boost, or as a primer 
followed by two boosts. In a control experiment anti-HA total IgG titers were compared after 
three intramuscular vaccinations with Ribi-adjuvanted, LTR192G-adjuvanted or non-adjuvanted 
influenza virus. In this experiment the possible advantage of incorporating Amioca® starch in the 
spray-dried powder formulations was also determined by comparing the immune response after 
intranasal vaccination with virus antigen only formulated in SD 25/75 and SD 0/100. 
Before priming and 10 days after each administration, blood samples were collected from the 
marginal ear vein of the rabbits. The blood samples were centrifuged (700 x g, 5 min) to prepare 
serum. One day after blood collection, nasal washes were taken. Each nostril was washed with 
600 µl PBS (pH 7.4) using a micropipette. Serum samples and nasal washes were stored at –20°C 
and thawed before analysis. 
 
6.1.2.4. ELISA assays 
 
ELISA was used to determine hemaggluttin (HA)-antibody titers in individual rabbit sera. A 
recombinant HA preparation used for coating the ELISA plates was produced as follows: 
pCAGGS vector encoding the cDNA of HA from A/Victoria/3/75 truncated at amino acid 
residue Ile186 (HA2 numbering) was transfected into HEK293T cells (Vanlandschoot et al., 
1993). This truncated form of HA is secreted into the growth medium because the membrane 
anchor is absent. Twenty-four hours after transfection, cells were washed and kept in serum-free 
culture medium supplemented with insulin, transferrin and selenium. Growth medium was 
collected 72 h after transfection, and 50 µl of HA-containing medium was used for coating the 
wells of 96-well MaxiSorp immunoplates (Nunc, Roskilde, Denmark). After HA-coating, the 
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wells were blocked with 4% skimmed milk in PBS buffer. All subsequent steps were performed 
in a volume of 100 µl per well, and the wells were washed three times between incubation steps 
with PBS + 0.05% Tween 20. The presence of HA-specific IgG in the samples was determined 
by incubating 1/3 serial dilutions of serum samples in the HA-coated wells, starting with a 1/100 
dilution, for 1 h. After washing, HA-specific IgG was detected with horseradish peroxidase-
conjugated anti-rabbit serum (specific for total rabbit IgG and raised in donkey; Amersham 
Biosciences, Buckinghamshire, UK). After washing, plates were incubated for 5 min with 
tetramethylbenzidine substrate (Sigma-Aldrich). The peroxidase reaction was stopped by adding 
an equal volume of 1 M H3PO4. Antibody titers are defined as the reciprocal of the highest 
dilution with an OD450 that is at least three times the value obtained with pre-immune serum. 
 
6.1.2.5. Hemagglutination inhibition test 
 
A hemagglutination inhibition (HAI) test was performed according to the guidelines of the 
World Health Organization (WHO, 2002) to check neutralizing capacities of two-fold serial 
dilutions of the immune sera. Briefly, immune sera were treated as follows: inactivation of 
complement was done by heating the sera at 56°C for 10min. Aspecific agglutinins were removed 
by pre-treatment of each volume of serum with four volumes of RDE (cholera filtrate from 
Vibrio cholerae culture fluid, Sigma). Finally 10 volumes of the treated sera were adsorbed to one 
volume of 50% chicken red blood cells (RBCs) in PBS. Diluted pre-treated serum samples were 
mixed with two hemagglutination units of inactivated X47 virus in a final volume of 50 μl and 
incubated for one hour at room temperature. Afterwards, an equal volume of a 0.5% RBC 
suspension was added and the hemagglutination inhibition titers were recorded 30-60 minutes 
after RBC addition. The end point titer was the reciprocal of the dilution at which complete 
inhibition of hemagglutination still occurred.  
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6.1.2.6. Powder characteristics 
 
6.1.2.6.1. Rheological properties 
The elasticity (G’) and viscosity (G’’) of the SD 0/100, 25/75, 50/50, 85/15, 100/0 powder 
formulations were determined by means of a TA Instruments AR 1000-N Rheometer (Zellik, 
Belgium). Different powders were dispersed in simulated nasal fluid (SNF) (10%, w/w) before 
measuring G’ and G’’. The measurements were performed at 32 ± 0.5°C using a cone of 4 cm 
with an angle of 1° and applying an oscillation stress of 30 Pa and a frequency of 0.1 Hz. 
 
6.1.2.6.2. Particle size distribution 
Particle size distributions were measured by laser diffraction (Mastersizer-S long bed; Malvern 
Instruments, Malvern, UK).  The powder formulations were dispersed into the dry powder cell of 
the Mastersizer using the same device as used during the rabbit immunization studies. All 
measurements were performed in triplicate. The particle size distributions were characterized via 
D (v, 0.1), D (v, 0.5) and D (v, 0.9) and the span of the distribution is defined as [D (v, 0.9)-D (v, 
0.1)] / D (v, 0.5)]. 
 
6.1.2.7. Statistics 
 
Antibody titers in sera obtained from the different groups of rabbits were tested for statistically 
significant differences using a Wilcoxon rank-sum test, a non-parametric alternative to the two-
sample t-test. Statistical analysis was performed with the software package SPSS for Windows 
(v.16.0.2, SPSS, Chicago:, IL, USA).   
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6.1.3. Results 
 
6.1.3.1. Intranasal delivery of influenza virus antigen formulated in a mucoadhesive powder        
induces systemic IgG responses 
The aim of this study was to evaluate the immunogenicity of different intranasally (IN)-
administered bio-adhesive dry powder vaccine formulations. Whole heat-inactivated influenza A 
virus was used as the vaccine antigen and a rabbit model for the intranasal administration (Callens 
and Remon, 2000). As a positive control, the vaccine, adjuvanted with Ribi or LTR192G, was 
administered intramuscularly (IM). The LTR192G adjuvant was used throughout the intranasal 
immunization experiments. For IN administration, the influenza vaccine was combined with a 
spray-dried mixture of different ratios of Amioca® starch and crosslinked poly(acrylic acid) 
(Carbopol®). An attempt to use a non-bioadhesive powder formulation as a control failed due to 
an unknown incompatibility between the inactivated influenza virions and lactose, the filler in the 
non-bioadhesive powder formulation. The incompatibility was seen after lyophilisation because 
the whole inactivated influenza virus (WIV) incorporated in lactose was a sticky substance, 
impossible for IN administration. Therefore, IN administration of inactivated influenza virus 
combined with LTR192G in PBS was used as a control. 
Total serum IgG responses directed against homologous HA were highest in all three IM groups. 
Interestingly, Ribi and LTR192G had negligible adjuvant effect since similar levels of anti-HA 
serum IgG levels were detected in all three IM groups (Figure 1 A-C). In a pilot experiment using 
the IN dry powder mixtures, inactivated influenza X47 virus incorporated in SD 25/75 and SD 
0/100 mixture were compared (Figure 1 D-E). Although serum anti-HA IgG levels were two 
orders of magnitude lower compared to the IM groups, a priming and boosting effect was 
detected with specific antibody titers in the range of 1/1000. No statistically significant difference 
in anti-HA IgG levels was seen between the SD 25/75 and SD 0/100 vaccinated groups. 
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However, in the absence of Amioca® the synergistic effect on bioadhesion when both polymers 
are combined is missing (Callens et al., 2003). Therefore, in subsequent experiments we used 
Amioca®-containing dry powder mixtures. Because the IM group served merely as a positive 
control and because adding LTR192G to the IM-administered heat inactivated whole virus 
preparation did not enhance the seroconversion rate in the IM groups, only a Ribi-adjuvanted IM 
positive control group was included in subsequent experiments.  
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Figure 1. Serum anti-HA IgG antibody titers in New Zealand white rabbits (n=6) immunized IM (A-C) 
or IN (D-E) with influenza virus. Intramuscular immunizations consisted of antigen mixed with Ribi 
adjuvant (A), LTR192G (B) or without adjuvant (C). SD 25/75 (D) and SD 0/100 (E) powders were used 
for intranasal immunizations. All rabbits received one primer and two booster injections. 
 
Next an SD 25/75 dry powder mixture was compared IN with a dry powder containing only 
Amioca® (SD 100/0) to test a potential benefit of the negatively charged Carbopol® for the 
induction of HA-specific serum responses. Neither IN delivery of PBS with 100 μg heat-
inactivated X47 virus formulation nor the negative control powders (SD 25/75 and SD 100/0 
without antigen) resulted in serum HA-specific antibody titers differing from the background 
signal (Figure 2). High HA-specific IgG titers were induced in the IM injected positive control 
group after the first and the second boost. IN groups that received antigen formulated in SD 
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100/0 or SD 25/75 also seroconverted. As in the first experiment, specific IgG titers were 
approximately 100-fold lower compared to the IM group. Based on the Wilcoxon rank-sum test, 
titers in the SD 25/75 group were not significantly different from the IM group after two boosts. 
The SD 25/75 formulation appeared to work better than the SD 100/0 formulation: HA-specific 
serum IgG titers after one boost with virus antigen formulated in SD 25/75 were higher than the 
SD 100/0 formulation (purple bars in Figure 2). It can be concluded that a formulation of 
inactivated influenza virions with Amioca® (SD 100/0) or Amioca®/Carbopol® (SD 25/75) can 
be used intranasally to induce systemic HA-specific IgG responses. In addition, combining 
Amioca® with Carbopol® in a 25/75 ratio improved the kinetics of the immune responses 
compared to a pure Amioca® formulation. 
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Figure 2. Serum anti-HA IgG antibody titers in New Zealand white rabbits (n=3 for IM route, n=6 for 
IN route) immunized with influenza virus + adjuvant (Ribi adjuvant for IM route, LTR192G for IN 
route) and administered in different formulations: PBS for IM and IN routes (groups A and B), and 
starch/Carbopol® powders (SD 25/75 and SD 100/0) for IN route (groups C and D). SD 25/75 and SD 
100/0 IN without influenza virus (groups E and F) were administered IN as negative control. (* p < 0.05; 
** p < 0.01) 
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6.1.3.2. Influence of the ratio of Amioca® to Carbopol® 974P on systemic IgG responses 
 
To investigate the efficacy of different ratios of Amioca® to Carbopol® 974P, influenza virus 
antigen combined with LTR192G was incorporated in SD 25/75, SD 50/50 and SD 85/15 dry 
powder mixtures, i.e. containing decreasing percentage of Carbopol®. The influence of these 
carriers having different viscosity-enhancing properties on the serum-specific HA-antibody 
response was measured 10 days after each of three IN administrations. Figure 3 shows a 
significant difference in IgG levels after three administrations between SD 25/75 and all other 
SD ratios tested. There was also a clear difference in the kinetics of the IgG titers between the 
different nasally administered powders: IgG titers after the first booster were higher when more 
poly(acrylic acid) was incorporated in the formulation. 
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Figure 3. Serum anti-HA IgG antibody titers in New Zealand white rabbits (n=6) immunized with 
influenza virus + LTR192G administered in different formulations: starch/Carbopol® powders (SD 
25/75, SD 50/50 and SD 85/15) by the IN route (groups A, B and C). SD 25/75 without influenza virus 
was administered IN as negative control (group D). (* p < 0.05; ** p < 0.01) 
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6.1.3.3. Influence of booster immunizations on systemic IgG responses 
 
Induction of strong immune responses by IN vaccination usually requires booster immunizations 
(Verweij et al., 1998; de Haan et al., 2001; Singh et al., 2001; van der Lubben et al., 2003). We 
compared different IN booster regimens by immunizing rabbits with virus antigen + LTR192G 
in SD 25/75 or SD 100/0, followed by one or two booster vaccinations, or without boosting. 
Serum samples of all groups were taken on days 31, 52 and 73 (10 days after each administration) 
to evaluate the persistence of HA-specific IgG in the blood. 
Three immunizations with influenza virus formulated in SD 25/75 elicited the highest IgG titers 
(Figure 4). One or two IN immunizations (groups F and E, respectively) with antigen formulated 
in SD 100/0 gave low IgG titers in serum prepared on day 52 (second bleeding), and the titer on 
day 73 (third bleeding) was even lower. By contrast, groups that received antigen in SD 25/75 
once (group C) or twice (group B) still showed a high titer on day 73.  
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Figure 4. Serum anti-HA IgG antibody titers in New Zealand white rabbits (n=6) immunized intranasally 
with influenza virus + LTR192G in starch/Carbopol® mixtures in ratios of 25/75 (groups A-C) and 
100/0 (groups D-F). The graph represents titers in serum samples for each group after the primer (groups 
C and F), after a primer and one booster vaccination (groups B and E), and after a primer plus two 
boosters (groups A and D).  (* p < 0.05) 
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In this experiment, no statistically significant difference between groups vaccinated with SD 
25/75 and SD 100/0 could be detected, but the effect of boosting was statistically significant as 
indicated in Figure 4. 
 
6.1.3.4. Intranasal delivery of influenza virus antigen formulated in a mucoadhesive powder 
      does not induce mucosal IgA responses 
 
Mucosal immunization can induce a local immune response, and so IgA levels in nasal lavages of 
the rabbits after three IN administrations were measured. No IgA levels were detected in the 
nasal washes whereas low HA-specific IgG titers were only detected in nasal lavages of rabbits 
receiving two antigen boosters in SD 25/75 (data not shown).  
 
6.1.3.5 Intranasal delivery of influenza virus antigen formulated in a mucoadhesive powder 
      induces systemic hemagglutination inhibition serum responses 
 
The protective potential of currently licensed influenza vaccines correlates with the level of 
hemagglutination inhibitory (HI) serum antibody levels. Therefore, we determined HI serum 
titers in a chicken red blood cell HI assay using homologous X47 virus. Although IM vaccination 
with Ribi-adjuvanted antigen induced recombinant HA-specific serum titers that were 100-fold 
higher compared to those raised with antigen formulated in SD 25/75 (Figure 2), the differences 
in HI titer were much lower between the IM and the IN groups (Figure 5). HI titers induced by 
IM vaccination with Ribi-adjuvanted antigen were two-fold higher than after IN vaccination with 
SD 25/75 and four-fold higher than after IN vaccination with antigen formulated in Amioca® 
alone (SD 100/0). 
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Figure 5. Hemagglutination inhibition titers of pools of the serum samples shown in Figure 1. (A) New 
Zealand white rabbits immunized with Ribi-adjuvanted WIV via the IM route (n=3), with (B) SD 25/75 
and (C) SD 100/0 powder vaccines via the IN route (n=6). (D) Hemagglutination inhibition titers of 
pooled serum samples from rabbits that received SD 25/75 without antigen (n=6) were used as negative 
control. 
   
6.1.3.6. Powder characteristics 
 
6.1.3.6.1. Rheological properties 
 
The viscosity and elasticity after dispersion in simulated nasal fluid (SNF) of the SD powders 
containing Amioca® and Carbopol® 974P in different ratios are shown in Table 1. The storage 
modulus (G’) reflects the solid-like component of a visco-elastic material and will be large if a 
sample is predominantly elastic or highly structured. The loss modulus (G’’) is a measure of the 
liquid-like component which will be large when a sample is predominantly viscous (Ceulemans 
and Ludwig, 2002). In case of a crosslinked system G’ (elastic) >> G’’ (viscous), while G’ > G’’ 
indicates a network consisting of secondary bonds and G’ < G’’ a physically entangled polymer 
solution (Fery, 1970). The elasticity or storage (G’) modulus of the SD 25/75 and SD 50/50 
powders were higher compared with Carbopol® 974P formulations (SD 0/100), while their G’’ 
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values were slightly higher. Spray-drying an aqueous dispersion of starch and poly(acrylic acid) 
had a synergistic effect on the rheological properties, which increased the residence time in the 
nasal cavity and allowed more time for antigen uptake. This was reflected in higher IgG titers 
obtained with the SD 25/75 vaccine formulation after one booster. The G’ and G’’ values of the 
pure Amioca® formulation (SD 100/0) were extremely low because Amioca® is nearly soluble in 
water. 
 
Table 1. Rheological properties (G’ or elasticity and G’’ or viscosity) of aqueous dispersions prepared 
using spray-dried Amioca®/Carbopol® 974P (SD, ratio: 0/100, 25/75, 50/50, 85/15 and 100/0) (n = 3, 
mean ± S.D.). 
Powder ratio G’ (Pa) G’’ (Pa) 
SD 0/100 2572 ± 378 239 ± 29 
SD 25/75 5124 ± 517 428 ± 68 
SD 50/50 5829 ± 588 382 ± 64 
SD 85/15 2396 ± 200 203 ± 5 
SD 100/0 0.0086 ± 0.0104 0.0388 ± 0.0134 
 
6.1.3.6.2. Particle size 
 
Table 2 shows the particle size distribution of the different powder ratios. Although the median 
particle size of pure Carbopol® 974P and Amioca® (d (v, 0.5) = 47 and 33 µm, respectively) was 
slightly lower than the particle size of the spray-dried mixtures (about 60 µm), all powders had an 
optimal size for deposition in the nasal cavity. In addition, the spray-dried starch/Carbopol® 
mixtures yielded a narrow particle size distribution, whereas pure starch and Carbopol® also had a 
fraction of larger particles (d (v, 0.9) of 195.7 and 321.7 µm, respectively, versus about 100µm for 
the powder mixtures). 
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Table 2. Particle size of spray-dried Amioca®/Carbopol® 974P (ratio: 0/100, 25/75, 50/50, 85/15 and 
100/0) (SD 0/100, SD 25/75, SD 50/50, SD 85/15 and SD 100/0) after lyophilisation (n = 3, mean ± 
S.D.). 
Powder ratio D (v,0.1) (µm) D (v,0.5) (µm) D (v,0.9) (µm) Span 
SD 0/100 16.4 ± 0.1 47.5 ± 0.7 195.7 ± 86.1 3.8 ± 1.7 
SD 25/75 24.0 ± 4.0 54.2 ± 4.5 107.9 ± 6.8 1.6 ± 0.2 
SD 50/50 29.8 ± 0.6 61.7 ± 0.2 111.0 ± 1.8 1.3 ± 0.0 
SD 85/15 33.3 ± 0.5 66.2 ± 0.2 87.5 ± 41.9 0.8 ± 0.6 
SD 100/0 14.0 ± 0.5 32.5 ± 0.1 321.7 ± 170.5 9.5 ± 5.2 
 
 
6.1.4. Discussion 
 
These results demonstrate that spray-dried Amioca®/Carbopol® 974P powders are a promising 
delivery platform for IN vaccination. Heat-inactivated whole virus influenza vaccine was 
successfully incorporated in different SD powders, and both recombinant HA-specific serum 
IgG titers as well as HI serum responses were induced after IN administration in rabbits. One 
important reason for this success is presumably the viscosity-enhancing capacity of the powders, 
since the same dose of antigen plus LTR192G adjuvant administered IN in liquid PBS buffer did 
not induce seroconversion at all. The nasally administered powders can interact with the nasal 
mucosa, thereby slow down the rate of mucociliairy clearance, and increase the time available for 
drug absorption (Soane et al., 1999). The combination of spray-dried maize starch (mainly 
consisting of amylopectin) and a polymer based on cross-linked acrylic acid, in this case 
Carbopol® 974P, amplified the mucoadhesive capacity of the formulation. A stronger HA-specific 
IgG response was seen when poly(acrylic acid) is incorporated in the formulation in comparison 
with a formulation based only on Amioca® (SD 100/0) (Figures 2-5). Callens and Remon 
obtained a significant increase in insulin bioavailability when 10% cross-linked poly(acrylic acid) 
was added to a viscosity-enhancing formulation containing starch (Callens and Remon, 2000). 
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Higher poly(acrylic acid) concentrations probably increased the residence time of the powder in 
the nasal cavity and positively influenced the bioavailability of insulin. However, compared to 
drug administration, vaccination may require much smaller amounts of antigen, because when a 
plateau in antigen response is reached, higher amounts of antigen would not bring the response 
to a higher level (Illum, 2006). Li et al. (2006) suggested that enhancing in vivo absorption with 
Carbopol gel formulations goes beyond mucoadhesion and involves enhancement of tight-
junction permeation. One explanation for the increase in paracellular transport by poly(acrylic 
acid) can be found in its influence on the epithelial tight junctions by binding of extracellular Ca2+ 
to the polyanionic polymer (Leuβen et al., 1994; Leuβen et al., 1995). This effect was found to be 
effective in opening tight junctions and establishing paracellular transport (Borchard et al., 1996). 
Another factor contributing to the higher paracellular transport in function of the poly(acrylic 
acid) content was proposed by Wang et al. (Wang et al., 2006). In their study the nasal absorption 
of insulin significantly increased when it was formulated in a dry powder containing aminated 
gelatin microspheres which were capable to absorb a lot of water. Similarly, our SD powders 
absorbed water from the nasal mucosa, which might have caused temporary dehydration of the 
epithelium and opening of the tight junctions, likely resulting in increased permeability through 
the paracellular way. 
 
To elicit a humoral immune response, the intranasally administered antigen has to be presented 
to lymphoid tissue containing antibody-producing cells, i.e. the NALT. Afterwards, the antigen is 
drained to the posterior cervical lymph nodes, from where a local immune response can be 
evoked (Pereswetoff-Morath, 1998). Factors such as the relatively short residence of antigen in 
the nasal cavity, slow transport of antigens across the epithelial membranes, and poor 
immunogenicity of most antigens sparked the development of a number of strategies to increase 
the immune response induced after intranasal administration (Lemoine et al., 1998). In our study 
this included the use of a mucoadhesive delivery system. However, achieving efficient nasal 
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vaccine absorption by including mucoadhesive components is not sufficient on its own to induce 
an immunological response as the incorporation of an immunostimulant in the formulation is 
essential. Inflammation, irritation and damage to the mucosal membrane are important factors 
that may stimulate an immunological reaction (Gizurarson et al., 1994; Gizurarson et al., 1998). 
In this study, the heat-inactivated influenza virus X47 was combined with an LTR192G adjuvant 
(ratio of 10/1 (w/w)) in the SD formulations. Genetically detoxified mutants of heat-labile 
enterotoxin (LT) have been identified as potent adjuvants for inducing local and systemic 
responses (Vajdy and O’Hagan, 2001). Using the native Escherichia coli heat-labile enterotoxin as 
an adjuvant promoted the production of high IgA and IgG levels, but local and systemic side 
effects were also reported (Tamura et al., 1994a, Tamura et al., 1994b, Hashigucci et al., 1996). 
Dickinson and Clements constructed a modified Escherichia coli heat-labile enterotoxin in which a 
single amino acid in the trypsin cleavage site within the A subunit was substituted by site-directed 
mutagenesis (Dickinson and Clements, 1995). This non-toxic mutant, designated LT(R192G), 
retained its mucosal adjuvant properties.  
The beneficial effect of Carbopol® might extend beyond “passive” lengthening of the residence 
time (shown in higher G’ and G’’ values of SD 50/50 and SD 25/75) and slowing the release of 
the antigen at mucosal contact sites. Like chitosan, another well-known enhancer of mucosal 
contact and bioavailability of incorporated compounds after IN administration (Shahiwala and 
Misra, 2001), Carbopol® can exert some “active” adjuvant effects as well. Recruitment of immune 
cells to the site of Carbopol® binding has been illustrated for Amioca/Carbopol® powders in 
rabbits after IN administration (Callens et al., 2001). In addition, intraperitoneal injection of 
Carbopol® was reported to induce an innate antiviral effect in mice, probably by activation of 
macrophages and production of interferon, which may be an extra advantage in vaccinations 
against viral pathogens like the influenza virus (de Clercq and Luczak, 1976).  
In contrast to the IM formulation, intranasal administration of influenza virus in PBS did not 
induce a HA-specific IgG response (Figure 2). In a study by Singh et al. (2001), HA-specific 
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serum IgG titers were high in rabbits after IN administration of a solution containing HA 
combined with LTR72 adjuvant. However, the LT-based adjuvant dose (25 µg/rabbit) in that 
study was five times higher than used here. Amidi et al. (2007) reported on the IN vaccination of 
mice with N-trimethylchitosan-based nanoparticles loaded with influenza subunit antigen. A 
substantial response was obtained in serum samples of 5 out of 8 mice after 2 booster 
immunizations with the negative control (i.e. inactivated influenza antigen in PBS solution 
without adjuvant). However, the animals were slightly anesthetized before vaccination, which 
may have prolonged the residence time of the liquid in the nasal cavity.  
A single virus inoculation (priming) with SD 25/75 or SD 100/0 powder did not evoke a 
response in serum or tissues (Figure 4). The second intranasal inoculation with a soluble antigen 
(first booster) induced a response in serum and in the posterior cervical lymph nodes 
demonstrating formation of immunological memory (Kuper et al., 1992). Although vaccination 
with SD 100/0 resulted in a similar response after booster vaccinations, the adjuvant properties 
of poly(acrylic acid) are beneficial for the SD 25/75 powder. In addition, combining starch with 
poly(acrylic acid) improved the ease of use (e.g. reproducible filling of the delivery system) since 
the electrostatic properties of the formulation increased at higher Amioca® content.  
One of the major advantages of nasal immunization is that it can induce mucosal immunity at the 
nasal epithelium. M-cells in the upper nasopharyngeal tissue can take up antigen and transport it 
to the professional antigen-presenting cells, which can elicit local mucosal as well as systemic 
immune responses. The nasal associated lymphoid tissue (NALT) is populated with B-, T- and 
dendritic cells that can effectively induce antigen-specific Th-cells, CTLs and IgA B-cell 
responses (Van Roosmalen et al., 2006). IgA responses have been described after IN 
immunization of rabbits with alginate microspheres carrying tetanus toxoid (Tafaghodi et al., 
2006), mice or rats with chitosan powder or nanoparticles carrying influenza virus (Bacon et al., 
2000; Illum et al., 2001; Huang et al., 2004; Amidi et al., 2007), and mice with surf clam 
microparticles carrying influenza virus (Ichinohe et al., 2006). In our study no significant IgA 
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titers were obtained. Similar to our study, however, no mucosal response was detected after 
administration of influenza virus via esterified hyaluronic acid microspheres in rabbit nostrils 
(Singh et al., 2001; Wimer-Mackin et al.; 2006). The antigen type, the extent of exposure to the 
antigens, and the priming route can affect the type and/or intensity of the immune response 
(Hameleers et al., 1990; Hameleers et al., 1991; Kuper et al., 1992). In a rat study it was shown 
that IN administration of soluble antigens induced a systemic immune response at the superior 
cervical lymph nodes, whereas at the posterior cervical lymph nodes particulate and soluble 
antigens would elicit a mucosal response. The balance between activation in the superior and 
posterior cervical lymph nodes would therefore determine the type of immune response after 
intranasal immunization (Kuper et al., 1992). It is not known whether starch/carbopol powders 
stimulate NALT, and so it is unclear why we did not obtain a mucosal response. The absence of 
an IgA response may be related to the antigen type, i.e. an inactivated influenza virus. Cox et al. 
(2004) asserted that inactivated influenza vaccines elicited serum antibody responses, but mucosal 
IgA antibody and cell-mediated immunity were poorly induced. In contrast, live cold adapted 
influenza vaccine can elicit long-lasting, broader humoral and cellular immune responses that 
closely resemble natural immunity . 
Functional assays as the hemagglutination inhibition test can give a more quantitative idea of 
vaccine efficacy. We demonstrated the induction of serum HI titers in sera from rabbits that had 
received three IN immunization with SD 25/75 and SD 0/100. The difference in HI titer 
between the IM and the IN groups was much lower than the total anti-HA titer as measured in 
ELISA using homologous recombinant secreted hemagglutinin as the capturing antigen. A 
possible explanation for this discrepancy might be the conformational quality of the 
hemagglutinin in the heat-inactivated whole virus antigen at the moment of vaccine 
administration. Formulation of WIV with Ribi adjuvant might lead to disruption of membrane 
fractions, HA trimers falling apart into monomers and maybe even partial unfolding of the HA 
molecule due to the lipid components of the Ribi-adjuvant. Antibodies raised after IM 
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vaccination with Ribi-adjuvanted antigen could therefore recognize epitopes on the HA molecule 
that are also accessible on the partially monomeric recombinant HA molecules that were used for 
coating of the ELISA plates (see Section 2) but that are not accessible on the WIV virions that 
were used in the HI assay. Gulati et al. (2007) also reported that a significant amount of the 
antibodies in humans raised after vaccination with whole virus or split vaccines were directed to 
so called “unfoldons”, denatured glycoproteins or internal viral proteins and these anti-unfoldon 
antibodies might not contribute to protection as neutralizing antibodies against influenza are 
conformation-dependent (Knossow et al., 2002). It is possible that the trimeric state of HA in the 
antigen is better preserved after powder formulation and therefore gave raise to a qualitatively 
better response, however, this was not studied in more detail in the present study.  
  
 6.1.5. Conclusion 
 
In conclusion, we developed a mucoadhesive dry powder formulation as a novel delivery 
platform for nasal vaccination. The systemic response after nasal vaccination with influenza virus 
in a viscosity-enhancing Amioca®/Carbopol® 974P powder resembled that after IM 
administration. The viscosity-enhancing capacity of each of the formulation components and the 
irritating capacity of poly(acrylic acid) (cfr. Chapter 6.2.) might have an adjuvant function in 
obtaining the high immunological response. This powder formulation could be a promising 
vehicle for nasal delivery of influenza antigens and possibly other antigens as well. 
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 6.2.1. Introduction 
 
Mucosal vaccination induces little or no immune response when no adjuvant is used (Gizurarson 
et al., 1998). It was hypothesized that the immune response after nasal administration of the 
bioadhesive Amioca®/Carbopol® 974P powder to rabbits was not only due to the adjuvant effect 
of the LTR192G adjuvant, but also the Amioca®/Carbopol® 974P powder carrier itself. An 
adjuvant is any substance that enhances the immunogenicity of substances mixed with it. 
Immunogenicity can be enhanced by microbial constituents (e.g. LTR192G) which signal 
macrophages to become more effective antigen-presenting cells. Consequently, the production of 
inflammatory cytokines is increased and a potent local inflammatory response is obtained 
(Janeway et al., 2001). Based on the in vivo nasal toxicity of Carbopol® 971P previously assessed 
in rabbits and its ciliotoxicity in primary human nasal epithelial cells (Ugwoke et al., 2000), the 
Amioca®/Carbopol® 974P carrier used in the vaccine formulations could have an extra 
immunostimulatory effect. 
 
The irritation potential of the vaccine powder formulations was tested with the Slug Mucosal 
Irritation (SMI) assay developed by Adriaens and Remon (1999). The use of invertebrates as 
model organism for screening toxicological effects of chemicals on mucosal surfaces was 
preferred based on ethical and financial considerations. The hermaphroditic slug Arion lusitanicus 
was selected as test animal as its body wall is covered with a single-layered epithelium containing 
ciliated cells, cells with microvilli and mucus-producing cells. The amount of mucus production 
after contact with the vaccine powder was a measure for irritation while protein release and 
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enzyme release were an indication for the tissue damaging effect (Adriaens and Remon, 1999, 
2002, 2003; Dhondt et al., 2004, 2005). 
 
The present study was performed to evaluate if the enhanced immunoresponse after 
administration of heat inactivated influenza virus incorporated in Amioca®/Carbopol® 974P was 
partially due to the Carbopol® 974P fraction causing mucosal damage. Disruption of the integrity 
of the mucosal epithelium would increase the antigen uptake through the nasal epithelium and 
improve the immune response. 
 
 6.2.2. Materials and methods 
   
6.2.2.1. Materials 
  
Phosphate buffered saline (PBS, pH 7.4) (2.38 g Na2HPO4.2H2O, 0.19 g KH2PO4 and 8.0 g NaCl 
per liter distilled water) and sodium lauryl sulphate (SLS) were obtained from Sigma Diagnostica 
(Bornem, Belgium). Drum dried waxy maize starch (DDWM) and spray-dried Amioca® starch 
were obtained by National Starch and Chemical Company (Bridgewater, New Jersey, USA). The 
spray-dried (SD) mixtures of Amioca® and Carbopol® 974P were prepared in different weight 
ratios by the National Starch and Chemical Company (SD 0/100, 25/75, 50/50, 85/15 and 
100/0). Carbopol® 974P was supplied by Noveon (Cleveland, Ohio, USA). The heat-inactivated 
(56°C, 30’) X47 (H3N2) influenza virus was prepared at the Department for Molecular 
Biomedical Research (VIB and Ghent University, Ghent, Belgium). LTR192G (heat-labile 
enterotoxin R192G mutant) was kindly provided by Prof. John Clements (New Orleans). All 
other chemicals were of analytical grade. 
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6.2.2.2. Preparation of the powder formulations 
 
The following amounts of spray-dried mixtures of Amioca® and Carbopol® 974P were used:  480 
mg SD 0/100, 522 mg SD 25/75, 565 mg SD 50/50, 625 mg SD 85/15, and 650 mg SD 100/0. 
Each mixture was dispersed in 15 ml distilled water and neutralised (except SD 100/0) to pH 7.4 
with 2 M NaOH. Heat-inactivated X47 influenza virus and LTR192G adjuvant were added to 
obtain a concentration of 5 and 0.5 µg per mg SD, respectively. To obtain a powder, the aqueous 
dispersion was freeze-dried in an Amsco-Finn Aqua GT4 freeze-dryer (Amsco, Hürth, 
Germany). The dispersion was frozen to 228 K within 175 min at 1000 mbar. Primary drying was 
performed at 258 K and a pressure of 0.8–1 mbar for 13 h, followed by secondary drying at an 
elevated temperature (283 K) and reduced pressure (0.1– 0.2 mbar) for 7 h. After freeze-drying, 
the powder was manually milled at low relative humidity (20%) and ambient temperature. 
Vaccine powders were stored in a desiccator at 4–8°C until use. Negative control powders were 
pure Amioca® and DDWM. Positive control powders were prepared by mixing Amioca® and 
DDWM with SLS. 
 
  6.2.2.3. Slug Mucosal Irritation test 
 
 6.2.2.3.1. Experimental procedure of Slug Mucosal Irritation test 
 
The Slug Mucosal Irritation (SMI) assay according to the methodology described by Adriaens and 
Remon (2002) is a model to predict the mucosal irritation potency of pharmaceutical 
formulations. The test has been modified for bioadhesive powders (Adriaens and Remon, 1999; 
Adriaens et al., 2003). Slugs (Arion lusitanicus) weighing between 2.5 and 4.0 g were used. The 
irritation and tissue damaging potency of the SD powders, negative and positive controls were 
evaluated by placing 5 slugs per treatment group daily during 30 min (contact period) on 20 mg 
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powder for 5 successive days. After each 30-min contact period the slugs were transferred to a 
fresh Petri dish and 1 ml PBS was added. After 60 min the PBS was collected with a micropipette 
and the slugs were placed in a fresh Petri dish containing 1 ml PBS which was collected after 60 
min. The PBS samples were analyzed for the presence of proteins and enzymes (LDH and ALP). 
Afterwards, the slugs were placed in a Petri dish on a membrane filter (cellulose acetate 0.45 µm, 
Sartorius, Goettingen, Germany) moistened with 2 ml PBS until the next contact period. A 
schematic overview is given in Figure 1. 
 
 
Daily during 5 successive days 
30’ Contact Period with 20 
mg of the test substance 
Transfer slug to new petri 
dish. Add 1 ml PBS and 
remove this after 1 h. 
Transfer slug to new petri 
dish. Add 1 ml PBS and 
remove this after 1 h. 
Measure Mucus 
production 
Irritation 
Tissue damage 
Measure Protein, 
LDH & ALP release 
in samples 
Calculate Total Mucus 
production 
Calculate Mean Protein, 
Mean LDH release and 
count number of slugs 
inducing ALP release 
Test procedure (5-day) 
Sample 1 
Sample 2 
n=5 
Endpoints Calculations Prediction Model 
 
30’ CP 
Cut-off values for the Total Mucus 
production are used to classify the 
compounds into  non-irritants, mild, 
moderate & severe irritants. 
 
 
 A decision tree combining the 
results of the Mean Protein, Mean 
LDH and number of slugs showing 
ALP release is used to convert the 
results into tissue damage grades: 
minimal, slight, moderate and 
severe tissue damage 
 
 
Figure 1. Overview of the Slug Mucosal Irritation test procedure; this procedure was repeated during 5 successive 
days. 
 
  6.2.2.3.2. Determination of endpoints 
 
 6.2.2.3.2.1. Mucus production 
The amount of mucus produced during each contact period was measured by weighing the Petri 
dishes with the test item before and after each contact period. The mucus production was 
expressed as % of the body weight. The slugs were weighed before and after each contact period 
of 30 min. 
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6.2.2.3.2.2. Determination of protein concentration 
The total protein concentration in the PBS samples was determined with a NanoOrangeTM 
protein quantitation kit (Molecular Probes, Leiden, The Netherlands) (Harvey et al., 2001). The 
NanoOrangeTM reagent allowed accurate detection of proteins in solutions at concentrations 
between 10 ng and 10 µg/ml. Bovine serum albumin was used as a standard. The fluorescence 
measurements were carried out on a fluorometer (Wallac 1420 multilabel counter, PerkinElmer, 
Turku, Finland) using excitation/emission wavelengths of 485/590 nm. The protein 
concentration was expressed as µg/ml. 
 
 6.2.2.3.2.3. Determination of LDH and ALP activity 
The lactate dehydrogenase activity (LDH, EC 1.1.1.27) and alkaline phosphatase activity (ALP, 
E.C. 3.1.3.1.) were measured with an enzyme kit (LDH/HBDH 2.8 and ALP 6, ABX diagnostics, 
Montpellier, France). The enzyme activity measurements were conducted on a Cobas Plus 
analyser (ABX, Brussels, Belgium) at a temperature of 37°C. The enzyme activity was expressed 
as U/l. 
 
 
 6.2.2.3.3. Interpretation of the results 
 
Based on the endpoints of the Slug Mucosal Irritation assay the irritation potency and tissue 
damaging effect of the powder formulations were estimated using a classification prediction 
model. The irritation potency was estimated by the total mucus production (4 classes: non-
irritant, mild, moderate and severe irritant). The cut-off values for solids were used for 
classification. The total mucus production was calculated by taking the average of the 5 slugs 
after adding up mucus production per slug after 5 contact periods.  
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The tissue damage was predicted by the mean protein and LDH release and by the number of 
slugs that showed ALP release (4 classes: no, mild, moderate and severe tissue damage). The 
mean protein release over the samples from day 2 until day 5 was calculated for each slug and 
afterwards the mean was calculated. For calculating the overall mean LDH release, all contact 
periods were taken into consideration. A classification prediction model that distinguishes 
between irritation (mucus production) and tissue damage (release of proteins and enzymes) is 
shown in Figure 2 (Adriaens et al., 2005). 
 
 
 
 
 
 
 
Figure 2. The Slug Mucosal Irritation test prediction model that distinguishes between irritation potency and tissue 
damage.  
 
 6.2.2.3.4. Acceptance criteria 
 
The following criteria had to be met in order to consider the results of the set-up of the SMI 
assay as valid: 
• The negative control powders (DDWM and Amioca®) should be classified as non-
irritant (total mucus production < 7%) and should induce minimal tissue damage 
(mean protein release < 25 µg/ml.g, mean LDH release < 1 IU/l.g and no ALP 
release). 
• The positive control powders (DDWM/SLS 80/20 and Amioca®/SLS 80/20) should 
be classified as a severe irritant (total mucus production > 20%) and should result in 
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severe tissue damage (ALP release in 4 of the 5 slugs or mean protein release > 100 
µg/ml.g). 
 
 6.2.3. Results 
 
The aim of this study was to compare the mucosal irritation potency of the different vaccine 
powder formulations (whole inactivated influenza virus incorporated in SD 100/0, SD 85/15, SD 
50/50, SD 25/75 and SD 0/100) using an alternative mucosal irritation test on slugs. The 
irritation potency was assessed by the release of proteins and enzymes (LDH and ALP) from the 
body wall. The observations made during this study were related to the results of the vaccination 
study (cfr. Chapter 6.1). The results of the mucosal irritation test of powders are shown in Table 
1. 
 
Table 1. Effect of whole inactivated influenza virus (WIV) formulated in spray-dried 
Amioca®/Carbopol® 974P (ratio: 100/0, 85/15, 50/50, 25/75 and 0/100) (SD 100/0, 85/15, 50/50, 
25/75 and 0/100) on the endpoints of the Slug Mucosal Irritation test (mean ± S.D., n=5). 
Formulation Total MP (%) Protein 
(µg/ml.g) 
LDH 
(U/l.g) 
ALP 
   (U/l.g)   n/5 
Irritation/
Damage 
DDWM 6.0 ± 1.4 20 ± 8 - -        0 NI/No 
Amioca® 4.5 ± 1.3 25 ± 9 0.0 ± 0.1 -        0 NI/Mild 
DDWM/SLS 
80/20 
32.7 ± 8.0 102 ± 55 2.6 ± 2.0 -        0 Sev/Sev 
Amioca®/SLS 
80/20 
31.7 ± 7.4 135 ± 37 3.3 ± 1.7 -        0 Sev/Sev 
SD 100/0 + WIV 7.3 ± 1.3 20 ± 13 0.1 ± 0.2 -        0 Mild/No
SD 85/15 + WIV 9.3 ± 1.7 13 ± 4 - -        0 Mild/No
SD 50/50 + WIV 16.5 ± 2.1 40 ± 29 0.1 ± 0.2 -        0 Mo/Mild
SD 25/75 + WIV 18.6 ± 2.4 32 ± 6 0.2 ± 0.2 -        0 Mo/Mild
SD 0/100 + WIV 21.7 ± 2.1 29 ± 12 - -        0 Sev/Mild
MP: mucus production in % (w/w) of the body weight  Sev: severe 
Mo : moderate       NI: non-irritating 
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The powder formulations induced a higher mucus production compared to the negative controls 
(DDWM or Amioca®) but lower than the positive controls (DDWM or Amioca® combined with 
20 % sodium laurylsulfate (SLS)). A dose-response relation was found: a higher Carbopol® 974P 
concentration in the formulation resulted in more mucus production by the slugs after the 
contact period with the vaccine formulation (Figure 3).  
The amount of mucus produced per day by the positive control slugs decreased after repeated 
contact periods, whereas the mucus production of the slugs in contact with the test formulations 
remained constant. This phenomenon was more significant after contact of the slugs with the 
Amioca®/SLS formulation. This indicated that the mucus-secreting cells of the positive control 
slugs were severely and irreversibly damaged after repeated contact. In contrast, the cells of slugs 
treated with the vaccine powders sufficiently recovered between the contact periods. 
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Figure 3. Total mucus production (% initial body weight) of slugs after contact with the vaccine powder 
formulations (mean ± S.D.). 
 
The protein release was higher than 25 µg/ml.g when at least 50% Carbopol® was incorporated in 
the formulation. SD 50/50, SD 25/75 and SD 100/0 combined with whole inactivated influenza 
virus were classified as mild tissue damaging, whereas the other vaccine powders induced no 
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tissue damage. However, the protein concentrations in the PBS samples of the positive control 
slugs were clearly higher and the release increased after each contact period. Protein release after 
the first contact period was not taken into account because this initial protein release was not due 
to contact with the possible irritating vaccine powder, but to a stress reaction of the slugs after 
their first contact period with PBS.  
 
Only 2 of the 5 slugs treated with the SD 100/0, SD 50/50 and SD 25/75 vaccine formulations 
released low amounts of LDH after the 4th contact period. In contrast all slugs released LDH 
after the third contact with the DDWM/SLS positive control, while three slugs already produced 
LDH after the second contact with Amioca®/SLS. In contrast, none of the tested formulations 
induced an ALP release. 
Based on the endpoints of the SMI assay and the prediction model, the vaccine powder 
formulations were classified according to their irritation potency and tissue damaging capacity 
(Table 1). Formulations with a high Amioca®concentration (i.e. SD 100/0 and SD 85/15) were 
mildly irritating and induced no tissue damage. Inactivated influenza virus incorporated in SD 
50/50 or SD 25/75 was classified as moderately irritating. After incorporation of the inactivated 
virus in pure Carbopol® 947P (SD 0/100), the formulation was classified as severely irritating. 
When at least 50% Carbopol® 947P was incorporated in the vaccine powder, the formulation was 
classified as mildly tissue damaging. The negative control DDWM powder was classified as a 
non-irritant inducing no tissue damage. The second negative control powder (Amioca® starch) 
was classified as mild tissue damaging. However, it should be mentioned that this was a 
borderline classification: the protein release was 25 µg/ml.g when the slugs were placed on 
Amioca® while the limit for protein release for the non-tissue damaging classification was 
25µg/ml. The positive control powders were severe irritants causing severe damage to the 
mucosal tissue after contact. 
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6.2.4. Discussion 
 
It was remarkable that a dose-response relation was found between the quantity of Carbopol® 
974P incorporated in the powder formulation and the mucus production by the slugs which is a 
measure for irritation. The immune responses (Figure 3, Chapter 6.1) showed a significant 
difference in IgG levels after 3 intranasal administrations of SD 25/75 in comparison with the 
other SD ratios tested. There was also a clear difference in the kinetics of the IgG titers between 
the different nasally administered powders: IgG titers after the first booster were higher when 
more poly(acrylic acid) was incorporated in the formulation. This indicated that the adjuvant 
effect of Carbopol® 974P (as identified via the SMI test) had an impact on IgG titers of the 
serum samples. 
Caution is required when interpreting the increasing mucus production at higher Carbopol® 974P 
concentration. Probably water was absorbed by the mucoadhesive vaccine powder formulation 
from the foot mucosa of the slugs as Mortazavi and Smart (1993) demonstrated that 
mucoadhesive materials can dehydrate mucus gels and interact with mucus glycoproteins. It was 
suggested that water uptake from the slug mucosa increased at higer Carbopol® concentration. 
The slugs placed on the vaccine formulations produced lower amounts of mucus in comparison 
with the positive control slugs. Moreover, only low LDH release was measured after contact of 
the slugs with all vaccine powders.  These results indicated that none of the vaccine formulations 
were severely irritating or tissue damaging. This degree of irritation contributed to the adjuvant 
effect but was rather limited, indicating that are no risks to use these powders for vaccination in a 
clinical setting. 
Recent studies reported the use of Carbopol® as adjuvant in vaccination studies. A pig vaccine 
study evaluated if adjuvants differed in their ability to trigger lesions associated with porcine 
circovirus type 2 (PCV2) (Hoogland et al., 2006). An aqueous Carbopol dispersion was compared 
to a water-in-oil emulsion and aluminium hydroxide as adjuvants for nasal delivery of PCV2. 
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Under the conditions of this study, oil-in-water adjuvanted vaccines were more likely to enhance 
PCV2-associated lesions than Carbopol or aluminium hydroxide adjuvanted vaccines. 
Minke et al. (2006) developed a DNA plasmid and live-vectored canarypox vaccine for protection 
of ponies against a virulent equine herpes type 1 virus. The efficacy of the vaccine was greatly 
enhanced after incorporation of Carbopol® 974P as adjuvant in the intramuscular formulation. 
Using the Carbopol adjuvant in the vaccine there was nearly no virus excretion from the ponies 
after intranasal challenge with a virulent strain of equine herpes virus type 1. 
  
6.2.5. Conclusion 
 
The vaccine powder formulations based on spray-dried mixtures of Amioca® starch and 
Carbopol® 974P in different ratios (SD 85/15, SD 50/50 and SD 25/75) combined with 
inactivated influenza virus and LTR192G adjuvant were classified as substances causing mild or 
moderate tissue irritation and no to mild tissue damage. A larger fraction of Carbopol® 974P 
slightly increased the irritating capacities of the powders which contributed to the adjuvant effect 
necessary for increasing the efficiency of the vaccine. Already after the first booster 
administration influenza virus nasally administered via the SD 25/75 powder showed similar IgG 
levels compared to an IM formulation (Chapter 6.1). The irritating effect of poly(acrylic acid) was 
reversible and acceptable which indicated that the powders can be safely used for single drug 
delivery in case of nasal vaccination. 
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6.3. Stability of whole inactivated influenza virus in phosphate buffered 
saline versus Amioca®/Carbopol® powders 
 
6.3.1. Introduction 
 
A potential problem associated with the use of many biopharmaceuticals, such as proteins and 
vaccines is that they are generally produced in aqueous environment. The dispersion in water 
leads to physical or chemical degradation of the therapeutics (e.g. denaturation, aggregation, 
hydrolysis or oxidation) (Wang, 1999; Wilschut et al., 2007). In this study, vaccine formulations 
were freeze-dried to remove water from the active component and to avoid these potential 
problems. Moreover, the preparation of an influenza vaccine powder might even allow long term 
storage. Currently liquid influenza vaccines need to be stored at low temperature (2-8°C). This 
relatively narrow temperature range requires a well-controlled cold chain, which makes the 
process of distribution and storage complicated and expensive. The influenza vaccine powder 
formulation should be more stable at ambient temperatures and not sensitive to freezing stress. 
These properties would reduce the dependency on cold-chain facilities and would therefore be 
attractive for the integration of the vaccine logistics with general drug distribution, especially in 
developing countries. Moreover, a stable vaccine formulation would facilitate stockpiling of 
potential vaccines against pandemic viruses and thus provide an immediate availability and simple 
distribution of the vaccine in a pandemic situation. Combining these advantages of dry powder 
formulations with the development of needle-free dosage forms, vaccine delivery should be more 
easy and accessible in both developed and developing countries (Amorij et al., 2008). 
In this study, whole inactivated influenza virus was incorporated in a mucoadhesive powder 
formulation (consisting of starch and a poly(acrylic acid)) and in a phosphate buffered saline 
solution. To investigate the stability of the virus in the formulations, both preparations were 
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stored at different temperatures (-20°C, 4°C, room temperature). Stability was investigated at 
different time points (3, 6 and 12 months) checking virion integrity and virion antigenicity. 
 
 6.3.2. Materials and methods 
 
6.3.2.1. Materials 
 
Phosphate buffered saline (PBS, pH 7.4) (2.38 g Na2HPO4.2H2O, 0.19 g KH2PO4 and 8.0 g NaCl 
per liter distilled water) was obtained from Sigma Diagnostica (Bornem, Belgium). The spray-
dried (SD) mixture of Amioca® and Carbopol® 974P (ratio 25/75) was prepared by the National 
Starch and Chemical Company (SD 25/75). The heat-inactivated (56°C, 30’) X47 (H3N2) 
influenza virus was prepared at the Department for Molecular Biomedical Research (VIB and 
Ghent University, Ghent, Belgium). LTR192G (heat-labile enterotoxin R192G mutant) was 
kindly provided by Prof. John Clements (New Orleans). All other chemicals were of analytical 
grade. 
 
  6.3.2.2. Methods 
 
 6.3.2.2.1. Preparation of the formulations 
 
270 mg SD 25/75 was dispersed in 8 ml distilled water and neutralised to pH 7.4 with 2 M 
NaOH. Heat-inactivated X47 influenza virus and adjuvant LTR192G was added to the aqueous 
dispersion to obtain a final concentration of 5 and 0.5 µg per mg SD, respectively. To obtain a 
powder, the aqueous dispersion was freeze-dried in an Amsco-Finn Aqua GT4 freeze-dryer 
(Amsco, Hürth, Germany). The dispersion was frozen to 228 K within 175 min at 1000 mbar. 
Primary drying was performed at 258 K and a pressure of 0.8–1 mbar for 13 h, followed by 
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secondary drying at an elevated temperature (283 K) and reduced pressure (0.1–0.2 mbar) for 7 h. 
After freeze-drying, the powder was manually milled at low relative humidity (20%) and ambient 
temperature.  
Heat-inactivated X47 influenza virus (H3N2) and LTR192G adjuvant were also dissolved in LPS-
free phosphate buffered saline (pH 7.4) at 1000 µg/ml and 100µg/ml respectively, for evaluation 
of the stability in aqueous medium. 
 
6.3.2.2.2. Storage conditions 
 
Whole inactivated influenza virus (WIV, strain X47) formulated in the spray-dried 
Amioca®/Carbopol® (SD 25/75) powder mixture or in PBS were filled in 10 ml borosilicate 
serum vials (Wheaton, NJ, USA), containing 50 mg powder or 250µl PBS per vial (corresponding 
to 250µg WIV and 25µg LTR192G).  Sealed vials were stored at three different temperatures (-
20°C, 4°C and room temperature (RT)). Cold-storage rooms type SPA 024C (GEA, Küba 
Kältechnik, Germany) were used. Stability of the virions was tested after 0, 3, 6 and 12 months. 
 
6.3.2.2.3. PAGE – Western blot to define virion integrity  
 
Structural integrity of the X47 influenza virus was assessed by PAGE and Western blot analysis. 
Five microgram of influenza virus in one milligram of dried Amioca®/Carbopol® powder was 
resuspended in 100 microliter of phosphate buffered saline (pH 7.4) and boiled for five minutes 
in laemmli buffer (0.125M Tris/HCl pH 6.8; 8.3% (w/v) SDS; 10% (v/v) glycerol) supplemented 
with beta-mercapto ethanol. Samples were then loaded onto 8% polyacrylamide gel and 
elecrophoresed at 100V for 1h. 
For Western blotting, proteins were transferred onto nitrocellulose membrane after separation on 
PAGE and probed with anti-X47 HA polyclonal sera raised in rabbit. The bound antibodies were 
149
Chapter 6.3. Stability of whole inactivated influenza virus in phophate buffered saline versus Amioca®/Carbopol® powders 
 
detected using anti-rabbit IgG antibodies raised in Donkey and conjugated to horseradish 
peroxidase (Amersham Biosciences). Addition of tetramethylbenzidine substrate gives a 
colorimetric reaction proportional to the amount of bound antibody. The peroxidase reaction 
was stopped by adding an equal volume of 1 M H3PO4. 
 
6.3.2.2.4. ELISA to define virion antigenicity  
 
ELISA was used to determine changes in antigenicity of the hemagglutinin integrity. 96-well 
MaxiSorp immunoplates (Nunc, Roskilde, Denmark) were coated over night with anti-HA 
antibodies (50µl of a 1/1000 dilution in PBS buffer) raised in rabbit and HPLC purified on a 
protein A column at the Department for Molecular and Biomedical Research. After coating with 
anti-HA antibodies, the wells were blocked with 1% bovine serum albumin in PBS buffer. All 
subsequent steps were performed in a volume of 100 µl per well, and the wells were washed three 
times between incubation steps with PBS + 0.05% Tween 20. Powders were dispersed in PBS to 
dissolve the virion and PBS liquid formulations were used as such. The presence of WIV in the 
samples was determined by incubating the samples in the anti-HA-coated wells for 1.5 h. After 
washing, WIV was detected after incubating the wells with 1/1000 dilution of serum derived 
from a mouse that survived a challenge with X47 virus followed by an incubation step with 
horseradish peroxidase-conjugated anti-mouse serum. After washing, plates were incubated for 5 
min with tetramethylbenzidine substrate (Sigma-Aldrich). The peroxidase reaction was stopped 
by adding an equal volume of 1 M H3PO4. Titers are defined as the reciprocal of the highest 
dilution with an OD450 that is at least two times higher than the background signal. 
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6.3.3. Results 
 
6.3.3.1. Virion integrity 
 
Although similar amounts of virus were loaded on the polyacrylamide gel, due to the high 
sensitivity of the Western blotting technique, bands detecting hemagglutinin (HA) from virions 
incorporated in the powder formulation were more intense due to minor differences in amounts 
of virus. This was seen for all analyses at the 4 time points. The lower detection signal for the 
virus in PBS is therefore not due to disintegration of the virions.  
 
Figure 2. Detection of hemagglutinin on the 
same blot as shown in Fig1, but after a longer 
illumination time until background signal was 
detectable. Samples identified with ‘nihil’ 
contained no WIV. 
Figure 1. Detection of hemagglutinin, the main 
surface antigenic determinant of influenza 
virions, in WIV stored for 12 months at 
different conditions (-20°C, 4°C and room 
temperature (RT)) after PAGE and Western 
blotting. Samples identified with ‘nihil’ contained 
no WIV. 
 
Absence of laddering on a Western Blot after PAGE using polyclonal anti-HA antibodies was a 
measure for conservation of virion/HA integrity. No laddering of the viral HA could be detected 
on Western Blot in the sub-50kD range (Figure 1), suggesting that the virion integrity was 
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preserved for all formulations under the different conditions of storage over a period of 12 
months. Figure 2 shows the same blot but with a much longer illumination time allowing the 
detection of background signal, but no HA-specific breakdown products smaller than 50kD. 
 
6.3.3.2. Virion antigenicity 
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Figure 3. Antigenicity of WIV after formulation in phosphate buffered saline (PBS) or 
Amioca®/Carbopol® (AC), stored under different conditions (-20°C, 4°C and room temperature (RT)) 
and estimated after 0, 3, 6 and 12 months. 
 
Figure 3 shows the results of the sandwich ELISA which is a measure for changes in antigenicity 
of hemagglutinin, the principal surface antigen of influenza virions. Titers detected for all groups 
at all time points deviated from the titers detected at day 0 with a factor 2 at maximum. Based on 
these data it was concluded that the titers of the virions in the different formulations did not 
change significantly over time for the different conditions tested. Because titers were a measure 
for HA-stability and antigenicity, the virions were stable in the powder formulation as well as in 
PBS liquid over a period of 12 months. 
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6.3.4. Conclusion 
 
It was concluded that the whole inactivated influenza virus (X47 strain) incorporated in a spray-
dried Amioca®/Carbopol® powder formulation or in a liquid PBS formulation was stable during a 
12 month period at all storage conditions. Stability included virion integrity and virion 
antigenicity, which were quantified via a Western blot after PAGE and an ELISA assay, 
respectively. In case of the influenza virus the mucoadhesive powder formulation offered no 
advantage towards stability in comparison with the liquid formulation. However, the immune 
response induced after intranasal administration of the mucoadhesive vaccine powder 
formulation was superior to the liquid formulation as a similar response was obtained as after 
intramuscular administration. 
Formulation of vaccines in a dry powder could reduce the storage and transport costs of vaccine 
pharmaceuticals, as the use of cold-chain is not necessary. Moreover, it opens the possibility to 
develop novel needle-free dosage forms for nasal delivery. 
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Chapter 7. General conclusion and future perspectives  
 
The objective of this doctoral thesis was to improve the mucoadhesive properties of a 
starch/poly(acrylic acid) powder intended as carrier for nasal drug delivery.  
To avoid fast clearance of the formulation from the nasal cavity, viscosity-enhancing and 
mucoadhesive polymers have been designed to slow down mucociliairy clearance and to prolong 
residence time between formulation and nasal tissues. In this study, a spray-dried combination of 
maize starch (Amioca®, mainly consisting of amylopectine) and a cross-linked acrylic acid-based 
polymer (Carbopol® 974P) was used to amplify the mucoadhesive capacity of the formulation. 
 
In a first phase of the study the Amioca®/Carbopol® powder formulation (ratio: 25/75) was 
subjected to a heat treatment procedure. This induced low levels of crosslinking in the spray-
dried powder which were responsible for a significant increase in nasal bioavailability of peptides 
in comparison with a non-heat-treated reference formulation. After optimisation of the heat 
treatment conditions (temperature and duration as variables), the best powder characteristics 
were obtained with a carrier heated at 120°C during 1h. Heating at these conditions induced 
crosslinking between the powder components which was responsible for a higher water-
absorbing capacity and increased viscosity and elasticity values. The fast hydration rate of the 
powder opened the tight junctions as the epithelial cells shrinked, whereas the higher viscosity 
reduced mucociliairy clearance and prolonged the residence time of the formulation in the 
nostrils. After nasal delivery of insulin (5808 Da) incorporated in a heat-treated (120°C, 1h) 
Amioca®/Carbopol® powder, a reproducible bioavailability of 30% was obtained. When the same 
powder carrier was used for nasal delivery of salmon calcitonin (3432 Da) and somatropin (22 
kDa), bioavailabilities of 10 and 28%, respectively, were obtained.  
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A second part of the study aimed to develop a powder suitable for nasal drug delivery via a one-
step manufacturing process. The Amioca®/Carbopol® mixture was co-spray-dried with 
metoprolol tartrate (as model molecule) and nasally administered to rabbits. The study 
demonstrated that co-processing via co-spray-drying did not have an added value towards the 
bioavailability of metoprolol tartrate after nasal delivery. 
 
A third application investigated in this thesis was nasal vaccine delivery. Heat-inactivated 
influenza virus combined with an LTR192G adjuvant was incorporated in the Amioca® 
starch/poly(acrylic) acid powder mixture and nasally administered to rabbits. After nasal delivery 
of this vaccine formulation, the systemic response was similar to an intramuscular administration. 
Because of the viscosity-enhancing capacity of each of the formulation components and the 
slightly irritating capacity of poly(acrylic acid) (measured with the Slug Mucosal Irritation test), 
the powder carrier had an adjuvant function in eliciting a strong immunological response. 
Current inactivated influenza vaccines are generally administered via intramuscular injection. 
Besides the intramuscularly or subcutaneously administered inactivated vaccines, also a live 
attenuated influenza vaccine (LAIV) for nasal delivery, such as the recently in the USA 
authorized Flumist® is on the market. Flumist® consists of a cold-adapted virus that is capable to 
grow in human nasal cavities (±32°C) but not in internal organs as the lungs (>37°C). The 
vaccine is formulated as nasal spray which produces aerosols with large droplets which are 
deposited in the nasopharynx (Abramson, 1999). The underlying idea of vaccination with LAIV 
via the upper respiratory tract (nose) is to induce a secretory and systemic immune response that 
more closely resembles the immune response observed after natural infection (Amorij et al., 
2008). Nasal delivery of liquid LAIV vaccine is the only non-parenteral immunization method 
that is commercialized so far. Nasal delivery of influenza vaccine powders is attractive because 
devices have been developed for intranasal delivery (Sullivan et al., 2006). Besides our study, 
limited number of pre-clinical studies on nasal delivery of vaccine powders has been reported. In 
156
Chapter 7. General conclusion and future perspectives 
 
a study of Huang et al. (2004) it was shown that nasal delivered whole inactivated influenza 
vaccine powder co-formulated with a mucoadhesive compound elicited significant serum 
antibody and nasal IgA responses in rats. Further clinical studies should be performed to show 
the efficacy of this vaccine powder in humans. 
 
In summary, the Amioca®/Carbopol® (ratio: 25/75) powder formulation is an interesting 
platform for nasal delivery of peptides (insulin, salmon calcitonin, somatropin). After heat 
treatment of the powder carrier at 120°C during 1h, high bioavailabilities were obtained. Because 
of the high variability after nasal delivery of peptides incorporated in the heat-treated powder 
formulation, the most promising application of this vehicle is probably nasal delivery of influenza 
antigens and possibly other antigens as well. 
 
In this study, the effect of nasal delivery was determined via in vivo experiments using rabbits as 
animal model. However, future research is needed to confirm the effectiveness of these powder 
formulations after nasal delivery of peptides and antigens to humans. For example, a cross-over 
study comparing calcitonin bioavailability after nasal administration of the commercial nasal spray 
(Miacalcic®) and the mucoadhesive Amioca®/Carbopol® formulation could be performed. 
 
Another factor that has to be optimised before commercial use of the powder is the delivery 
device. Choosing the right drug delivery system and correct mode of administration, it is possible 
to adjust the deposition pattern which is determined by the aerodynamic properties of the 
powder and thereby optimize the nasal absorption rate. Furthermore, powder properties such as 
particle size and shape, density and flow characteristics have an influence on the distribution in 
the nose. Nasal powders can be delivered by insufflators, mono- or multi-dose powder inhalers 
or pressurized metered dose inhalers (Kublik and Vidgren, 1998).  
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Summary 
 
The interest in and importance of systemic drug delivery via the nasal route have expanded in 
recent decades since nasal administration offers an interesting alternative for the conventional 
oral and parenteral drug delivery routes. In this thesis, the nasal route was selected as an 
alternative route for peptide and vaccine delivery. Chapter 1 describes the advantages as well as 
the drawbacks of the nose as drug delivery target. Moreover, a comparison is made between 
conventional liquid nasal sprays and nasal dry powder formulations. 
 
The first part of Chapter 2 describes the anatomy and physiology of the nose. The barriers 
(mucociliairy clearance, enzymatic degradation and drug transfer through mucus and epithelium ) 
which have to be overcome prior to systemic absorption of drugs via the nasal mucosa are 
detailed in a second part of this chapter. Because rabbits are used as test animals in this study, the 
advantages of this in-vivo model are discussed and a comparison is made between the nasal 
cavity of rabbits and humans. Since the properties of the nasal formulation determine the extent 
of drug absorption from the nasal cavity, the different formulation approaches and their effect on 
bioavailability are also reviewed: nasal drops or sprays versus mucoadhesive powder 
formulations, chitosan- and carbomer- containing powders, microspheres and nanoparticles. 
 
A spray-dried combination of maize starch (Amioca®, mainly consisting of amylopectine) and a 
cross-linked acrylic acid-based polymer (Carbopol® 974P) was used as powder carrier to amplify 
the mucoadhesive capacity of the formulation. Peptides like insulin, salmon calcitonin and 
somatropin were incorporated in this mucoadhesive powder carrier as well as the conventional 
drug metoprolol tartrate. Inactivated influenza virus was incorporated in the powder to obtain a 
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vaccine formulation. In Chapter 3 the characteristics of the components of the nasal powders 
were described in detail.   
 
In Chapter 4.1. the Amioca®/Carbopol® powder formulation was subjected to a heat treatment 
procedure. After heat treatment the water-absorbing capacity, viscosity and elasticity of the 
muco-adhesive powder increased. NMR analysis in combination with FT-IR indicated that heat 
treatment induced a low degree of cross-linking between the polymers. Nasal administration of 
Amioca®/Carbopol® 974P powders without heat treatment resulted in an absolute bioavailability 
in rabbits of 8.2 ± 3.0 % for insulin. Due to the difference in water-absorbing capacity (which 
opened the tight junctions of the nasal mucosa), elasticity and plasticity (which reduced 
mucociliairy clearance and prolonged residence time) heat treatment at 120°C improved the 
bioavailability: 26.4 ± 21.9, 36.5 ± 11.0 and 19.3 ± 17.3 % after heat treatment during 30min, 1h 
and 4h, respectively. Heat treatment at 60°C was less efficient. Chapter 4.2. aimed to investigate 
the universal applicability of the heat treatment procedure by nasal administration of other 
peptides. Bioavailabilities of 10 and 28% were obtained when salmon calcitonin and somatropin, 
respectively, were incorporated in heat-treated (120°C, 1h) Amioca®/Carbopol® 974P powder 
which meant a significant increase in comparison with the reference formulations. 
 
In Chapter 5 the Amioca®/Carbopol® mixture was co-spray-dried with metoprolol tartrate (used 
as model molecule) in order to develop a powder suitable for nasal drug delivery via a one-step 
manufacturing process. The bioavailability of metoprolol tartrate after nasal administration of this 
powder to rabbits was compared with powders manufactured via other procedures: (a) freeze-
drying of a dispersion prepared using the co-spray-dried powder, (b) freeze-drying of a dispersion 
prepared using a physical mixture of drug and mucoadhesive polymers. After coprocessing via 
spray-drying a low bioavailability (BA 10.8 ± 2.3%) was obtained, whereas manufacturing 
procedures based on freeze-drying yielded a higher BA: 37.9 ± 12.8% using the coprocessed 
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powder and 73.6 ± 24.9% using the physical mixture. The higher bioavailability was due to the 
deprotonation of poly(acrylic acid) during neutralisation of the dispersion prior to freeze-drying. 
This induced repulsion of the ionised carboxylgroups and a lower interaction between 
poly(acrylic acid) and starch, creating a less compact matrix upon hydration of the polymer and 
allowing an easier escape of metoprolol tartrate from the matrix. This study showed that co-
processing of a mucoadhesive Amioca®/Carbopol® 974P formulation with metoprolol tartrate 
via co-spray-drying did not provide an added value towards the bioavailability of the drug after 
nasal administration of the mucoadhesive powder. 
 
In Chapter 6.1. the Amioca®/Carbopol® 974P powder formulations spray-dried in different 
ratios (ratio: 0/100; 25/75; 50/50; 85/15; 100/0, w/w) were used as carriers of a viral antigen. A 
comparison of these formulations for intranasal delivery of heat-inactivated influenza virus 
combined with LTR192G adjuvant was made in vivo in a rabbit model. Individual rabbit sera 
were tested for seroconversion against hemagglutinin (HA), the major surface antigen of 
influenza. The powder vaccine formulations were able to induce systemic anti-HA IgG 
responses. The presence of Carbopol® 974P improved the kinetics of the immune responses and 
the level of IgG titers in a dose-dependent way which was correlated with the moderately 
irritating capacity of the formulation. In contrast, mucosal IgA responses were not detected. It 
was demonstrated that the use of bioadhesive carriers based on Amioca® starch and poly(acrylic 
acid) facilitates the induction of a systemic anti-HA antibody response after intranasal vaccination 
with a whole virus influenza vaccine. 
As obtaining an immune response after mucosal vaccination is frequently correlated with the use 
of an adjuvant, it was hypothesized that the immune response after nasal administration of the 
bioadhesive Amioca®/Carbopol® 974P powder to rabbits was not only due to the adjuvant effect 
of the LTR192G adjuvant, but also to the Amioca®/Carbopol® 974P powder carrier itself. 
Therefore the irritation potential of the vaccine powder formulations was tested with the Slug 
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Mucosal Irritation (SMI) assay in Chapter 6.2. The vaccine powder formulations based on spray-
dried mixtures of Amioca® starch and Carbopol® 974P in different ratios (SD 85/15, SD 50/50 
and SD 25/75) combined with inactivated influenza virus and LTR192G adjuvant were classified 
as substances causing mild or moderate tissue irritation and no to mild tissue damage. A larger 
fraction of Carbopol® 974P slightly increased the irritating capacities of the powders which 
contributed to the adjuvant effect necessary for increasing the efficiency of the vaccine. Already 
after the first booster administration influenza virus nasally administered via the SD 25/75 
powder showed similar IgG levels compared to an intramuscular formulation. The irritating 
effect of poly(acrylic acid) was reversible and acceptable which indicated that the powders can be 
safely used for single drug delivery in case of nasal vaccination. 
In Chapter 6.3. the stability of the virus in the formulations was investigated. Whole inactivated 
influenza virus was incorporated in the mucoadhesive powder formulation and in a phosphate 
buffered saline solution. Both preparations were stored at different temperatures (-20°C, 4°C, 
room temperature). Stability was investigated at different time points (3, 6 and 12 months) 
checking virion integrity and virion antigenicity. The whole inactivated influenza virus (X47 
strain) incorporated in a spray-dried Amioca®/Carbopol® powder formulation or in a liquid PBS 
formulation was stable during a 12 month period at all storage conditions. Stability included 
virion integrity and virion antigenicity, which were quantified via a Western blot after PAGE and 
an ELISA assay, respectively. In case of the influenza virus the mucoadhesive powder 
formulation offered no advantage towards stability in comparison with the liquid formulation. 
However, the immune response induced after intranasal administration of the mucoadhesive 
vaccine powder formulation was superior to the liquid formulation as a similar response was 
obtained as after intramuscular administration. 
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Het belang van systemische toediening van geneesmiddelen via de neus is de laatste decennia 
enorm toegenomen omdat nasale toediening een interessant alternatief biedt voor conventionele 
geneesmiddelentoediening (bijvoorbeeld via de orale of parenterale route). In deze 
doctoraatsthesis werd de nasale route geselecteerd als alternatieve toedieningsweg voor peptiden 
en vaccins. Hoofdstuk 1 beschrijft zowel de voor- als de nadelen van de neus als 
toedieningsplatform. Daarnaast wordt een vergelijking gemaakt tussen de nasale sprays en droge 
poederformulaties. 
 
Het eerste deel van Hoofdstuk 2 beschrijft de anatomie en fysiologie van de neus. In 
tegenstelling tot de uitzonderlijke eigenschappen van deze toedieningsroute moeten ook sommige 
barrières worden overwonnen. Dit zijn de mucociliaire klaring, de geneesmiddelentransfer 
doorheen het slijmvlies en het epitheel en de afbraak door enzymen en worden gedetailleerd 
besproken. Omdat konijnen worden gebruikt als proefdieren in deze studie, worden de voordelen 
van dit in vivo model besproken en wordt een vergelijking gemaakt tussen de nasale caviteit van 
het konijn en de mens. Omdat de eigenschappen van de nasale formulatie de 
geneesmiddelabsorptie vanuit de nasale caviteit bepaalt, worden verschillende formulaties met 
hun invloed op de biologische beschikbaarheid besproken:: nasale druppels of sprays, 
mucoadhesieve poederformulaties, poeders op basis van chitosan of carbomeren, microsferen en 
nanopartikels. 
 
Een gesproeidroogd mengsel van mais zetmeel (Amioca®, met amylopectine als 
hoofdbestanddeel) en een gecrosslinkt polymeer op basis van acrylzuur (Carbopol®) werd 
gebruikt als carrier tijdens de gehele studie om de mucoadhesieve capaciteit te versterken. 
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Peptiden zoals insuline, zalmcalcitonine en groeihormoon en het conventionele geneesmiddel 
metoprolol tartraat werden verwerkt in de drager. Om op basis van het poeder een vaccin te 
bereiden werd er ook een geïnactiveerd influenza virus in verwerkt. In Hoofdstuk 3 werden de 
karakteristieken van de componenten van de nasale poeders in detail beschreven. 
 
In Hoofdstuk 4.1. werd de Amioca®/Carbopol® poederformulatie onderworpen aan een 
hittebehandeling. Na de hittebehandeling werden stijgende waterabsorberende capaciteit, 
viscositeit en elasticiteit van het mucoadhesieve poeder gemeten. NMR analyse in combinatie met 
FT-IR toonde aan dat de hittebehandeling een lage graad van crosslinking tussen de polymeren 
induceerde. Na nasale toediening van Amioca®/Carbopol® poeders die geen hittebehandeling 
kregen bij konijnen, werd een biologische beschikbaarheid van 8.2 ± 3.0 % voor insuline 
gemeten. Door het verschil in waterabsorberende capaciteit (verantwoordelijk voor het openen 
van de tight junctions in de nasale mucosa), elasiticiteit en plasticiteit (die de mucociliaire klaring 
reduceerden en de verblijftijd verlengden) verbeterde hittebehandeling bij 120°C gedurende 1u 
sterk de biologische beschikbaarheid: 26.4 ± 21.9, 36.5 ± 11.0 en 19.3 ± 17.3 % na 
hittebehandeling respectievelijk gedurende 30min, 1u en 4u. Hittebehandeling bij 60°C was 
minder efficiënt. In Hoofdstuk 4.2. werd onderzocht of de hogere nasale biologische 
beschikbaarheid na hittebehandeling van de carrier ook geldt voor andere peptiden. Biologische 
beschikbaarheden van 10% en 28% werden verkregen na nasale toediening van respectievelijk 
zalmcalcitonine en groeihormoon in een hittebehandelde (120°C, 1u) Amioca®/Carbopol® 
poeder carrier, welke significant hoger waren dan de referentie. 
 
In hoofdstuk 5 werd het Amioca®/Carbopol® mengsel gecosproeidroogd met metoprolol 
tartraat (model molecule) om een poeder te ontwikkelen in een één-staps-proces geschikt voor 
nasale geneesmiddelentoediening. De biologische beschikbaarheid van metoprolol tartraat na 
nasale toediening van dit poeder bij konijnen werd vergeleken bij poeders geproduceerd op 
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verschillende manieren: (a) vriesdrogen van een dispersie gemaakt op basis van gecosproeidroogd 
poeder, (b) vriesdrogen van een dispersie gemaakt op basis van een fysisch mengsel van 
geneesmiddel en mucoadhesieve polymeren. Na coprocessen via sproeidrogen werd een lage 
biologische beschikbaarheid (10.8 ± 2.3%) gemeten terwijl bereidingswijzen op basis van 
vriesdrogen hogere biologische beschikbaarheden opleverden: 37.9 ± 12.8% na toediening van 
het gecosproeidroogde poeder en 73.6 ± 24.9% na toediening van het fysisch mengsel. De 
hogere biologische beschikbaarheid kan verklaard worden door deprotonatie van het 
poly(acrylzuur) tijdens neutralisatie van de dispersie voor sproeidrogen. Dit induceerde afstoting 
van de geïoniseerde carboxylgroepen en een verminderde interactie tussen poly(acrylzuur) en 
zetmeel. Daardoor wordt een minder compacte matrix gecreëerd na hydratatie van het polymeer 
die een gemakkelijkere vrijstelling geeft van metoprolol uit de matrix. Deze studie toonde aan dat 
coprocessing van een mucoadhesieve Amioca®/Carbopol® formulatie met metoprolol tartraat via 
cosproeidrogen geen toegevoegde waarde opleverde om de biologische beschikbaarheid van het 
geneesmiddel na nasale toediening van het mucoadhesieve poeder te verhogen. 
 
In Hoofdstuk 6.1. werden gesproeidroogde Amioca®/Carbopol® poederformulaties in 
verschillende verhoudingen (ratio: 0/100; 25/75; 50/50; 85/15; 100/0, g/g) gebruikt als carriers 
voor virale antigenen. Er werd een vergelijking gemaakt tussen deze formulaties voor nasale 
toediening waarin hitte geïnactiveerd influenza virus en LTR192G adjuvant werden verwerkt in 
het konijn als in vivo model. Konijn serumstalen werden getest op seroconversie tegen 
hemagglutinine (HA), het belangrijkste oppervlakte antigen van influenza. De poeder vaccin 
formulaties induceerden allen systemische anti-HA respons. De aanwezigheid van Carbopol® 
verbeterde niet alleen de kinetiek van de immuunrespons maar ook de hoeveelheid IgG titers. 
IgG titers waren hoger wanneer meer Carbopol® in de poeders werd verwerkt wat kan verklaard 
worden door de licht irriterende capaciteit van de formulatie. Daarentegen werden geen IgA’s 
gedetecteerd. Het gebruik van bioadhesieve carriers op basis van Amioca® zetmeel en 
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poly(acrylzuur) vergemakkelijkt de inductie van systemische anti-HA antilichamen na nasale 
vaccinatie met influenza virus. 
Omdat het bekomen van een immuunrespons na mucosale vaccinatie vaak gecorreleerd is met 
het gebruik van een adjuvant, werd de hypothese gemaakt dat de immuunrespons na nasale 
toediening van het bioadhesieve Amioca®/Carbopol® bij konijnen niet alleen te wijten is aan het 
adjuvant effect van de LTR192G adjuvant, maar ook aan de carrier zelf. Daarom werden de 
irriterende capaciteit van de vaccin poederformulatie getest gebruik makend van de mucosale 
irritatietest op slakken in Hoofdstuk 6.2. De vaccin poederformulaties op basis van 
gesproeidroogde mengsels van Amioca® zetmeel en Carbopol® 974P in verschillende 
verhoudingen (85/15, 50/50 en 25/75) waarin geïnactiveerd influenza virus en LTR192G 
adjuvant werden verwerkt, werden geklassificeerd als mild of matig irriterend en niet of mild 
weefsel beschadigend. Een grotere hoeveelheid Carbopol® 974P in de carrier droeg bij tot hogere 
irritatie van het poeder en het adjuvant effect nodig voor een efficiënter vaccin. Reeds na de 
eerste booster van het influenza virus nasaal toegediend in de Amioca®/Carbopol® 25/75 
formulatie werden vergelijkbare IgG titers gemeten als na de intramusculaire formulatie. Omdat 
het irriterend effect van poly(acrylzuur) reversiebel en accepteerbaar was, kan gesteld worden dat 
dit poeder een veilige carrier is voor nasale vaccinatie. 
In Hoofdstuk 6.3. werd de stabiliteit van het virus in de formulaties onderzocht. Geïnactiveerd 
influenza virus werd verwerkt in een mucoadhesieve poederformulatie en in een fysiologische 
zoutoplossing (PBS). Beide preparaten werden bewaard bij verschillende temperaturen (-20°C, 
4°C, kamertemperatuur). Stabiliteit werd onderzocht op verschillende tijdstippen (3, 6 en 12 
maanden) door nagaan van de virion integriteit en antigeniciteit. Het geïnactiveerd influenza virus 
(X47 stam) geïncorporeerd in een gesproeidroogd Amioca®/Carbopol® poeder of een vloeibare 
PBS was dus stabiel gedurende 12 maanden bij alle omstandigheden waarin ze bewaard werden. 
Onder stabiliteit werd virion integriteit en antigeniciteit verstaan, respectievelijk bepaald met een 
Western blot na PAGE en een ELISA assay. In het geval van influenza virus was er geen 
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voordeel qua stabiliteit bij nasale toediening in een mucoadhesieve poederformulatie in 
vergelijking met de vloeibare formulatie. De immuunrespons geïnduceerd na nasale toediening 
van de vaccin poederformulatie was daarentegen hoger dan bij de vloeibare formulatie want er 
werd een vergelijkbare respons bekomen al bij de intramusculaire formulatie. 
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